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Recent epidemiological evidence suggests that up to 15% of worldwide tuberculosis 
(TB) cases may be attributable to tobacco smoking. The aim of the studies reported 
here was to gain insights into the effects of exposure to cigarette smoke on human 
cells that form part of the innate immune system of host defence in the lung. 
Methods: 
First, a reliable method for exposing human cells in vitro to cigarette smoke was 
developed. In order to reliably establish the tuberculous infection status of 
volunteers, a series of experiments were performed to evaluate current and new 
methods of testing for latent tuberculosis infection. These included comparing the 
performance of the tuberculin skin test with interferon gamma release assays (IGRA). 
Quantitation of host defences in vitro involves an assessment of bacterial load, the 
performance and utility of several methods used for this purpose were evaluated and 
compared. Finally, I examined the effects of cigarette smoke extract and nicotine 
exposure on the function of human macrophage cell lines, monocyte-derived and 
alveolar macrophages (from healthy adults). Functional tests included the uptake of 
and cytokines responses to mycobacterial infection and the killing or stasis of BCG 
organisms. 
Results: 
The studies of IGRA tests confirmed significant short-term variability of the test 
results. An analysis of cut-points identified a zone in which results should be 
considered of uncertain significance. A boosting effect of tuberculin skin testing on 
IGRA responses was confirmed. The study of methods for determining mycobacterial 
load established that colony forming units (CFU) on solid media was the most labour-
intensive but cheapest. BACTEC-MGIT-960 liquid culture had a lower detection 
threshold «10 organisms) than Xpert-MTB/RIF (-100 organisms) but significantly 
longer turn around time. Cigarette smoke extract (CSE) did not reduce mycobacterial 
uptake by either monocyte-derived or alveolar macrophages, but containment of 
intracellular organisms was reduced in 5 day cultures. In addition, production of 











Nicotine alone reduced IL-l0 production. The partial suppression of TNF-a 
production did not appear to be mediated via nicotine receptors. 
Conclusions: 
The studies evaluating the interferon gamma release assays have improved 
understanding of the variability of test results in individual patients, the 
interpretation of equivocal test results and the impact of prior exposure to tuberculin 
testing, each of which will have an impact on the use of these tests in research and 
clinical practice. The formal comparison of mycobacterial load assays, under 
standardised conditions, provides a useful guide to the selection of the optimal test 
for each indication. Demonstration of the performance, advantages and 
disadvantages of each, serves as a guide for clinicians and researchers. 
The experiments on the pulmonary effects of cigarette smoke confirm that exposure 
has a significant effect upon innate host defences. Significant reductions in the 
production of key cytokines implicated in defences against mycobacteria were 
observed, not attributable to impairment of mycobacterial uptake by cigarette smoke 
extract exposure. Furthermore control of intracellular mycobacterial growth was 
impaired by cigarette smoke extract exposure. 
These data have important implications for individuals and for public health 
strategies to address the tuberculosis epidemic. Tobacco cessation is imperative, but 
given the deleterious effects of nicotine, inhaled forms of nicotine used in nicotine-
replacement therapies, may not reduce the risk of TB. Although there are likely to be 
several mechanisms responsible for susceptibility of smokers to tuberculosis, these 
data may be used to motivate for tobacco control and smoking cessation strategies as 











1 Introduction and literature review 
1.1 Objectives and rationale 
Tobacco smoking is the single most preventable cause of death in the world today 
with an estimated 1.3 billion smokers worldwide. 1 Eight percent of all adult deaths 
(> 5million people) per year are attributable to tobacco with more than 80% of those 
deaths occurring in the developing world.1 Current estimates of tobacco smoking 
rates are 49% for men and 8% for women in low- and middle-income countries and 
37% for men and 21 % for women in high-income countries.2 
One-third of the world's population aI;e thought to be latently-infected with M. 
tuberculosis (M.tb).3 Each year approximately 9.4 million new cases of active 
tuberculosis (TB) are diagnosed with a resultant 1.7 milli n deaths.3 In Africa and 
particularly in South Africa, the TB epidemic is out of control with an incidence rate of 
approximately 971 per 100,000 people per year.3 Although an association between 
tobacco smoke and TB has been debated for over a century,4 clear epidemiological 
evidence has only recently emerged. 
There are three comprehensive independent systematic reviews and meta-analyses 
that have synthesized evidence for the association between TB and tobacco 
smoking.2, s, 6 Smoking is associated with an increased risk of M,tb infection (relative 
risk-l.8), progression to active TB disease (relative risk-2.2) and increased mortality 
(relative risk -2.0).2, 5, 6 Consequently, up to 15% of worldwide TB cases each year 
may be attributable to tobacco exposure'? This estimated population-attributable 
fraction of - 15% for smoking is higher than that for HIV -11 %.8 
There are currently very few data examining the direct effects of tobacco smoke or 
nicotine on defence mechanisms in human tuberculosis infection. I therefore set out 
to examine the effects of tobacco smoke on human immune responses to 
mycobacterial infection, in support of the hypothesis that exposure to tobacco smoke 











The effects of tobacco smoke on the immune system have been extensively studied 
and several reviews on the subject have been published.9-14 Interactions between 
smoke exposure and susceptibility to several infective agents have been described 
and studied, but there is almost no data on susceptibility to infection with M.th or 
BeG. Several approaches, most involving animal models, have been used to examine 
the effects of smoking on immune function. These models have generally involved 
exposing the animals to cigarette for days or weeks and examining their response to 
an infective challenge. Animal models however, may have little relevance to human 
disease and direct evidence from the study of human tissues in vivo or in vitro are 
likely to be more informative. 
Demonstrating mechanisms in human cells that may explain the link between 
smoking and TB infection is the primary aim of the research reported in this thesis. 
Five questions are addressed: 1) What is the effect of tobacco smoke on 
mycobacterial uptake by human macrophages? 2) What is the effect of tobacco 
smoke on cytokine production in response to infection? 3) What mechanism or 
mechanisms are responsible for these abnormal cytokine responses? 4) Are the 
abnormalities in cellular function observed attributable to the nicotine fraction of 
tobacco smoke? 5) What is the effect of tobacco smoke on mycobacterial stasis or 
killing and on macrophage survival? 
A human macrophage model of in vitro infection with mycobacteria and in vitro 
exposure to cigarette smoke extract and nicotine was developed. Three human 
macrophages systems were used: human myelomonocytic cell line (THP-1) 
macrophages, human monocyte-derived macro phages and human alveolar 
macrophages from healthy non-smokers. BeG, a well accepted representative 
mycobacterial strain used in research on tuberculous immunity was selected for 
these experiments in order to establish and develop the methods and obtain data on 
cigarette smoke extract exposure and mycobacterial human cell interactions. The 
findings of these experiments with BeG pave the way for future confirmatory work 











Methods for in vitro exposure of cells to cigarette smoke have not been standardised 
and several techniques have been described. A common approach has been the 
preparation of a cigarette smoke extract by drawing air through a cigarette and 
bubbling it through a liquid medium. The current project demanded a standardised 
and reproducible cigarette smoke extract (CSE) to which to expose cell preparations. 
The first task was therefore to develop a reliable "smoke extract generation device" 
and a technique for exposing human cells to CSE in vitro. 
The cell preparations used to examine the effect of in vitro mycobacterial infection 
status on immunological responses were monocyte-derived and alveolar 
macrophages obtained from healthy HIV negative volunteers without clinical 
evidence of tuberculous disease. In a high burden setting like South Africa, many 
such volunteers are likely to have been infected with tuberculosis, that is, may have 
latent infection. Since this was likely to influence the in vitro responses of their cells 
in culture, it was important to establish the latent infection status of all subjects who 
donated blood mononuclear cells or alveolar macrophages for experiments. 
Currently, there is no gold standard definition for latent TB infection (L TBI) nor is 
there clarity of what LBTI signifies. On the one hand, individuals with L TBI may be 
considered to represent those in whom sterilising immunity has failed - a susceptible 
immunological phenotype. On the other hand, since fewer than 10% of latently 
infected individuals develop active disease, L TBI may also be considered a protective 
phenotype. This lack of clarity on the significance of L TBI, in terms of immunological 
and host defence competency, prompted the investigation and review of current 
understanding of this state and of methods for diagnosing it. 
Understanding of the significance of L TBI and its diagnosis has been revolutionized 
by the recent development of tests of antigen-specific T-cell responses to 
mycobacterial antigens. Historically, the tuberculin skin test (TST) has been the 
standard test for identifying patients with L TBI. However, limitations of this test, in 
terms of accuracy and reliability are well known.15 IFN-y release assays (IGRAs) that 
utilise peripheral blood-derived T-cell responses to relatively TB-specific antigens, 
early secreted antigenic target 6 kDa (ESAT-6) and culture filtrate protein 10 (CFP-











However, there have to date been widely divergent views on how the TST and IGRAs 
should be employed in screening for LTBI. Some guidelines have suggested that TST 
should be replaced by IGRAs,17, 18 while others suggest that TST should be used as the 
initial screen for LTBI and that IGRA be used to confirm the TST results.19, 20 A 
weakness of these recommendations is that most are based on clinical research 
performed in low TB prevalence settings. Their appropriateness in high prevalence 
areas needs to be assessed. 
In investigating screening for L TBI in our high prevalence area, I initially adopted a 
dual approach, using both the TST and IGRA. However, two technical questions arose 
on which there appeared to be little or no published data: 21, 22 First, was the 
uncertainty on what constitutes a significant change in IFN-y response, given that 
IFN-y responses in individual subjects appear to vary over time. The second was the 
influence of a prior TST on subsequent IGRA test results. I therefore conducted 
studies on the within-subject variability of the IFN-y responses over time, examined 
the reliability of cut-points used to define presumed LTBI and studied the effect of a 
TST on subsequent IGRA test responses. Using this information I was able to more 
accurately characterise the infection status of the participants enrolled in the studies 
of cellular responses to BeG infection and cigarette smoke. 
A further developmental component of this body of work, necessary for assessing 
mycobacterial stasis or killing, was to develop a reliable method for quantifying 
mycobacteria in test specimens. Such methods are also relevant for research on new 
drugs and vaccines in tuberculosis, and have many other uses.23-26 I evaluated and 
compared five methods for quantifying mycobacteria, some established and others 
experimental. 
At present, the lack of mechanistic data on the relationship between smoking and 
poor TB outcomes is fuelling uncertainty about the importance of this association. 
Should the epidemiological link between smoking and TB be backed up by a 
mechanistic explanation, it would add credibility to and enhance advocacy to include 
tobacco cessation and prevention programs as part of National and global TB control 











whereby host immunity to tuberculosis is subverted in vivo. If specific constituents of 
cigarette smoke such as nicotine were shown to impair immune responses to 
mycobacterial infection, this would have implications for the selection of tobacco 
cessation strategies; using nicotine replacement therapy and the therapeutic use of 
nicotine-containing products such as electronic cigarettes. 
Findings of this research will be of particular relevance in developing countries like 
South Africa, India and China, where the prevalence of both tuberculosis and tobacco 











1.2 The epidemics of tobacco smoking and tuberculosis 
At the beginning of the 21st century we are facing the convergence of several 
epidemics with considerable consequences for global respiratory health. At the end 
of the 19th century a similar pattern was seen as tobacco smoking was widespread 
and increasing after the invention of the cigarette-rolling machine in 1881.27 
Furthermore, the discovery of Mycobacterium tuberculosis by Robert Koch one year 
later in 1882 occurred during a time that tuberculosis (TB) was rampant in many 
parts of the world. 
Nearly 100 years later, smoking is at an all time high with over 6,319 billion 
cigarettes consumed per year.27 Tuberculosis remains uncontrolled in the developing 
world with increasing rates of multi-, extensively- and pan-drug resistant 
tuberculosis.3 Tobacco smoking, TB, in addition to HIV infection and chronic 
obstructive pulmonary disease (COPD), are colliding on a global scale with the 
epicentre in sub-Saharan Africa. 
1.2.1 Tobacco smoking 
Approximately one-third of the world's population are active smokers (-3 billion 
people).1 Tobacco smoke is known to be carcinogenic, the primary etiological factor 
for chronic obstructive airways disease (COPD) and a key component in promoting 
cardiovascular disease. It is considered to be the single most preventable cause of 
death in the world today. Eight percent of all adult deaths (> 5 million people) each 
year are attributable to tobacco smoking and of the 8 leading causes of death, all 
except diarrhoeal disease have a tobacco attributable component.1 (Figure 1-1) 
Although no tobacco attributable fraction for HIV is included in this figure, there is 
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suggest that the inhalation of the smoke of cigarettes does not aid in the outbreak of 
pulmonary tuberculosis".4 Since then many more studies have examined this 
association and have been confounded by the strong association of both tuberculosis 
and smoking with poverty, overcrowding, malnutrition and alcohol use; all of which 
are risk factors for tuberculosis. However, there are now three comprehensive 
systematic reviews and meta-analyses that have synthesised the evidence for the 
association between TB and tobacco smoking.2, 5, 6 These have examined the 
association of smoking and TB for three outcomes: TB infection (defined as a positive 
tuberculin skin test), active TB disease and death due to TB. Table 1-1 provides the 
outcome-specific pooled relative risk estimates from the 3 meta-analyses. 
Table 1-1 The association between smoking and the relative risk of latent tuberculosis 
infection, progression to active disease and mortality from active TB disease. 
Pooled relative risk (95% C.I.) 
Meta-analysis TB infection TB disease TB mortality 
[Reference] [n= -6 studies] [n= -15 studies] [n= -5 studies] 
Slama et al. 200i -1.8 (1.S-2.1) -2.3 (1.8-3.0) -2.2 (1.3-3.7) 
Lin et al. 20075 -1.7 - 2.2 (1.S-2.8) -2.0 (1.6-2.6) -2.0 (1.1-3.5) 
Bates et al. 20076 -1.7 (1.S-2.0) -2.3 (2.0-2.8) -2.1 (1.4-3.4) 
n= number of studies in the meta-analysis 
It is evident from these meta-analyses that smoking approximately doubles the 
relative risk (RR) of each outcome, namely TB infection (RR -1.5), active TB disease 
(RR -Z.O) and TB mortality (RR -Z.O). The evidence is strong for TB disease, but 
relatively weaker for latent TB infection. Due to the widespread nature of tobacco 
smoking the population attributable risk (PAR %) is high. For example, ifthe relative 
risk for TB disease is estimated at 1.5 and population exposure to tobacco smoke is 
30%, the PAR% is approximately 15%. In other words, 15% of the TB cases in the 
world each year may be attributable to tobacco exposure.37 The estimated 
population attributable fraction for smoking (- 15%) is indeed higher than that for 











Table 1-2 Population attributable fraction of several risk factors for TB 
Risk factor Population attributable fraction 
Tobacco smoking 15.8% 
HIV 11% 
Malnutrition 26.9% 
Air pollution 22.2% 
Alcohol abuse 9.8% 
Diabetes 7.5% 
Data reproduced from Li:innroth et al. 8 
Since the publication of these meta-analyses, newer studies have been published and 
confirm the association between smoking and TB. In a large case-control study from 
India, Jha et al. reported excess TB deaths among smokers, as compared with non-
smokers among both women (RR, 3.0; 99% CI, 2.4 to 3.9) and men (RR, 2.3; 99% CI, 
2.1 to 2.6).38 A subsequent large case-control study from India reported that those 
who both smoked cigarettes and drank alcohol had considerably higher active TB 
incidence rates than those who did neither (TB incidence RR 3.5).39 
Similar results have been reported fr m Taiwan and China. In a prospective cohort 
study from Taiwan, Lin et al. reported that current smoking was associated with an 
increased risk of active TB (adjusted OR, 1.94; 95% confidence interval, 1.01-3.73).40 
In a case-control study from two rural areas of China, Wang et al. reported an 
adjusted OR of 1.93 (95% CI: 1.51-2.48) for smoking and TB disease.41 A cohort 
study in Brazil looked at the association between smoking and a fourth outcome, TB 
relapse. They reported that smoking was independently associated with relapse of 
TB, as defined by the requirement for re-treatment within 3-5 years after successful 
completion of TB treatment. After adjusting for socioeconomic variables and alcohol, 
the OR for relapse was 2.53 (95% CI, 1.23,5.21).42 
A mathematical modelling study by Lin and colleagues further supports the 
association between smoking and TB.43 Taking into account the accumulation of 
hazardous effects of risk factors on COPD and lung cancer over time, and dependency 











provided directly observed treatment short-course (DOTS) coverage remains at 80%, 
smoking cessation would reduce the projected annual TB incidence in 2033 by 14-
52%. This is in addition to the potential prevention of 26 million deaths from COPD 
and 6.3 million deaths from lung cancer ifboth smoking and solid fuel usage ceased.43 
An interaction between TB and HIV infection became evident soon after the HIV 
epidemic started with new associations continuing to be recognised, including 
treatment-related complications and drug interactions.44 The effect of the HIV 
epidemic on TB has been well documented with incident rates of TB particularly in 
Africa, rising rapidly as a result of HIV.45 The risk of active TB doubles in the first 
year of HIV co-infection46 and the risk of developing active disease in those who have 
latent tuberculosis infection (LTBI) is approximately 10% per year.47 HIV-TB co-
infected individuals have reduced survival48 and are at higher risk for subsequent 
opportunistic infections.49. 50 In overcrowded and po r living conditions, the 
combined effect of the two epidemics is magnified as evidenced by greater than 
2000/100 000 population prevalence rates in certain South African communities.51 
Added complications in co-infected individuals include drug-resistant TB and 
immune reconstitution inflammatory syndrome (IRIS).52 
Causality between tobacco smoke and COPD is well established and it remains the 
primary risk factor for COPD.53 In addition to the documented dose dependent risk of 
COPD from tobacco smoke,54 the importance ofthe "total burden of inhaled particles", 
including occupational, household and environmental exposures, is increasingly 
being recognised.55-58 Post-tuberculous 'obstructive airways disease' was described in 
the 1950s-1960s by several authors.59-62 Hallet and Martin reported that: "It is 
increasingly evident that a diffuse obstructive pulmonary syndrome is often 
associated with tuberculosis."61 They observed that in the 1800's Laennec had 
reported the association of emphysema with TB.60 Although this association 
continues to be widely recognised by clinicians in developing countries,63-65 it has 
been poorly studied.65, 66 In addition to the burden of tobacco smoking, air pollution 
(indoor and environmental) and poverty, HIV is prevalent in many developing 
countries, particularly in sub-Saharan Africa. HIV infection alone is now being 
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Figure 1-5 The effects of tobacco smoke on host immunity 
The effects of tobacco smoke on components of the immune system with particular emphasis on the 
pulmonary defences are depicted.73 
1.3.1.1 Tobacco smoke and the airways 
Tobacco smoke has several effects on the structure and function of the respiratory 
tract. Mucus hyper secretion occurs as a result of gland hyperplasia74 and direct 
secretogogue effects of nicotine,75 In addition, it has effects on ciliary function76-78 
resulting in impaired airway clearance,79, 80 The effect on ciliary function is mediated 
in part by acrolein as well as acetaldehyde (found in both tobacco smoke and 
alcohol),78 At a cellular level, there is increased peribronchial inflammation81,82 and 
increased permeability.83 
1.3.1.2 Peripheral blood 
Smokers have raised peripheral blood white cell counts84-86 and in heavy smokers 
(>50 pack years) alterations in the CD4:CD8 ration is evident.87 Immunoglobulin 
levels are also reduced by 10 to 20% in smokers.88-9o Smoking also raises CRP and 
fibrinogen levels important additional markers of cardiovascular disease.91, 92 
1.3.1.3 Alveolar and cellular level 
Smokers have increased alveolar macrophages in bronchoalveolar lavage fluid,93-95. 
reduced surfactant A and D96 and altered immunoglobulin levels.97, 98 Alveolar 
macrophage phagocytic function is impaired in smokers (human and mice-exposed). 











haemophilus, 100, 101 Staphylococcus, 93, 102 Streptococcus,103 CryptocoCCUS104 and 
Candida.10s A reduced phagocytic index has also been demonstrated in short-term 
cigarette smoke «24 hour) exposure models.102, 103, 105, 106 
The impact of both tobacco smoke and individual components of tobacco smoke 
(nicotine and acrolein) on cytokine responses have been widely investigated. 
Cigarette smoke exposure reduced TNF alpha in response to non-typeable 
Haemophilus injIuenzae infection,107 and nicotine has been shown in models of 
Legionella infection to reduce production of IL-6, IL-12 and TNF-a, but not IL-10.10B 
In peripheral blood mononuclear cell models, smoke exposure reduced TNF-a, IL-1j3 
and IFN-y whereas acrolein reduced TNF-a and IL-2 production by T-cells following 
PMA stimulation.109, 110 Two bronchoalveolar lavage cell models have shown 
reduction in TNF-a and IL-1j3 from BAL cells stimulated by LPS94 and IFN-y and IL-2 
from BAL cells stimulated by PMA.111 In a contrasting inflammatory model of 
ulcerative colitis, nicotine reduced IL-10, but not IL-2 and TNF-a production.112 
1.3.2 Mycobacterial immune responses 
The immunological mechanisms that underpin the mechanistic link between smoking 
and TB are unclear, though several have been proposed.113, 114 There is a paucity of 
data in both humans and animal models directly investigating the effect of tobacco 
smoke on immune responses to mycobacterial infection/exposure.11S, 116 In a mouse 
model of tuberculosis and smoke exposure, Shang and colleagues showed an 
impaired immune response to infection in mice exposed to cigarette smoke over a 14 
week period with resultant higher loads of bacilli in the lungs and spleen of exposed 
mice.116 Several of the altered immune responses shown in non-tuberculosis 
cigarette smoke exposure models, may be relevant to the smoking and tuberculosis 
association. 
Cytokines crucial to the immune response to tuberculosis such as IFN-y, IL-12 and 
TNF-a are reduced by smoke exposure. In addition, TNF-a production is reduced by 
nicotine through an interaction with a7 nicotinic acetylcholine receptors. lOB 











has been shown in some non-TB macrophage models to be reduced by smoke 
exposure,119, 120 but increased in others.121-123 Furthermore, cigarette smoke prevents 
pathogen-specific expansion and activation of CD4 T cells124 and reduces IFN-y 
producing adenoid-specific CD4 and CDB T cell numbers,119 Other potential 
mechanisms by which smoking may attenuate pulmonary immunity include, 
increased oxidative stress on the lung, mechanical disruption of ciliary function and 
other clearance mechanisms in the tracheo-bronchial tree. 125 
Given the large body of evidence of the negative effects of tobacco smoke on 
immunity, it is likely that smoking will additionally impair TB specific human 
pulmonary immune responses, although this is as yet unproven. 
1.4 Determining L TBI status in healthy subjects 
In many countries with a low incidence of tuberculosis (TB), serial (repeated) testing 
for latent TB infection (LTBI) is done for individuals at high risk of TB exposure.21 
There is however no gold standard for defining L TBI. Asymptomatic infection by 
M.tb organisms is detected by the demonstration of a cutaneous delayed 
hypersensitivity reaction to the intra-dermal injection of purified protein derivative 
(PPD) - the tuberculin skin test (TST). The diagnosis is 'presumed' and until the 
development of the interferon gamma release assay, this was the only test available. 
Although widely used, the TST has limitations in accuracy and reliability.15 
Furthermore, interpretation of serial TST results is complicated by the problems of 
non-specificity, boosting, conversions, and reversions.126-12B 
Recently, the development of more specific in vitro assays for L TBI - interferon-
gamma (IFN-y) release assays (IGRAs), has offered an alternative approach to LTBI 
diagnosis,129 IGRAs are blood tests based on IFN-y release after stimulation by 
relatively TB specific antigens such as early secreted antigenic target 6 (ESAT-6), 
culture filtrate protein 10 (CFP-10) and TB7.7. These antigens are more specific to M. 











highly specific, also in BCG vaccinated populations.16, 130 IGRAs additionally have 
features that make them ideal for serial testing: they are more specific than TST, they 
are ex-vivo assays and can be repeated any number of times without sensitisation and 
boosting. The testing protocol does not require a second visit to read the TST 
response, and unlike the TST there is no need for a baseline two-step testing protocol. 
While some guidelines have recommended the use of IGRAs for serial testing,17, 18 
others have been more cautious.19, 20 Some guidelines have suggested that TST may 
be replaced by IGRAs,17, 18 while others have suggested initial testing with TST, with 
IGRA as a follow-up option to confirm TST results.19, 20 Regardless of the approach, 
widespread use of IGRAs in serial testing is hampered by lack of evidence on several 
key questions:21, 22 1) What is the within-person reproducibility of T cell responses 
over time (in other words, what amount of variation is expected when IGRAs are 
repeated)? 2) Given a certain degree of "inherent variability", how does one interpret 
a single test result close to the assay cut point? 3) Will a TST boost or affect the 
results of subsequent IGRA testing and what is the optimum time gap between the 
two tests? 4) What is an IGRA "reversion" and what threshold should be used to 
define reversion? 5) What is the clinical significance and prognosis of an IGRA 
reversion? 6) What is an IGRA "conversion" and what threshold (cut-off) should be 
used to define conversion? 7) What is the prognosis (Le. predictive value) of an IGRA 
conversion and will treatment of individuals with IGRA conversions reduce their risk 
of progression to active disease? 
To achieve an accurate and consistent definition of LTBI in our research subjects, I set 
out to answer some of the questions outlined above. Further details and rationale for 
the study are provided in Chapter 3. 
1.5 Quantifying mycobacterial load in research studies 
In recent years, tuberculosis research has increased dramatically as new vaccines, 











and drug resistant tuberculosis.131-133 Accurate determination of mycobacterial load 
is a basic requirement of many laboratory and clinical studies. Although several 
techniques exist to determine bacillary load in clinical and research samples, each is 
associated with limitations including, their cost, methodological complexity, delay in 
obtaining results (turn-around-time) and the detection limits of the test. 
Culture on solid media using colony forming units (CFU), is widely considered to be 
the gold standard for determining the number of viable organisms in clinical or 
laboratory samples, but is labour intensive and has a long turn-around-time.134, 135 
Several alternative techniques are however available to determine mycobacterial 
burden. These include the incorporation of tritiated uracil into mycobacterial DNA, 
bioluminescence assays that use a reporter construct, quantitative real-time 
polymerase chain reactions (PCR) and time to positivity (TTP) in automated liquid 
culture systems (BACTEC MGIT 960]. 
Bioluminescence and uracil incorporation assays both provide rapid turn around 
time and are extensively used in laboratory studies.25, 136, 137 They however have no 
application in clinical studies due to the requirement for specific M.tb-Iuciferase 
constructs and susceptibility to bacterial contamination respectively. Quantitative 
and conventional PCR that amplify M.tb-specific DNA to determine mycobacterial 
burden has been limited by the inability to distinguish viable from degraded 
organisms and detecting M.tb-specific mRNA from viable organisms by RT-PCR is 
technically challenging.138 More recently, newer technologies such as the Xpert@ 
MTBjRIF system (Cepheid, Sunnyvale, USA) have been developed for the rapid 
detection of TB using clinical samples. It may represent an accurate quantitative tool 
as through an intermediary wash step, contaminating DNA is discarded. Only DNA 
from intact organisms trapped in a mesh is amplified in the PCR step.139.140 
Liquid culture using the automated BACTEC 960 MGIT system is also a very attractive 
technology for both clinical and laboratory studies. Already incorporated into EBA . 
studies,134, 135 time to positivity has been well equated with bacterialload.135, 141, 142 
Although the semi-automation, high discriminative ability and low detection 











and cost exceed those of solid culture.143 To establish the optimal methods for 
quantifying mycobacterial load in this research project, a comparative study of 
available techniques was performed. Further details and rationale for the study are 
contained in Chapter 4. 
In summary, the review of the literature on the association between tobacco smoke 
and tuberculosis confirms that although substantiated epidemiologically, further 
work was required to identify mechanisms underlying this association. To date most 
work on this subject has been performed in animals, but studies in humans are 
lacking. To study this association in humans, the infection status of subjects had to be 
accurately established. The tuberculin skin test, the standard test for this purpose 
has significant limitations, but newer interferon gamma release assays show promise 
for improving this assessment, but require further study to improve their application 
and interpretation of results. Several techniques to quantify mycobacterial load in 
this study were available, but the most suitable required clarification. 
The questions identified as requiring study were as follows: 
1. How could a consistent definition of latent TB infection in the research subjects 
be achieved? 
2. What mycobacterial quantification assay would be most suitable? 
3. What is the effect of tobacco smoke on mycobacterial uptake by human 
macro phages? 
4. What is the effect of tobacco smoke on cytokine production in response to 
infection? 
5. What mechanism or mechanisms are responsible for these abnormal cytokine 
responses? 
6. Are the abnormalities in cellular function observed attributable to the nicotine 
fraction of tobacco smoke? 
7. What is the effect of tobacco smoke on mycobacterial stasis or killing and on 
macrophage survival? 












2 General methods and validation 
2.1 Subject recruitment 
2.1.1 Latent TB infection and monocyte-derived macrophage (MOM) studies 
Volunteers for the latent TB infection and monocyte-derived macrophage (MDM) 
studies included health care workers, medical students and laboratory personnel. 
Participants were in good health and informed consent was obtained prior to 
participation in L TBI screening and phlebotomy. (Details about subject recruitment 
for the LTBI study are provided in Chapter 3. 
2.1.2 Alveolar macrophage studies 
Ethical approval from the University of Cape Town Health Sciences Research Ethics 
Committee was obtained to undertake bronchoscopy and lavage of healthy 
volunteers in addition to venesection. Participants were adult staff-members from 
within the Groote Schuur Hospital complex and asymptomatic tuberculosis-exposed 
family members of participants enrolled in on going local TB diagnostics studies. 
All subjects provided informed consent prior to participation in the study and were 
compensated according to local ethical policy. Only physically healthy subjects were 
enrolled for bronchoscopy. Exclusion criteria included asthma, uncontrolled 
hypertension, ischaemic heart disease, diabetes, pregnancy and immunosuppression. 
A CXR was performed to exclude any active respiratory disease and a full blood count, 
and coagulation profile was done to screen for possible bleeding tendencies. Details 
of bronchoscopy preparation and lavage techniques are detailed in section 2.2.4. 
2.2 Acquisition and preparation of human cells 
2.2.1 THP-1 cells 
Frozen stocks of the human myelomonocytic cell line THP-1 (American Type Culture 
Col- lection) in a volume of O.5ml were thawed in a 37°C water bath and transferred 











small volumes of RPMI (Roswell Park memorial Institute)-1640 with 25mM Hepes 
and L-glutamine (Biowhitiker; Lonza, Wakersville, MD, USA) containing 5% foetal 
bovine serum (FBS)(Gibco®; Invitrogen, Grand Island, NY, USA) to a volume of Iml. 
Further diluting of the cells was performed slowly to preserve the integrity of the 
cells until a total volume of 15ml was obtained. 
The cells were subsequently washed 3 times at 1100rpm for 10min at 4°C. The final 
cell pellet was resuspended in 10ml of complete medium (10% FBS in RPMI). The 
cells were transferred to 25cm2 cell culture flasks (.2flm vent cap, #430639, Corning; 
Corning, NY, USA) and incubated at 370C in a 5% C02 humidified incubator for 48 
hours. Culture flasks were placed upright until significant cell growth had occurred 
then placed horizontally and maintained at lxl0s cells per ml concentration by twice 
weekly replacement of fresh media. 
In order to differentiate THP-l cells into adherent cells, 2xl0s cells/ml per well were 
seeded in a 24 well plate (Falcon; BD Biosciences, San Jose, CA, USA) in complete 
medium with the addition of PMA (phorbol 12-myristate 13-acetate, Sigma, St Louis, 
MO) at a final concentration of 5pg/ml for 48 hours. Fresh complete medium was 
added to the resultant adherent macrophages after 48 hours. 
2.2.2 Peripheral blood mononuclear cells (PBMC) 
Peripheral blood was collected into sodium heparin VACUTAINER® tubes and diluted 
with an equal volume of Ca+ and Mg+ free phosphate buffered saline (PBS). 
Peripheral blood mononuclear cells (PBMC) were isolated by density sedimentation 
using Ficoll-Hypaque (Sigma-Aldrich, Steinham, Germany) using standardised 
techniques. Briefly, diluted blood in PBS was layered onto Ficoll and centrifuged at 
400g for 25 minutes at room temperature. The resultant interface was removed and 
washed twice with PBS and centrifuged at 300g for 10 minutes. After the final wash 











2.2.3 Preparation of monocyte-derived macrophages 
PBMCs (obtained by density sedimentation as described in 2.2.2) were seeded at a 
concentration of 1x106/ml into either 24 well plates (Corning) or 96 well plates 
(Corning) for mycobacterial uptake studies or cytokine and mycobacterial stasis 
assays, respectively. The cells were incubated at 37°C with 5% C02 for 6 days to 
ensure that the monocytes had acquired a macrophage phenotype (MOM). The 
adherent macrophages were presumed to be at 1x105/ml, as mononuclear cells 
comprise approximately 10% of monocytes. Non-adherent cells were removed by 
washing with warmed RPMI prior to any further experiments. 
2.2.4 Harvesting and preparation of alveolar macrophages 
2.2.4.1 Bronchoscopy and lavage 
2.2.4.1.1 Participant safety 
To determine whether the subjects were presumed latently infected with TB, 
interferon gamma release assays (IGRA) including QuantiFERON®TB Gold-in-Tube 
and T-SPOT.®TB, in addition to a tuberculin skin test (TST) were performed. HIV 
testing was performed following appropriate counselling. All subjects undergoing 
bronchoscopy were evaluated by a certified pulmonologist (respiratory physician) 
and the CXR, safety bloods and medical history were reviewed prior to the procedure. 
All participants undergoing bronchoscopy signed a separate informed consent form. 
An experienced bronchoscopist performed all lavages. Additional safeguards 
undertaken to minimise risk included the following: 
• Neither brushings nor transbronchial biopsies were taken. 
• Participants with asthma, ischaemic heart disease, uncontrolled hypertension, 
any arrhythmia or significant medical disorders were excluded. 
• Venous access was maintained during the procedure and pulse and oxygen 
saturation monitored continuously. 
• Supplemental oxygen was provided during the procedure to minimise the risk 











• Participants were nil per mouth for at least 6 hours prior to the procedure and 
remained starved for at least 3 hours after the procedure to minimise the risk 
of aspiration. 
• Full resuscitation facilities were available and intensive care facilities, if 
required, were accessible . 
• Sedation with midazolam was allowed in 1mg increments until conscious 
sedation was achieved. Using this approach it was unlikely that doses greater 
than O.OSmgjkg would be required. At this dose, respiration was not 
adversely affected. 
• The total amount of lignocaine used as topical anaesthesia was maintained 
below the 6-Bmgjkg maximal recommend dose144• 145 thus providing a margin 
of safety. 
• All bronchoscopes were sterilised prior to bronchoscopy so that there was no 
risk of transmission of infection to study subjects. 
• Subjects were monitored during recovery and were not allowed to drive a 
vehicle once discharged (following sedative drug administration). Subjects 
were provided with an emergency number to contact the research team at all 
times, and a telephonic follow-up was performed one-week post procedure. 
2.2.4.1.2 Bronchoscopy and lavale technique 
Alveolar lavage cells were obtained by bronchoscopy as follows. Following the 
administration of local anaesthetic gel and spray to the nose and pharynx, a flexible 
video-bronchoscope was passed through a nostril to the level of the vocal cords. 
Further lignocaine was sprayed onto the cords. No fluid was aspirated prior to 
passing the cords to minimize the risk of contamination of the bronchoscope suction 
channel with nasopharyngeal organisms. 
Following further administration of lignocaine to the lower airways, the tip of the 
bronchoscope was wedged into the right middle lobe bronchus. A 300ml lavage 
using sterile saline, in 60 ml aliquots with a dwell time of 10 seconds was performed 
with low suction «20cm H20). The lavage fluid was aspirated into a sterile glass 
container and a maximal return attempted (patient tolerance and physical return). 











2.2.4.2 Preparation of alveolar macropbages 
The volume of the BAL fluid obtained was documented. The BAL was passed through 
2-ply gauze to remove any mucus and particulate debris then transferred into sterile 
50ml conical tubes. Following centrifuging at 300g for 10 min at room temperature, 
the resultant pellets were combined and reconstituted with 50 ml PBS. The cells 
were washed and centrifuged at 300g twice more then resuspended in 2ml of RPMI 
containing 10% human AB serum and 0.1 %Fungin™ (lnvivogen, France) and 
100u/ml penicillin (Sigma Aldrich). A diff quick cell count and viability count was 
determined by counting on a haemocytometer with trypan blue exclusion dye (Sigma 
Aldrich). Appropriate cell concentrations were prepared for each of the various 
experiments performed. Non-adherent cells were washed off after three hours. 
2.2.5 Assessing macropbage viability 
Several techniques were used to determine macrophage viability dependent on the 
specific experimental question. To determine viability of macrophages exposed to 
cigarette smoke, macro phages were stained with trypan blue exclusion dye and 
counted using a haemocytometer. For flow cytometry experiments, macrophage 
viability was determined by 7 AAD viability dye (eBiosciences) staining. Immediately 
prior to acquisition of the cells 10~ of 7 AAD was added to the cells. Once acquired 
the cells were analysed on a F ACSCalibur flow cytometer using Cell Quest software to 
determine the proportion of viable cells. For fluorescent microscopy, 7 AAD was 
added to the cell suspension (or culture medium of adherent cells) immediately 
before viewing under a fluorescent microscope. 
2.3 Preparation of mycobacterial stock 
Mycobacterium Bovis Bacillus Calmette Guerin expressing green fluorescent protein 
(BCG-gfp); a kind gift from Prof. B Ryffel, Institute of Infectious Diseases and 
Molecular Medicine, University of Cape Town, South Africa was grown in 
Middlebrook 7H9 broth (Difco, Detroit, Michigan) supplemented with 10% OADC . 
(oleate-albumin-dextrose-catalase) enrichment media (Becton Dickenson) and 0.02% 











HygnlIllycin Il (SOug/Ill I; Iloeh,-inger MJnnheim, GemlJny) for se lect ion oj 
rcwmbil1~l1l mycob"Ucri<l 'mol ulltures were growil ~I 3TC in ~ ~% CO, hUJl\id i fi~ ti 
chamher Jnd shaken and J ssessed daily for growth. At mid-log phJ5C th e cultliles 
whl'C(' SIl;lP f.-ozen ill 10% glycero l and stored at ·80"r.. 
To determine the colony forming units (CrU) , :J tuhes ofthe frozen IJU.i were thawcd. 
Tlip b~c i l l i were subjectcd to soniCJt ion (M in-oson lJ l tr~solli( Cell disruptor, Mi soni x 
Inc FJrIll ingdd le, NY, USA] in order to di~pcrse d umps of orgJnisms and obtai n 
single bacilli in suspens ion. IJCG were then plated onto Middlebrook 71110 agar 
plates (Falco n, IJD Microhiology Systems, Maryland, USA, as shown hclow] for 
uetcrmination of CFIJ hy counting tlie colonies using In Olympus S75 1 microscope 
(Olympus CoqXlration, Hamburg, Gerrndny). Cultures Were set up in tripl iCJ te Jnd 
plated onto a p lJte with 6 gr ius, so thJtthe ~ve rdge of6 rep licJ tes WJS determined in 
each of the tr iplicate cultures. (figure 2-1]The C]iUs were enumerated hetween day 
10 Jnd ddy 14. CFU/mlwerc determincd hy mu ltip lying tlie mCdn colony count (016 
squares) by 100 (as 10~ 1 was pldted) and then multipl ied by the uilut ion fa ctor_ 
Figure 2·1 Micro·grid 7H10 aga r ptate 
Culture < were ,et up in u-i pl ,,",e < uSln ij plate, wit , grids .s 'h ow n [a,h grid comp ri, ed of bx6 squ>re l 10 
for ~."h trl p l",te ,here wer e 6 sQ u.,o, ~",h g'" '" g .1 to 1>1 of l~ sq u>re ; for e . , h resu lt 
2.4 Infection of macrophages 
Monocyte-derived macrophages were infected with BCG-gfp at a multipl icity of 
infection (MOl) of 2'1 Jnd lor alvcoiJr macrophagcs Jt an MOl oILS :L Thcse MOl 
Were chosen bdsed on preliminary optimisJt ion experinJents dem()nstrJting tha t 











macro phages, aliquots were thawed and mycobacterial clumps disrupted by passing 
the bacteria through a 27g insulin syringe several times. After 18 hours the 
macro phages were washed with warm PBS to remove any bacteria that did not gain 
access into the cells. 
2.4.1 Determination of mycobacterial uptake by flow cytometry 
Flow cytometric analysis was performed to determine the number of macrophages 
containing intracellular BCG-gfp. Cold PBS with 20mM EDTA (Sigma-Aldrich) was 
added to all wells for 10 minutes to facilitate detachment of adherent macro phages. 
Macrophages were washed in PBS containing 1% human serum and 0.1% sodium 
azide (Sigma-Aldrich) and resuspended in the same buffer (FACS buffer). 
Immediately prior to acquisition of the cells, 10111 of 7 AAD (eBiosciences) was added 
in order to establish cell viability. Once acquired, the cells were analysed on a 
FACSCalibur using Cell Quest software. The BCG-gfp, read in the FI1 channel, was 
plotted against the 7 ADD that was read in the F13 channel, thereby determining 
mycobacterial uptake and macrophage viability. 
2.5 Cytokine assays 
Cytokine concentrations were determined using commercially available ELISA kits. 
Supernatants were removed from the culture wells containing infected and 
uninfected macrophages and spun down to remove cellular debris. Where possible, 
supernatants from multiple wells for each experimental condition were pooled. 
Triplicates of each experimental condition were prepared whenever sufficient cells 
were available. Supernatants were stored at -80°C to enable batching of the ELISAs. 
ELISAs were performed according to the manufacturers instructions following 
thawing of supernatants (methods described below for each cytokine). All individual 
samples were run in triplicate wells for each ELISA performed. Mean cytokine 












2.5.1 Interferon gamma (IFN-y) 
IFN-y concentration was determined using the QuantiFERON®-TB Gold (In-tube) 
whole blood IFN-gamma ELISA kit (Cellestis, Carnegie Victoria, Australia). Briefly, 
supernatants were thawed and brought to room temperature with the specified kit 
reagents. Replicate kit standards were prepared ranging from 0-41U/mI (160pg/ml). 
50111 of supernatant was combined with 50111 of reconstituted conjugate and 
incubated for 120 min after which the plates were manually washed 6 times with 
wash buffer. After a 30 minute incubation with enzyme substrate the reaction was 
stopped and the optical density (OD) values were obtained within 5 minutes with a 
450nm filter and a 620nm reference filter. OD values were manually inputted into 
the QuantiFERON®-TB Gold IT Analysis Software (Cellestis). Automated software 
quality control confirmed validity of the data and generated IFN-y concentrations for 
each well. 
2.5.2 Tumour necrosis factor alpha (TNF-a) 
TNF-a concentration was determined using the Human TNF-a Ready-SET-Go! ELISA 
Kit (eBiosciences, #88-7347). Briefly, supernatants were thawed and brought to 
room temperature with the specified kit reagents. Standards were prepared to 
generate a standard curve range of 4 - 500 pg/ml. 100111 of supernatant was 
combined with 100111 of conjugate and incubated overnight at 4°c' After 5 manual 
washes with diluted wash buffer, 100111 of detection antibody was added to each well 
and incubated for 1 hour. A further 7 wash steps were followed by the addition of 
100111 of substrate. The subsequent 15-minute incubation was halted by 50111 of stop 
solution. The plate was read within 5 minutes using a wavelength of 450nm. OD 
values were manually entered into an Excel spreadsheet and a standard curve was 
generated using the serial standard dilutions. TNF-a concentrations were then 
calculated by reading the OD of the test samples offthe standard curVe. 
2.5.3 Interleukin 10 (IL-10) 
IL-l0 concentration was determined using the Human IL-l0 Ready-SET-Go! ELISA Kit 
(eBiosciences, #88-7906). Standard preparation was the same as for TNF-a except 












2.6 I'repal',ltion nfcig<lreUe smoke extract 
2 .6 .1 Cil.:drctte hrllnd 
Cig" ,.el l~ smoke e.,I,-"cl (C~E ) w,,' ubldmed from Ihe cum \.""liuH uf commet ci" lly 
availahle me uium t~r ( 10 ml.: tar & (l.g mg nicotine) M~rl horo )(~d(j (I'hill,p J>lnrns, 
USA J nr,<l '-e l I "' . A ' ''lr,le C I nun con " " n i ng -II) , n rl ,V,du" lIy w,'" jJ )>c d (;i gOl'Nte CO'lon , 
Wd' )1u rcha,~d dnd t he ",d,v"lu.,1 hoxe, were 'lor~d '" , e"I~d pLl , ti c hag' a l 10'e 
until requ i r~d for LI <e_ ' ., In <1i " i<1u,] 1 hoxc, were " ll owPd 10 p(j '!lliil rJ te tn ,nnhient 
1'0flm tpm I'P l'O UIl'~ ,1 n d hu m1<lily ave" '18 hOLl ,·s prio ,' to '1 se in p"pe"j m~nt s_ 
2.6.2 Ciga,.~tte smoking apJ,aratllS 
A st,llld,lr<liz.'d dg,]reU ~·sm oki n e ,kvicc ",os fon s trLl ctp'1 hosed o n th e ,lPI'"r.HUS 
u ,ed In ,ever,,1 '( lI di~, publi 'hed by Free..:! "nd w·wurke,-".l" "- L'l'l (Figu r" L·lJ /I 
,illgil' filte red l'igdrett e Wd' cOllneltell v ia 5rnrn h Lgh flu\\' PVC (lIhmg (G ibl' '') IU " 
peristaltic pump (~t i nl]:>Illse " evolu tin n, Ci lwnJ- t\ skri le 50ce comc,,1 tuhe (Con \l n ~. 
(",-ning NY, USA] v,,,'\~ in ,p)'ipd mlllw "" th rhe rig,l re ttP ond I h ~ pL"np 1I,ing .l ruhb e" 
5( oppe,- W] ( h (wo glJ" ( ub ~, d' COn nee lJOll lJo rl', F 0 ,. e .ll h e '( r~ ll JII e JJ< "-" (JO n, new 
s (e ri li sed lub ing J nd conneCllO n, we re u,ed , The , terile 50ml cunicdl fb sk Wd' II lled 
with 10ml wormed r~rC) RPM l and the ruhber s topper ami connect ions i" ,e rt ed 
into Ihe (ube under s(en le wll(lili on,. The lube and connectors whe,'e ( h~ n 
tran, terrcu lo t he fum e h oorl for preparation of the extr,lCt. 
Figure 1·2 C;g~rette ~mok;ng appar~W5 
Th e (1I:,,,ot« , mo'ine ' Pl"'rotUI Go n"," of t h< p"""t , lt ~ pl.m p Ileft ""ell, PVC tubi n~ "cd 9.lmI (0 , ;,,,1 
fI,,, wnt"c-', ~ cultl". ",,,,, ,um Im ldd l. p,,,,,I), '>'T1Q'e e,h.u, t'n~ "It .,- p",,~e t ~ro ueh the Gult,>re 










2.6.] Opl imiS<ltion of cig~ reI te smolw extract prep" ration 
l.6.].1 Smol<ing lime 
/I II smoke ex lt"JCI prep.,rJl ioll \~.IS I-lE'r fun ned in" f"me ho uri. The houd COvet· WJS 
du,crilu lhe "HH~ h~igh l for alll'xperillll'n ls dnd the ~xlmCli"n f~1l ollly 'wildl~d Oto 
after u " n plpl ioll 01 tl". sm okiHg lilllP. ,\ tix"d pUIIlP ""Ie oj 4S RPM wilh Smm PVC 
tub inG .lchieved .1 t1r)\~ r.Ile of 12Scc /mill eq" ,vJ le,, 1 tu p"blished mH!oods.'U", Wi 
Sevpr,, 1 r i g")'~tt~ br~nd s wpre lesl~d to est"bl ish t llP limp I.lkptl 10 sm(,ke I h ~ 
Cj ~.ord\c lu \~j\hin.1 Un urlhe I' ite r. ( Figur e :~ · 3) 
, 
" T,' 
Figure 2·3 Smoking time for various cigarette brands 
Th,', tiree "'eo !n, ',dg"",,", or e"h br;"d \0 t>"o In I ,'n tro 'n th e file< ,," r",0(doo 'J~08 ' fi ,ed 
pUI"lP r"o. The iMilO"u,1 b,rs ropr."",,,, th r' 'n",,, "'M':"~ tire,',' witl' ,',,,,,," h,,, d .op:".,,~ 1I'e "',,".cd 
dovi,,>oo , Tho 0011 00 vor,;,,1 Ii,e rop ro,"o" teo 5re io 21 "" "Y10<io~ tire o' far teo br. ,d of o •• rotto 
,,, .d in . 1I " 'pe("",n1< 
USlll)\ the Marlboro Red '" cLgareltp, [,Ph ,l li p ~lorris. USA) al a fixed now ratp oj 
12Srr/mill, a smoking time of S minutes and 21 secunds after ,In ini ti,,1 S second 
ign ilwn period wa, e,tahlishptl. [Tahle ~ · l) Th" tlIne reliably slIlokPd the c igarette to 
Illrnm [= O.Bmlll) frolll th e ilIter, Smoke rema Ln ing with in the Sl1ml con ica l tube after 
completion of the 'making time, w", allowed to d issolve in the med iu m by gent le 










Table 2-1 Variability of 'smoking time' between cigarette brands and products within 
brand products 
Cigarette brand Mean time to burn to tcm of Standard Coefficient of 
filter deviation variance 
Aspen® 4min 44 sec 10 sec 3.5% 
Peter Stuyvesant® 6 min 16 sec 44 sec 11.7% 
Marlboro Red® 5 min 21 sec 8 sec 2.5% 
Marlboro Gold® 6 min 20 sec 15 sec 4.1% 
Camel® 5 min 15 sec 11 sec 3.5% 
The concentration of CSE produced by this method was defined (by convention) as a 
100% solution. Dependent on the experimental protocol, appropriate dilutions were 
prepared to produce a final concentration ranging between 0.1 % - 10% in cell culture 
medium. Cigarette smoke extract was produced freshly for each experimental 
intervention and was used within 20 minutes of preparation. Two aliquots of 100% 
cigarette smoke extract were immediately frozen and stored at -80°C for mass 
spectrometry determination of nicotine content. 
2.6.3.2 Determination of nicotine concentration 
2.6.3.2.1 Mass spectrometry 
The University of Cape Town Division of Pharmacology analytical & research 
laboratory performed the mass spectrometry for the determination of nicotine 
concentrations. 
Briefly, aliquots of cigarette smoke extract were analysed using a ABSciex 3200 
Qtrap mass spectrometer connected to an Aglient 1200 Series HPLC (High 
Performance Liquid Chromatography). A series of nicotine standards (Sigma) and 
quality controls were prepared in HPLC grade water (Merck, Germany). Standards, 
controls and unknowns were diluted 1000 fold, in 50% Acetonitrile: 0.1% Formic 
acid (Merck, Germany), with Reserpine (Sigma) as an internal standard. Sill of the 
samples were injected onto a Phenomenex Luna Hilic column (50 x 2mm x 3 micron), 











2.6.3.3 11epro<1u ciiJiIi!}' 0 f I he cir:~ reUe smoke ex t rile I 
2.6.:1.:1. I f. igan.'tte smoke extract reprn<1 uciiJi lity betw een hr;luds 
S M~ rlhoco R",l '" [ igordte, 110 mg t<lr <In<1 0.8 mg 1] jrOf ill€J w€re se~ " e~li.l 11 y 
srnok€rl lIs ill g lll€ sliH1dardi Leu I'w loco l. lnui" iuual niwt LHc ronce nlr~tions ,,"er~ 
ca lULblcd f(}r each o[ the []\'e rreporcd ext racts. The mc"n (Sllj conccntrJ(ion 01 
nicotine obtained Irom the :; < e ~u en ti.1I1y srnokp ri r ig,1relleS ,,",1 S 11.. 5(3.4 J .liM m I dnd 
lhe (oefr; cicnt of ,'ariance ""as ~ 8. 1 7%. Nicoti nc concentr"t ions arc known to \'" ry 
w ilhin brands (Marl!>(\rn G(\ld '" \'s . Mdrlho]"() Red':!) dnd within h rand pco(h](:t, 
(M arlho ]"() Red !!:' bo ught in Kenya \.,. Mar lI", r0 Rfrl ~' 1"'11gh t in AJJwrkJ J. '" 
The nirMine wnrentr<ltions of one low ldr and tW(} TIledillTIl ta,' brands (uscd in th,' 
snwking lim,' exper iments , I"l>vn in (Fi!:lLre ~ -3J were [()mpa rc d. Camet" (m(·d ium 
t" r: I() mg tar, lI .n mg nicotilwj, M'lrlboro Rprl '" (mpd jum tor: 10 mg t<lr, 0.8 mg 
nicotineJ <lnrl Marlb ,'ro Gt,l d'" (low lar, 0.8 mg id!', 0.$ m!: nico tiIle) ,~~w COmIJdW(\. 
NiCOline conccn lrdlions in CSE di[[ered aero," dlllhrec hrdm\". C~1i prepMed from 
C~llleP ci",d reltcs had till' highe't me,ln (Sll] conrentr,l tion or n irotil1f : 11.'I(2.1-J 
I.lgjml compa red to M<lrlbo ro Re d'" 9.1(1.9J ~!g/ml anrl M~rlboro Go ld'" 4.9(0.9J 
~!gjtlll: 1'<0.001. [Fij(urc 2-4) The coefficient o[ va ri ance wa.' sim il a r acro." a ll t h ree 
bra nd." 17.6%, 18.3% and 21.1% r€spe clivdy. 
Figure 2-4 Nicotine concentrations in ciguette smoke extract from different tobacco 
brands 
E"h b" rep ro,o," " 0 mo . n ni[.o( i, " mec. ntc"-o", i, pr" p"C"o d g, re\ ' " ., mo " ",t roct frum Iwo 
med· Jm oo d eno klw tor bro od. fivo cigorctle, wo ro ,moko(i for ooc h "rono "" it l- e rror ". r< r" p'",e nl ing 











2 .6.3 _3 .2 Cigarette smoke extract reproducibil ity over lime 
Two a ii<jllo lS o f ,. 11 pre ~ dred cigare tte 'llloke ~"tract we re imm pdiatf iy fro zen '''HI 
stored at -BO°C for Lllcr b.'tched nicotill e determill ,l(i ull Using lliwlirw , Iamlanls 
ran gl llg frum 30- 200 ~Lg/rnl the eneffi cient of v~ ri.," cc of the ma,. speClronwtfr 
determi lleti std ntiarrl U\lICellt r.l t ioll' Wd' 14.9% 
Reproducih ility of th e cigaT'etl~ f;.;lrilct waS ocst wlwn lIlu ltipl e extr.-.cis wc're 
produc~d on th e sam~ day (.et up phase ): med ~ [SD) n ico li ll e cnillelltr.l trnll of 
1"1..5(3 4J ~ l ~!rnl (()effici~llt of variance (CV')'o] 28.20/0. Durinr, the firsl 6·mu nl h 
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2.6.4 Statistical methods 
Data in the text are expressed as mean with standard deviation (SD) and in the 
figures as mean with standard error of the mean (SEM). Where data was not 
normally distributed, the data is reported as median with inter-quartile range. 
Statistical comparisons were made with the appropriate parametric and non-
parametric tests. For unpaired normally distributed data a t-test was used (with 
Welch's correction if unequal variance) and the Mann Whitney U test for non-
parametric data. Where paired data were analysed, the paired t-test or Wilcoxon 
matched-pairs signed rank test were used. For data involving more than two 
categories, an analysis of variance (ANOVA) was used: One-way ANOVA or repeated 
measures ANOVA as appropriate. To correct for multiple comparisons, the Tukey test 
was used. A p value of 0.05 was considered significant. Statistical analysis was 
performed using GraphPad Prism version 5.00 for Mac, GraphPad Software, San 
Diego California USA, www.graphpad.com. OpenEpi: Open Source Epidemiologic 
Statistics for Public Health, Version 2.3.1. www.OpenEpi.com. updated 2010/19/09 
and Excel®, Microsoft corporation, USA. In Chapter 3 specific statistical methods 











3 Clarifying the latent tuberculosis infection status of 
participants and evaluating the reproducibility, cut-
point reliability and TST-mediated boosting ofIGRAs 
3.1 Introduction 
Latent TB infection (L TBI) is an asymptomatic state with no clinical or radiological 
evidence of active TB but with viable M. tuberculosis (M.tb) organisms within body 
tissues. It is likely that not all individuals exposed to aerosolised M.tb droplet nuclei 
become infected. Some individuals may possess sterilizing immunity and may thus 
'clear' the organisms without mounting an immunological response. In others, 
organisms are phagocytosed by alveolar macrophages148-151 and dendritic cells152, 153 
and are transported to regional lymph nodes where T cells are primed and clonally 
expanded,36 In such individuals, a detectable immune response to TB antigens is 
likely. 
There is no gold standard for the diagnosis of L TBI. The tuberculin skin test (TST) 
was the favoured method for diagnosing presumed L TBI until the development of 
IFN-y release assays (I GRAs). IGRAs, which include QuantiFERON®TB Gold In-Tube 
(QFT) and T-SPOT.®TB (TSPOT), detect peripheral blood-derived T-cell responses to 
relatively M.tb-specific RD-1 (region of diffentiation-1) antigens including early 
secreted antigenic target 6 kDa (ESAT-6) and culture filtrate protein 10 (CFP-10). 
IGRAs have been shown to be sensitive and specific laboratory markers of presumed 
LTBJ.16 However, it is well documented that there is not 100% agreement between 
IGRA and TST results.16 This is due, in part, to the TST being a composite 48 to 72 
hour readout of the pro-inflammatory effects of antigen presenting cells, chemokines 
and lymphocytes in response to purified protein derivative (PPD), a culture filtrate of 
M. tuberculosis. In contrast, IGRA's represent a single cytokine response (IFN-y) after 
overnight stimulation of T-cells by relatively M.tb specific antigens (ESAT-6, CFP-10 
and also TB 7.7).154 
Identification and treatment of individuals with latent TB infection (LTBI) is an 
important public health control measure, which substantially reduces the risk of 











risk of infection such as contacts, health care workers, immunocompromised 
individuals and children who may benefit from chemoprophylaxis.1s7 In vaccine and 
therapeutic studies, accurate detection of latent TB infection is crucial in the 
assessment of efficacy of the interventions being used.1S8 Furthermore, 
determination of TB infection status forms the basis of epidemiological studies, 
following the course of the epidemic and for assessing risk factors for TB infection 
such as smoking, HIV and malnutrition. Individuals who have no evidence of 
presumed LTBI infection (TST and IGRA negative) but strong evidence of exposure to 
infectious individuals may presumably have 'sterilising immunity' though this is 
unproven. They display no evidence of immunological memory to TB. These 
individuals may serve as negative controls in experimental conditions examining the 
immune responses to either antigen or live organism exposure. 
There are widely divergent views on how the TST and IGRAs should be use to screen 
for L TBI. The US Centres for Disease Control (CDC) guidelines recommend that a 
single IGRA can replace the TST.17, 18, 1S9 The UK-based National Institute for Clinical 
Excellence (NICEFO and revised 2008 Canadian guidelines19 however recommend a 
two-step strategy namely a TST followed by an IGRA (up to 6 weeks later in the UK 
guidelines) for the detection of L TBI. 
As persons with LTBI (versus no LTBI) may have different cytokine and antigen-
specific host immune responses and profiles, and to delineate this from the effect of 
CSE, it was necessary to determine and standardise the L TBI status of the 
participants. To confirm the nature of the LTBI status in this research project, a dual 
approach was undertaken using both the TST and IGRA. This however raised several 
issues for which there was little published data: 21, 22 1) What magnitude of variation 
could be expected in IGRA responses when subjects had a confirmatory IGRA 1 to 2 
weeks after the first. 2) If significant variability is demonstrated, what is the 
appropriate cut point that should be used to define L TBI status (a positive test or 
conversion/ reversion if serial testing is used)? 3) Would the TST administered at the 
time of the first IGRA potentially affect the second test by 'boosting' the interferon 











subject variability of the IFN -y responses in our local population when serially testing 
individuals as well as the effect of an antecedent TST on subsequent IGRA responses. 
3.1.1 Hypothesis 
In a TB-endemic setting the within-person variability of IGRAs is high, variability 
about the cut-point is significant and TST administration will boost downstream RD-1 
antigen-specific host immune responses. 
3.1.2 Specific aims 
1) To determine the magnitude of within subject variability in a cohort of 
individuals from a high burden TB country and its impact on determining 
assay cut-points. 
2) To determine the effect of TST administration on subsequent IGRA (QFT & 
TSPOT) responses. 
3) To define thresholds for conversion (previously negative IGRA or TST 
becomes positive on retesting) and reversion (previous positive TST or IGRA 
becomes negative upon repeat testing) of antigen responses. 
3.2 Methods 
3.2.1 Subject recruitment & testing schedule 
Healthy health care workers, medical students and volunteers were recruited to 
undergo repeated IGRA testing prior to, and following a TST as shown in Figure 3-1. 
Information regarding previous TB, HIV status, smoking status, alcohol consumption, 
current TB symptoms and estimated level of domestic and occupational exposure to 
TB during the previous 3 months was recorded from each participant. In addition, 
exposures were recorded during the first 3 months of the study. 
Symptoms of active TB were sought at each visit and all subjects were followed up for 
6 months following the final blood sampling to document the development of 











active disease and to record changes suggestive of healed disease. A specialist 
pulmonologist and radiologist independently reported the Chest x-rays. 
TST 
a.1ml (2TU RT23 PPD) 
"Reproducibility phase" .1 "Boosting phase" 
Visit 1 Visit 2 Visit 3 Visit 4 Day +3 Day +7 Day +28 Day +84 
(Day -21) (Day -14) (Day -7) (Day 01 
T-SPOT:TB, QuantiFERON"TB Gold In-Tube, 
Figure 3-1 Sutaject testinc scheelule 
Commercially available interferon-y release assays (IGRA), were performed over a 4-month period, divided 
by a pre and post TST phase. QuantiFERON®TB Gold-IT as well as T-SPOT.®TB including additional PPD and 
HBHA (heparin binding haemagglutinin) responses were measured at each time point. The TST (tuberculin 
skin test) was administered on day a following venesection and read on day 3 (~72 hours). 
Subjects were allocated to three risk groups based on TB exposure. 
• High risk: exposure to TB patients on the majority of working days 
(respiratory clinic and thoracic surgery wards). 
• Medium risk: hospital workers without recognised exposure to TB patients 
(gastroenterology outpatients, rheumatology clinics). 
• Low risk: non-hospital workers with no known TB exposure (preclinical 
medical students and healthy volunteers from low TB risk urban areas). 
However, as South Africa is a high TB incidence country, it was not possible to 
rule out exposures in even the low risk group. 
High and medium exposure risk subjects were recruited from Groote Schuur Hospital. 
In Cape Town, South Africa there is currently no policy for latent tuberculosis 
screening of health care workers. 
3.2.2 Latent TB infection testing 











3.2.2.1 Tuberculin skin test 
A tuberculin skin test was performed at the fourth visit defined as study day zero. 
O.lml (2TU) of RT23 PPD (Staten Serum Institute, Denmark) was injected 
intradermally on the volar aspect of the non-dominant forearm. The extent of 
induration was read on day three (approximately 72 hours) using the ballpoint pen 
method i.e. the edges of induration being detected by increased resistance to 
movement of a pen across the skin. The two widest distances were recorded and the 
average diameter calculated to determine the extent of the induration. As all subjects 
were HIV un-infected, and BCG vaccination occurs at birth in South Africa, a cut-point 
of ~10 mm was used to define latent TB infection as per the South African guidelines. 
3.2.2.2 Interferon gamma release assays 
Both commercially available interferon gamma release assays were used: 
QuantiFERON®TB Gold In-Tube (QFT-GIT) (Cell estis, Victoria Australia) and T-
SPOT.®TB (Oxford Immunotec, Oxford, England). Both assays were performed at 
each predefined time point. (Figure 3-1) 
3.2.2.3 QuantiFERON®TB Gold-In-Tube 
The QuantiFERON®TB Gold In-Tube assay, was performed according to the 
manufactures' guidelines contained in the assay kit.160 In summary, 1ml of whole 
blood was collected directly into the provided nil, TB antigen and mitogen tubes and 
transported directly to the laboratory. After 16- 24 hours incubation, the tubes were 
spun down and the supernatants stored at 4°C. 
The QuantiFERON®TB GOLD (In-Tube Method) ELISA was carried out according to 
manufacturer's instructions. The ELISA was performed manually without automated 
washing or pipetting. After incubation of the ELISA plate, the optical density was 
read using an Organon Keknika ELISA plate reader (Anthos Labtec Instruments 
GmbH) with a 450nm filter and a 620 to 650nm reference filter. The OD values were . 
then entered into the QFT Gold analysis software v2.5 to calculate the IFN-y values 












The T -SPOT.®TB assay was performed according to the manufacturer's 
instructions.161 Preparation of peripheral blood mononuclear cells (PBMCs) for use 
in the T-SPOT.®TB assay are described in Chapter 2. 
In summary, PBMCs were purified from whole blood drawn into a heparin containing 
blood tube. After washing and counting, PBMCs were plated at a final concentration 
of 250,000 PBMCs per 100!!1 medium/well. The standard 4 wells containing ESAT-6, 
CFP-IO, positive and negative controls were prepared with four additional duplicate 
wells containing PPD 20!!g/ml (Staten Serum Institute, Denmark), and HBHA 
100!!g/mI162, 163 a novel antigen that may distinguish latent from active TB to evaluate 
within-subject variability for this antigen. After 24 hours incubation in a humidified 
C02 incubator, the plate was washed and incubated with the provided conjugate and 
substrate. Plates were allowed to dry overnight before spot counting was performed. 
Automated spot counting was performed using the automated AID reader (AID 
Autoimmun Diagnostika GmbH) employing standard reading software. Spot count 
settings were provided by Oxford Immunotec: (intensity: minimum = 35, maximum 
=250; size: minimum=70, maximum =20000; gradient: minimum =10, maximum =90) 
3.2.2.4.1 Assessing EllS POT automated reader variability 
It has been documented that IGRA responses are not constant over time. To establish 
the variability in a high burden setting, it was important to first establish the 
contribution of technical factors to variability. To determine the technical 
machine/apparatus variability for both assays, repeat analysis of the same assay 
plates was undertaken. 
3.2.2.4.1.1 Automated ELISPOT count variability 
For the assessment of apparatus induced variability in the ELI SPOT assay, three 
separate plates were read daily for three days using an AID EliSpot reader 











supplied by Oxford Immunotec were used throughout the study without changing the 
settings on the apparatus. Manual addition of spots (by marking spots thought by the 
operator to have been missed by the automated camera reading) was not performed 
and "spot removal (unmarking spots that were thought by the operator to have been 
over read) was only done if artefacts were present. A spot count of 250 spots was set 
as the limit for the maximum readable spot count. Higher counts were not analysed 
in the automated reader reproducibility tests. A total of 216 wells were read with the 
highest count of 129 spots per well. 
3.2.2.4.1.2 QuantiFERON®TB GIT ELISA reader variability 
For technical reasons it was not possible to assess the intra-test variability of the 
QuantiFERON®TB ELISA, in the same manner as performed for the T-SPOT.TB test. 
Instead, 'repeat counting' of the same ELISA plate was performed over two hours to 
determine the within-test variability. The ELISA plate was kept in the dark for the 
entire 2-hour period. 
3.2.3 Statistical methods used for the analysis of variability and boosting 
The data collected represented multiple tests, from multiple individuals, at multiple 
time points. Repeatability was assessed by the method of Bland.164 Wilcoxon-
matched pairs test, and where necessary, Mann-Whitney tests were used to compare 
subject time points following the TST. A P value of <0.05 was considered significant. 
Specific statistical methodology was required to perform the analysis of within 
subject variability over time, given the number of subjects, tests and time points. This 
analysis was undertaken with assistance from the faculty of statistical sciences at the 
University of Cape Town. (Section 3.2.3.1 and 3.2.3.2) 
3.2.3.1 Linear mixed effects model 
Linear mixed effect models were fitted to the logged QFT values assuming they were 
approximately normally distributed. Residual plots from the fitted models showed 











To assess reproducibility of the data, linear mixed effects models were fitted by 
residual maximum likelihood (REML) to the T-SPOT.®TB spot counts (TB antigen 
wells minus nil well) and logged (to normalize the distribution) QuantiFERON®TB 
GIT IFN-y responses (TB antigen minus nil). These models allowed the difference in 
both the mean change (i.e. expected values) at each time and the correlation structure 
and variance to be estimated (i.e. their covariance structure) and assessed. Akaike 
Information Criterion (AIC) was used to assess covariance structure (model fit). This 
criterion adjusts the log-likelihood for the number of parameters fitted assuming the 
same pattern for the mean value, so that models with different covariance can be 
compared. Residual plots from the fitted models showed that this assumption was 
valid. Assessment of variability was made from the REML plots as well as a 
coefficient of variance analysis (see3.2.3.2). 
3.2.3.2 Coefficient of variance analysis 
Mean IGRA responses were calculated for each subject over the four visits during the 
reproducibility phase. At QFT IFN-y values below 0.1, small numerical changes 
conferred very high variance in the QFT responses. As values below 0.1 are clinically 
meaningless, the final analysis was performed after excluding these values. Within-
subject variability was calculated by determining the mean standard deviation (SO) 
for all subjects over the reproducibility phase. Expressing this SO value as a 
percentage of the IFN-y response enabled calculation of the 95% confidence intervals 
(2S0) and hence test variability. For the T-SPOT.®TB responses, mean and standard 
deviations were calculated as above. Within-subject variability was reported as a 












3.3.1 Assessment of within-test variability of interferon gamma release assays 
3.3.1.1 Technical automated ELISPOT reader and ELISA within-test 
variability 
The AID ELiSpot automated reader was assessed by recounting the same three plates 
over three days as described previously. When repeat counting of the same wells 
over three days was performed, an increase in the variability (as denoted by the 95% 
confidence intervals) with increasing spot counts was noted. At spot counts of 0-2 a 
change of only one spot was accounted for by the 95% confidence intervals around 
the mean. This increased to 3 spots at values of greater than three. Table 3-1 
Table 3-1 Repeat counting of 216 ELiSPOT wells using the automated reader 
Spot count range Mean count SO Variance 
Spot counts 0-2 0.7 0.4 0.2 
Spot counts 3-8 5.7 1.4 3.7 
Spot counts 9-15 11.4 1.4 4.5 
Spot counts 16-30 21.1 2.2 10.8 
Spot counts >30 42.1 2.3 18.9 
3.3.1.2 QuantiFERON®TB GIT ELISA reader variability 
It was not possible for technical reasons to assess the ELISA machine variability in the 
same manner as the ELI SPOT reader. A single QuantiFERON®TB GOLD IFN-y ELISA 
plate was thus read repeatedly over two hours. (It is recommended by the 
manufacturer that the plate be read within 5 minutes of stopping the reaction.) No 
significant change in IFN-y values was noted within this 5-minute period when three 











Table 3-2 Variability in ELISA plate IFN-y values when optical density (00) readings were 
repeatedly performed over 2 hours 
Repeated readings at different time points 
Omin 2.5min 5 min 30min 60min 90min 120min 
Subject IFN-y IFN-y IFN-y IFN-y IFN-y IFN-y IFN-y Mean SO 
101 0.01 0.01 0.01 0.00 0.01 0.01 0.01 0.01 0.004 
102 0.02 0.00 0.01 0.01 0.02 0.01 -0.01 0.01 0.011 
103 0.55 0.55 0.55 0.55 0.55 0.54 0.52 0.54 0.011 
104 0.51 0.53 0.53 0.50 0.52 0.50 0.50 0.51 0.014 
105 0.03 0.06 0.06 0.02 0.06 0.05 0.04 0.05 0.016 
106 0.19 0.18 0.17 0.18 0.17 0.16 0.16 0.17 0.011 
107 2.39 2.36 2.37 2.38 2.40 2.39 2.39 2.38 0.014 
108 1.04 1.05 1.06 1.05 1.06 1.06 1.05 1.05 0.008 
109 0.05 0.05 0.05 0.05 0.02 0.05 0.02 0.04 0.D15 
1010 0.06 0.06 0.06 0.06 0.06 0.07 0.07 0.06 0.005 
1011 0.14 0.14 0.14 0.14 0.14 0.13 0.13 0.14 0.005 
1012 0.63 0.62 0.63 0.62 0.62 0.61 0.59 0.62 0.014 
1013 -0.05 -0.06 -0.05 -0.06 -0.08 -0.10 -0.10 -0.07 0.022 
1014 0.00 0.00 0.00 0.02 0.03 0.05 0.07 0.02 0.028 
10 15 0.01 0.01 0.02 0.01 0.01 0.02 0.01 0.01 0.005 
10 16 0.01 0.01 0.00 0.01 0.01 0.01 0.01 0.01 0.004 
10 17 0.01 0.00 0.00 0.01 0.01 0.01 0.00 0.01 0.005 
1018 -0.36 -0.35 -0.35 -0.35 -0.36 -0.35 -0.35 -0.35 0.005 
1019 -0.19 -0.19 -0.20 -0.19 -0.20 -0.19 -0.18 -0.19 0.007 
3.3.2 Demographic characteristics of study participants 
Twenty-eight healthy volunteers were recruited. Four participants failed to complete 
the study (one participant withdrew after the first visit, one did not receive a TST, one 
did not return for blood testing after the TST, and one subject withdrew consent 
during the study period). Thus, a total of 26 subjects were available for the 
reproducibility analysis and 24 for boosting analysis. Of the 26 subjects, 11 were 
classified as high risk, 10 as medium risk, and 5 as low risk for exposure. 
All subjects were HIV negative and reported receiving BeG vaccination at birth. A 
single subject recorded having TB disease 40 years previously. The exposure risk 
groups were similarly matched except that the low risk group was younger and 
exclusively of European ancestry. (Table 3-3) No episodes of unprotected TB 











Table 3-3 Demographic details of study participants 
Total High risk Medium risk Low risk 
Number of subject 26 11 10 5 
Age mean (SD) 39 (10) 43 (7)+ 41 (10)* 29 (11)+* 
Racial group 
Black African 4 (15%) 3 (27%) 1 (10%) 0 
Mixed ancestry 14 (54%) 7 (63%) 7 (70%) 0 
European ancestry 8 (31%) 1 (10%) 2 (20%) 5 (100%) 
Current smoker 6 (23%) 2 (18%) 3 (30%) 1 (20%) 
HIV status All HIV negative 
BCG vaccinated All vaccinated 
Previous TB (n) 1 1 0 0 
+ p=O.OS High vs. Low • p< 0.01 Medium vs. Low 
3.3.3 IGRA and TST agreement/discordance 
A total of 88 paired IGRA (T-SPOT.®TB and QFT-GIT) results were available for 
comparison prior to the TST administration. Multiple conversions or reversions, over 
the three week testing period, resulted in rates of discordant T-SPOT.®TB and QFT-
GIT results varying from 4% (1/25) to 11.5% (3/26). Overall, the rate of IGRA 
discordant results was 10% (9/88). TST positive IGRA negative discordance varied 
between 20% (5/25) to 24% (6/25) for QFT-GIT and 24% (6/25) to 32% (8/25) for 
T-SPOT.®TB. All discordant results (except one paired test at visit 4) were TST 
positive / IGRA negative. Rates of positive IGRA and TST results are shown in Table 
3-4. 
Table 3-4 Rates of QuantiFERON"'ra Gil aM T-SPOT:TI tfiscerdance durine the 
reproducibility (pre-TST) phase 
IFN-y release assay results TST results 
. 
Visits prior to No. of evaluable QFT GIT positive n T-SPOT. TB Discordant IGRA TST positive n 
TST paired results (%) positive n (%) results n (%) (%)* 
Visit 1 13* 7(54%) 5 (38.5%) 2 (15.4%) Not applicable 
Visit 2 25 9 (36%) 8(32%) 1 (4%) Not applicable 
Visit 3 24 9 (37.5%) 8 (33.3%) 2(8%) Not applicable 
Visit 4 (day of 
26 10 (38.5%) 9 (34.5%) 3 (11.5%) 15 (60%) 
TST) 
IGRA discordance was calculated for each visit using the available results. * No low risk subjects were 












3.3.4 Within-subject variability 
All 5 low exposure risk participants were IGRA negative and remained IGRA negative 
through out the study. Seven of the 21 medium or high-risk subjects had a 
conversion or a reversion around the manufacturer predefined cut-point (defined as 
~ 6 spot forming cells per well (SFC/well) for T-SPOT.®TB and IFN-gamma ~ 0.35 
IU Iml for QFT -GIT), at least once during the 3 week (4 test) reproducibility phase. 
(Table 3-5) Conversions or reversions were only seen in the high and medium 
exposure risk groups and occurred more commonly for the T -SPOT. ®TB (6 episodes) 
than for QFT-GIT (1 episode) p =0.049. (Table 3-5) If the FDA recommended T-
SPOT.®TB borderline zone of 5, 6 and 7 spots was applied to the results, 1 less 
conversion and 1 less reversion would have been defined. 
Table 3-5 Subjects demonstrating a change in IGRA status during the reproducibility 
(pre-TST) phase of the study 
Rept'd.cthility phase risits (1 weeks) 
Subject IGRAassay 
Visit 1 Visit 2 Visit 3 Visit 4 








QFT- GIP Positive (3.29) Positive (3.29) Positive (2.89) Positive (3.09) 
ls.smm 
TSPOT.®TB* Positive (0/6) Positive (6/7) NEGATIVE (3/5) Positive (5/14) 
QFT- GIT Positive (10.56) Positive (1.61) Positive (5.67) Positive (1.30) 
19mm 
T-SPOT.®TB NEGATIVE (0/0) Positive (0/22) Not done Positive (0/19) 
QFT- GIT Positive (1.64) Positive (0.95) Positive (0.99) Positive (0.66) 
19mm 
T-SPOT.®TB POSITIVE (1/6) Negative (3/3) Not done Negative (1/4) 
QFT- GIT Positive (3.61) Positive (2.02) Positive (3.70) Positive (1.07) 
No test 
T-SPOT.®TB NEGATIVE (1/3) Positive (4/6) Positive (60/85) Positive (17/7) 
QFT- GIT Positive (3.66) Positive (2.97) Positive (2.97) Positive (3.97) 
18.5mm 
T-SPOT.®TB Positive (0/7) Positive (0/10) Positive (1/60) NEGATIVE (0/0) 
QFT- GIT Negative (0.00) Negative (0.34) Negative (0.00) Negative (0.00) 
Omm 
T-SPOT.®TB Negative (0/0) Negative (0/0) Negative (4/2) POSITIVE (8/0) 
QFT- GIT Negative (0.23) Negative (0.10) POSITIVE (0.51) Negative (0.15) 
22mm 
T-SPOT.®TB Negative (0/0) Negative (3/1) Negative (2/1) Negative (5/2) 
The details of subjects who converted or reverted (defined as crossing the predefined manufacturer 
suggested cut-point of 0.35 IU/ml for QFT-GIT and ~ 6 spots for T-SPOT:TB) are shown. Subjects 1 and 12 
had T-SPOT:TB values within the FDA recommended borderline zone and would not be considered a 
conversion or reversion. All other subjects remained either positive or negative over the three-week 
reproducibility phase prior to tuberculin skin testing (TST) administration at visit 4 (day 0). The categorical 
results as well as the IFN-y responses (TB antigen minus nil) are detailed for each individual. Conversions 
and reversions are indicated by capital letters at the specific time-points. + QFT-GIT values are IU/ml. *T-













For the QFT -GIT assay, a linear mixed effects model, as well as coefficient of variance 
analysis was used to determine within-subject variability. Ninety-five percent of the 
variability of IFN-y responses (TB antigen minus nil control) occurred within 80% of 
the mean IFN-y response. Therefore an 80% increase or decrease in 
QuantiFERON®TB GIT IFN-y responses over the short-term can be regarded as within 
normal limits. 
For the T-SPOT.®TB assay, variability in IFN-y responses (TB antigen minus negative 
control SFC/well) increased with increasing spot counts. At a response of between 3 
and 8 spots, using a coefficient of variance analysis, a change of 3 spots in either 
direction accounted for 95% of the within-subject variability in either the ESAT -6 or 
CFP-10 well. The linear mixed effects model confirmed this. PPD, in contrast to 
HBHA and the standardised IGRAs, showed greater variability over time. (Figure 3-2) 
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Figure 3-2 Within subject variability for QuantiFERON"TB GIT and T-SPOT."TB including 
PPD and HBHA responses 
Reproducibility for the Interferon gamma release assays was measured over four visits: (A) 
QuantiFERON°TB-Gold-IT, (B) T-SPOT:TB using ESAT-6 and CFP-lO, and (e) PPO and HBHA ELiSPOT assay 
Log transformed data is presented. The manufacturer's predefined test cut-point is indicated by a stippled 
horizontal line, except PPO and HBHA where a laboratory derived cut-point was used. A dashed line depicts 
individual subjects who crossed the cut-point. 
3.3.5 Tuberculin skin test mediates IGRA boosting 
A significant increase in the mean QFT-GIT IFN-y levels was noted by day seven post-
TST, in comparison to the IFN-y levels observed during the pre-TST period (p=O.OOS). 
(Figure 3-3A) T-SPOT.®TB ESAT-6 (p= 0.029) and CFP-l0 (p=0.006) spot counts 
were also significantly raised by day 7, as compared to the spot counts observed 
during the pre-TST period. (Figure 3-3B) By contrast for PPD (p= 0.02) and HBHA 
(p=0.03), elevated spots counts were evident as early as day three post-TST. (Figure 
3-3C) In several subjects, elevated levels of IGRA responses were detectable for up to 
three months after the TST. 
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Figure 3-3 Boosting of interferon gamma responses following TST administration 
Post TST boosting of QuantiFERON®TB GOLD-IT (A), T-SPOT.®TB using ESAT-6 (B1) and CFP-1O(B2l. and 
PPD(C1) and HBHA(C2) ELiSPOT assay. The summation graph (right panel) shows mean IFN-y responses 











Because an ±80% variation in QFT-GIT IFN-y levels and ±3 spots in T-SPOT.®TB 
counts was observed during the reproducibility phase, boosting of IFN-y responses 
was defined as a >80% increase in IFN-y or a 3 spot increase from the pre-TST IGRA 
response. Boosting was demonstrated in 75% (6/8) of pre-TST IGRA positive 
subjects and in 12.5% (3/16) ofpre-TST IGRA negative subjects (who also converted 
to an IGRA positive status. (Table 3-6) All the IGRA negative subjects who boosted 
were TST positive. Details of IGRA negative subjects who boosted are outlined in 
Table 3-6. A detailed comparison of both IGRA assays results is contained in Table 
3-7. 
Table 3-6 Characteristics of individuals who were QuantiFERON'"TB GIT or T-SPOT."'TB 
negative, or with borderline results, who displayed boosting of their responses after 
TST administration 
Visit 
Pre TST "reproducibility phase" Post TST "boosting phase" 
Test format Visit 1 
Visit 
Visit 3 
Visit 4 Day Day Day Day 

































0 6 3 5 
--.-~---.----~ ~- ~----------- - -------------- - -- ---- ---_.--. 
6 7 5 14 
3.29 5.59 2.89 3.09 
No 1 No 2 
test test result 
result 3 available 2 
availabl 
e 0.19 0.16 0.26 
1 3 No 1 
test result 
6 3 available 4 
1.64 0.95 0.99 0.66 
0 24 33 40 
5 25 15 38 
2.48 9.72 12.29 11.72 
3 11 0 3 
3 0 0 0 
----------------_._--
0.18 5.30 1.59 4.20 
3 32 26 9 
._---------_ .. 
5 12 7 17 
----
1.10 7.20 11.04 5.12 
For each subject the individual IGRA results (where available) are tabulated across the table. The TST was 
administered at visit 4 (Day O).SFU= Spot forming units. Results in bold indicate where a significantly 











Table 3-7 Comparison of QuantiFERON'"TB GIT and T-SPOT:TB variability, borderline 
zones and proposed threshold for conversion 
QuantiFERON'"TB GIT T-SPOT.'"TB 
Manufacturer defined assay cut-point > 0.35 IU/ml ~ 6 Spots * 
Within- subject short term variability ± 80% of IFN-y response ± 3 Spots 
Borderline or uncertainty 0.2-0.7IU/ml 4 - 8 spots (inclusive) 
Proposed conversion threshold 
Increase from below 0.35 to above Increase from below 6 to above 9 spots 
0.7 IU/ml (inclusive) 
*The FDA borderline zone for result interpretation includes values of 5, 6 & 7 spots. 
3.4 Discussion 
The results of this study confirm that short-term variability in IGRA responses is 
common. During a three-week observation period 7/26 (27%) subjects 
spontaneously converted and reverted around the cut-point at least once. It is thus 
necessary, when interpreting IGRA results, to consid r within-subject variability and 
assay reproducibility. Secondly there was clear evidence of boosting of the IGRA 
responses in IGRA positive ("sensitized") subjects by day seven post-TST 
administration, which in several subjects persisted for at least three months. 
Significantly, boosting was not evident before day 3. Moreover, in 12.5% (3/16) of 
IGRA negative subjects boosting resulted in conversion to IGRA positivity (using 
manufacturer-recommended cut-points). The increases in IFN-y levels and spot 
counts were significantly greater than the random within-subject variability observed 
in these subjects. 
Data about within-subject variability and TST-induced boosting of IGRA responses 
are limited.165, 166 These data are summarised in Table 3-8 and Table 3-9. A recent 
study evaluated 3-month post-TST IGRA responses and found a 6% conversion rate 
(post-TST values were all close to the cut-point).165, 167 It is not clear from the 
reported results however, how much of this represented TST -mediated boosting 
rather than random within-subject variation. Pai and colleagues, in a study of 14 
subjects tested 4 times over 12 days, found that most within-subject variability could 











performed in high burden setting, evaluated a broader range of commercially 
available IGRAs, additional novel antigens, and studied variability over a longer 
period. Our results confirm that 95% of the variability over 3 weeks can be explained 
by a change, in either direction, of 80% of the average ELISA-derived IFN-y value 
(QFT-GIT) or a 3 spot change in the mean T-SPOT.®TB spot count. 
Instrument-specific variability contributed little to variability around the 
manufacturer-recommended, cut-points. At higher levels, there is greater within-
person variability. This may be related to a hitherto unexplained biological effect in 
addition to technical factors, as both the ELISPOT and ELISA plate reader have 
technical limitations reducing the accuracy of results at high levels. As the 
documented variability in both assays increase at higher levels, these variability 



















14 HeWs Likely but all 
Over a 2 weeks period, 2 of 14 persons had a QFT Subjects who had 
reversion. conversions or 
Veerapathran India (clinical and tests were All 
QFT-GIT 0,3,9,12 Yes With quantitative results, an increase in 16% of IFN-y reversions had initial 
et al 127 '08 (High) laboratory done within a vaccinated 
workers)* 2-week period 
response was considered within the 'normal' expected values close to the 
within subject variability. cut point 
Over a 3-week period, 7 of 26 persons had a conversion 
Subjects who had 
Likely but all QFT-GIT or reversion (1 QFT and 6 TSPOT.TS). 
Van Zyl-Smit et 
South 26 HeWs and 
tests All T- O, 7, 14, With quantitative results, a change of ±80% of any given 
conversions or 
Africa low risk 
were 
Yes reversions had initial 
al 126 '09 
(High) volunteers+ 
done within a vaccinated SPOT.TS 21 IFN-y response (QFT-GIT) or ±3 spots (T-SPOT.TS) was 
values close to the 
3 week period considered to fall within the 'normal' expected within 
cut point 
subject variability. 
27 HeW's Likely but all 
Over a 3-day period, no changes in qualitative results 
Detjen et al 168 South (Clinical and tests All 
were noted for 15 persons. With quantitative results, 
Africa 
were 
QFT-GIT 0,3 Yes considerable intra-individual variability occurred in the 
'09 
(High) 
laboratory done within a vaccinated 
magnitude of IFN-y responses; intra-class correlation 
workers)* 3-day period 
was 0.80. 
Selknap et al 169 
Unlikely and 
QFT-GIT Over a 3 week period, 7 of 117 (6%) persons had a 




done within a 
Unknown T- 0,7-21 Yes conversion or reversion with QFT-GIT and 8 of 105 
not yet available 
3 week period 
SPOT.TS (7.6%) with T-SPOT.TS 
Ringshausen et Germany 52% Over 18 weeks 6/18 (33%) had a reversion and 3/ 162 a 
Some subjects had 
al 170 '10 (Low) 
182 HeWs Unlikely 
vaccinated 
QFT-GIT 0, 126 No 
conversion 
TST 3 months prior 
to first IGRA 
* India and South Africa are high burden TB countries with high risk of exposure to health care workers (HCW). HCW's were divided into two groups - medical doctors or 
laboratory workers. + South Africa is a high burden TB country with high risk of exposure to health care workers (HCW). HCW's were stratified into: High risk (daily potential TB 
exposure) Medium risk (HCW, but no daily expected TB exposure) Low risk group (pre-clinical medical students and non-clinical volunteers) # updated preliminary data presented 
at the Second internationallGRA symposium. Daley C. Evaluation of interferon-g release assays in the diagnosis of latent TB infection in US healthcare workers: preliminary results 














Table 3-9 Studies on boosting effect ofTST on IGRA results 
Country/ Time points 
Paper Population recruited Subjects TST IGRA (days after TST 
(TB burden) administration) 
South Africa QFT-GIT 
van Zyl-Smit et 
al126 '09 
HCW's and healthy 24 2TU RT23 TSPOT.TB 0,3,7,28,84 
volunteers (High) 
USA 
Baker et al 171 
Immigrants/ refugees 
in US less than 6 114 5TU PPD-S QFT-GIT 0,14-112 
'09 
months (mainly high 
burden countries) 
Belknap et al 172 USA 
'09 HCWs (equal number 
5TU QFT-GIT 7-21+ 125 
Tubersol TSPOT.TB 
[abstract] # of TST +/TST -) (Low) 
Vilaplana et al Spain ELiSPOT & 
173 '08 TB researchers (Low) 








HCWs in pulmonary 
S9 2TU RT23 QFTG 
0,14-28 
medicine working >1 
year (Medium) 




'08 cohort (Low) Tubersol 
Richeldi et al
17S Italy, paediatric TB QFT-G 
70 & 81 5TU PPD S 0,56-77 
'08 * contacts (Low) /QFT-GIT 
Study 
Study results summary Comment conclusion 
on boosting 
Day 3: no categorical changes 
Day 7: Significant increase in mean IFN-y, QFT-GIT 
IGRA negative subjects 
1/12 (8%) negative to positive, 5/8 (62.5%) positive 
tin INF-y responses 
who boosted were TST Yes 
Day 7: T-SPOT."TB 2/16 (12.5%) negative to 
positive. 
positive,6/8 (75%) positive t in INF-y responses 
<35 days: 2nd IGRA 87%t in INF-y responses, *TST positive boosted 
35 -112 days: 69%2
nd 
IGRA tin INF-y responses by 82% whereas TST 
Yes 
IGRA positive 86% showed boosting* negative by 62% 
IGRA negative 68% showed boosting (p=0.06) 
Exact testing days not 
QFT-GIT: 12 (10%) negative to positive, 
specified 
T-SPOT."TB: 12 (10%) negative to positive 
Only IGRA negative 
Yes 
recruited 
TST status did not 
predict boosting 
IGRA neg / TST neg 5-60 x t@ day 7* (4 subjects) 
* Depending on antigen 
IGRA pos / TST pos 20-400 x t @ day 7* (3 
subjects) 
used Yes 
IGRA pos /TST neg 5-80 x t @ day7 * (2 subjects) 
+ Cellestis Ltd. 
Median IFN-y responses t @ visit post TST 
0.05 to 0.19IU/ml increase in TST positive group 
(p=O.Ol) 
Yes 
IGRA neg/ TST pos 3/18 (16.7%) became IGRA 
positive IGRA neg/TST neg zero became positive 
(p=O.l1) 
Day 84: 3/48 (6%) QFT negative became positive 
Non significant trend 
Day 84: Mean IFN-y responses t in initially QFT 
for inconsistent QFT 
Yes 
results to be discordant 
positive subjects 
by TST at baseline 
QFT-G: 1/51(2%) negative became positive (no 
change in mean QFT levels in negative subjects) No 










Country/ Time points Study 
Paper Population recruited Subjects TST IGRA (days after TST Study results summary Comment conclusion 
(TB burden) administration) on boosting 
The Netherlands 
*Boosting shown only 
Leyten et al 176 known TST Omm 0,3, (10,11)* 
Day 3: no categorical changes in two with delayed No @ 3days 
'07 (n=15) and known TST 
66 2TU RT23 
QFTGIT 
Dayl0: 1 negative to positive processing, and this Yes @ 10 
~10mm (n=51) (Low) 




0,42 Day 42: IGRA neg/ TST neg; 5(15%) became 
Only concordant 
Igariet al l77 '07 students, negative 33 3TU PPD QFT-G baseline negatives had Yes 





No qualitative results 
Naseer et al. 178 Subjects not specified 
Not 
0,2,42 Day 42: 3/9 (33%) QFT negative became positive 
reported 
'07 No Hx of TB contact 
10 reported QFT-G 
Day 42: ° T-SPOT negative became positive No boosting if blood Yes 
TSPOT.TB drawn at TST 
or disease (Low) 
administration 
Cellestis Int, 
IGRA negative 3 became positive (total number of 
Austra I ia - QFT Not Industry study not 
USA Package 
USA (Low) 530 
reported 







Richeldi et al 180 Italy 
0, 9, 15 24 
Month 24: all subjects remained IGRA negative, 
All subject TST and 
TB contacts 
44 5TU PPD 5 TSPOT.TB months (Post TB IGRA negative at first No 
'06 * (Low) 
exposure) 
although 3 converted by TST. 
visit 
This study primarily 
Nguyen et al 181 USA 5TU 0,84 (3 mol Day 84: 1/27 (4%) negative became positive 
investigated TST-TST 
'05 
Infectious disease 48 
Tubersol QFT- TB (p=0.10) 
boosting (PPD) No 
cohort (Low) responses) and 
discorda nce. 
-----------
# Updated preliminary data presented at the Second internationallGRA symposium. Daley C. Evaluation of interferon-g release assays in the diagnosis of latent TB infection in US 












In this high burden setting different exposure categories were used to control for 
chance M.tb exposure being an explanation for the observed boosting of RD-l 
responses. Thus, given similar boosting in the high and medium HeW exposure 
categories, and the temporal relationship of boosted responses to the TST, from a 
stable baseline, the effects seen are unlikely to be attributed to chance M.tb exposure. 
Secondly, for the purposes of generalising within-person variability to clinical 
practice, a diverse group of participants was needed. The finding that variability 
occurred in all groups increases the robustness of the findings. 
These data have several important implications. Firstly, they suggests that variation 
around the assay cut-points of 0.35IU/ml for QFT-GIT and 6 spots for TSPOT TB is 
present and assay results near these cut points should be interpreted with caution 
and within the clinical context. This borderline zone: (0.2 to 0.7 IUlml for QFT-GIT 
and 4 to 8 spots (inclusive) for T-SPOT.®TB) is in keeping with the "uncertainty zone" 
proposed for interpretation of serial IGRA results.182 Also, clinicians should be made 
aware of this and should not view minor elevations in IGRA test results as confirming 
new infection when serial testing is performed in health care worker monitoring. This 
is important as IGRA results are often dichotomised when reported to the referring 
clinician. Laboratories should provide absolute IFN-y or spot count results and avoid 
simply reporting results as positive or negative. 
Secondly, it provides clinically appropriate thresholds for conversions and 
reversions. The data supports the recommendation by Pai et al that a higher 
threshold (e.g. 0.70 IU/ml) for QFT-GIT should be used to define conversions.183 In 
order to avoid minor changes around the cut-off values being misinterpreted as real 
conversions. In addition these data provide evidence for the extent of an uncertainty 
zone for the TSPOT.TB assay of 4-8 spots, which has not previously been reported. 
Furthermore, a 9 or greater spot count threshold for a T -SPOT.TB assay conversion 
would be comparable to that suggested (0.7IU/ml) for QFT-GIT. Thirdly, by taking 
into account within-subject variability, boosting of IFN-y responses by the TST can 
clearly be defined (i.e. distinguishing boosting from random day-to-day variability). 
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Figure 3-4 Graphic depiction of the concept of "conversion and reversion" and "within-
subject variability" 
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This study prospectively evaluated both commercially available IGRA formats (T-
SPOT.®TB and QFT -GIT) using pre-specified end-points, after first defining within-
subject variability. These data indicate that the QFT -GIT or T -SPOT.®TB test result 
may be misleading if performed more that 3 days after TST in patients being 
evaluated by the 2 step strategy. Fortuitously this is a convenient time-point as it 
generally coincides with the date on which the TST should be read. A recent study 
from the Netherlands found no evidence of QFT-GIT boosting at the 3 day post-TST 
time-point but two subjects whose repeat testing was delayed to day 10 showed 
evidence of boosting.176 
A further significant observation in this study is that boosting by TST was more 
common in IGRA positive (Le. sensitized) subjects. This finding is in keeping with 
previously published data that suggest that only IGRA or TST positive subjects show 
post-TST boosting. 174 It is therefore reasonable to speculate that pre-dominantly 
those with pre-existing effectors memory T-cell responses, and hence L TBI, will boost 
their subsequent responses. However, the small sample size precludes any definite 
conclusions and several IGRA-negative/TST -positive subjects did boost their 
responses (it is possible that these subjects were sensitized to TB antigens, but not 
detected by the IGRA). It is interesting that a single TST, which contains only 
nanogram amounts of ESAT-6 and CFP-10, is sufficient to elicit a systemic T cell 
response. This supports the concept that the IGRAs detect recent exposure to TB 
antigen and hence LTBI. It is not clear what number of latent organisms (burden of 
infection) is required for a positive test result. 
The inability of RD-1 antigen responses to distinguish latent from active TB has 
prompted the search for alternative M.th-specific antigens. One such novel candidate 
is HBHA.188, 189 It is therefore useful to have data on within-subject variability for this 
antigen and the effect of TST on the results of this test. Interestingly, like PPD but in 
contrast to RD-1 antigens, HBHA-boosted responses were detectable by day 3. The 
reasons for this are unclear but may be related to differential modulation of antigen-











There are several limitations of this study. Firstly, the study population is small. 
However, as each subject had multiple tests performed over several weeks the 
number of tests evaluated was large (greater than 300). The conclusions are thus 
both clinically and statistically valid. On the other hand, as not all subjects 
demonstrated boosting in T cell responses, the study may not have been adequately 
powered to exclude the possibility that some subjects might demonstrate RD-l 
boosting before day three, post-TST. However, Ley ten and colleagues observed no 
QFT -GIT boosting at day 3 post-TSTP6 
Due to the high tuberculosis exposure in the health care workers, transient chance 
exposure as the cause of boosting cannot be ruled out. However, this is unlikely given 
that similar boosting patterns were seen in the different exposure risk categories and 
that the same boosting pattern was observed over several months of recruitment. It 
remains unclear how long the booster effect of tuberculin skin testing persists. 
There are three conclusions: 
Firstly, I have shown that there is significant within-subject variability of IFN-y 
responses over time. This variability can be used to define an 'uncertainty zone' 
around the cut-point where results are unreliable and necessitates repetition of the 
test. 
Secondly, based on these results, a threshold for a 'true conversion' in a high 
exposure environment has been proposed: An increase in IFN-y response from below 
0.35 IV/ml to above 0.70 IV/ml for QuantiFERON®TB Gold-IT, and from below 6 
spots to above 9 spots for the T-SPOT.®TB assay. This may explain much of what 
previously were regarded as conversions and reversions because of 'movement' 
across the cut-point. Larger long-term studies in different populations are necessary 
to establish the relevance of these findings to other parts of the world. 
Thirdly I have confirmed that IGRA results, in both IGRA positive and to a lesser 
extent in IGRA negative subjects, are influenced by recent TST administration. 











three-day cut-off appears to be a safe window within which to perform a 
standardised IGRA after TST. Results of IGRAs repeated one week after an initial 
IGRA test and TST may be falsely elevated. 
A gold standard definition for latent TB infection remains elusive and given the 
variability over time and discordant IGRA-TST results, LTBI remains a presumptive 
diagnosis. Individuals, who are both TST negative and have very low IFN-y response, 
are likely to be uninfected and test results are likely to remain negative over time. By 
contrast, individuals who have a strong TST response (>10mm) and IFN-y responses 
above the defined manufacturer's cut point for positivity are likely to be latently 
infected. Individuals who have either discordant results or results within the 
'uncertainty zone' should not be viewed as having LTBI. For researchers, stratifying 
subjects as double negative (IGRA and TST) or double positive provides greater 
confidence about the absence or presence of T cell memory. It remains unclear on 











4 Determination of mycobacterial burden 
4.1 Introduction/Background of assays 
Determination of mycobacterial load is an important measure in many laboratory and 
clinical studies including those assessing disease severity and the efficacy of new 
therapies and tuberculosis (TB) interventions,131-133 all of which have now become 
urgent with the emerging public health threat of mUltidrug and extensively drug 
resistant TB.192, 193 The usual method used for clinical purposes and in some studies 
is the grade of smear positivity on microscopy (scanty, 1+ 2+, and 3+). It is used to 
evaluate the infectiousness of cases in the context of public health contact tracing and 
screening,141, 194 but at best is semi quantitative. More accurate determination of 
mycobacterial numbers was required for the work described in this thesis, examining 
the effects of cigarette smoke on pulmonary immune responses and the 
mycobactericidal-modulating effect of cigarette smoke extract (CSE). 
Such methods are also necessary in translational research in research on drug and 
vaccines for tuberculosis, whether in humans or murine models of disease.23-26 
Although several techniques for determining mycobacterial burden exist, each is 
associated with significant limitations such as inaccuracy, turn-around-time, limited 
reproducibility, cost, methodological complexity, relative discriminative ability and 
detection threshold. 
Culture on solid media using colony-forming units (CFU) is widely considered to be 
the gold standard for determining the number of viable organisms in a specimen or 
experimental condition, but is labour-intensive and has a long turn-around-time.134, 
135 Alternative techniques include the incorporation of tritiated uracil into 
mycobacterial DNA, bioluminescence assays that use a reporter construct, 
quantitative real-time polymerase chain reactions (PCR) and time to positivity (TTP) . 
in automated liquid culture systems (BACTEC Mycobacterial Growth Indicator Tube 
(MGIT) 960). Each of the later has its own set of performance characteristics that 











More recently, newer technologies such as the Xpert MTBjRIF system (Cepheid, 
Sunnyvale, USA) have been developed for the rapid detection of TB using clinical 
samples. However PCR methods have been limited by their inability to distinguish 
viable from degraded organisms. Whilst detecting M.tb-specific mRNA from viable 
organisms is a potential solution, like PCR195, 196 real time PCR, is technically 
demanding.138 Xpert MTBjRIF has the potential to circumvent this problem as 
contaminating extracellular debris is removed in an intermediary step by washing. 
DNA from intact organisms trapped in a mesh is subsequently amplified by PCR.139, 140 
Its quantitative accuracy however, has not yet been compared to that of automated 
culture, uracil incorporation and bioluminescence techniques. 
There are limited reports comparing the performance of different mycobacterial load 
determination techniques in laboratory-based experiments. This study therefore 
compared the performance of five quantitative load determination techniques. 
4.1.1 Hypothesis 
Newer automated techniques for quantifying mycobacteria in human and 
experimental specimens may perform as well as traditional measures such as CFU 
determination of solid media and could have advantages, making them preferable for 
a variety of clinical and experimental uses. 
4.1.2 Specific aims 
1. To determine the performance of five assays to determine mycobacterial 
burden in serial dilutions of Mycobacterium bovis and Mycobacterium 
tuberculosis H37RV. The assays studied were: 
• Automated liquid culture (BACTEC-MGIT-960) 
• [3H]-uracil incorporation assays 
• Luciferase-reporter construct bioluminescence 
• Quantitative PCR using the Xpert -MTBjRIF system 
• Mycobacterial colony-forming units (CFU) using 7Hl0-Middlebrook . 











2. To determine the optimal assay for use in clinical and laboratory research by 
comparing: 
• Turn-around-time 
• Detection threshold 
• Dynamic range 
• Labour intensiveness/complexity 
• Reproducibility 
• Quantitative discriminative ability 
• Cost 
4.2 Methods for determining mycobacterial burden 
4.2.1 Preparation of mycobacteria for assays 
Detailed methods for the growth, storage and preparation of mycobacteria are 
outlined in Chapter 2. 
Briefly, both BCG and H37RV luciferase reporter constructs (pSMTl luciferase)197 
were used for all assays (gift of Muazaam Jacobs from the Institute for Infectious 
Diseases and Molecular Medicine University of Cape Town). Triplicate serial 
dilutions were prepared in sterile phosphate buffer solution (PBS) from the frozen 
stock for each strain in aliquots ranging from 1 to 1 X 106 CFU per ml. The five 
predetermined assays were each undertaken using one of the prepared aliquots. In 
addition, all dilutions were inoculated onto solid media to confirm the number of 
CFUs at each dilution. 
4.2.2 Solid culture determination of colony forming units (reference standard) 
Aliquots of 1, 10 and 100 CFU were plated in 6 replicates of 10 III on 7hl0 
Middlebrook enriched with OADC (oleate-albumin-dextrose-catalase). Plates were 
sealed in airtight bags and incubated at 37°C. Colonies were counted daily between 
days 7 and 14 using an inverted microscope. The colony counts were done over two 











4.2.3 Uracil incorporation assays 
200/l1 of each dilution was pipetted into 6 wells in 4 separate U-bottomed 96 well 
plates and SOul of 3H uracil (final concentration of l/lCiJwell) was added to each well. 
The plates were incubated for 24 hours at 37°C in a 5% C02 humidified chamber and 
harvested onto fibreglass filter mats. The discs were placed into scintillation bottles 
containing Iml of Quicksafe (Zinnser Analytic, Frankfurt, Germany) and the amount 
of tritiated uridine incorporated determined using a liquid scintillation counter and 
reported as counts per minute (CPM). 
4.2.4 Bioluminescence assay 
Luminescence was measured using a Modulus™ Microplate Multimode Luminometer 
(Turner). 25/l1 of 1% (v Iv) n-decyl aldehyde (Sigma), was injected into each well 
containing serial dilutions (1:10 with 0.25% Tween/PBS) to a final volume of 125/l1, 
using a 0.5s delay and 0.5s integration time. The final results were expressed as 
relative light units (RLU). 
4.2.5 Liquid culture 
A 500/l1 aliquot of PBS containing the specified number of organisms was injected 
into pre-prepared mycobacterial growth indicator tubes (MGITs) (Becton Dickinson, 
Sparks, Maryland) and the MGITs then incubated using the BACTEC-MGIT-960 
automated culture system, which monitors the tubes for the presence of growth on a 
constant basis. Each dilution was prepared in triplicate and blinded to the MGIT 
operator. Time to positivity was recorded by instrument as the time between start of 
incubation and detection of growth. 
4.2.6 Polymerase chain reaction (PCR) using Xpert® MTB/RIF assay 
A Iml serial dilution of H37RV and BCG was treated with sample buffer supplied by 
the manufacturer as recommended and 2 ml of the resultant mixture was later 
transferred into an Xpert MTB/RIF cartridge. The cartridge was loaded into the Gene 
Xpert IV instrument and the automated procedure started. Results and CT values of 











4.3 Determination of performance characteristics 
4.3.1 Turn-around-time 
The turn-around-time was defined as the time taken from the start of each assay after 
preparation of the aliquots, until a bacterial load determination was possible (either 
automated output or colony counting). 
4.3.2 Detection threshold 
The detection threshold was defined as the lowest colony number detected by the 
assay: The results from 2 out of 3 MGIT bottles, 2 out of 3 Xpert MTB/RIF cartridges 
or >50% of CFU/RLU/CPM replicates for a particular dilution were used as the 
reliable lower limit of detection for comparative purposes. 
4.3.3 Discriminative ability 
The ability of the assay to detect a difference between serial dilutions was assessed 
using a 1 way ANOVA with correction for multiple comparisons (Tukey). 
4.3.4 Reproducibility 
Reproducibility of each assay was determined by calculating the coefficient of 
variance (SO/mean) across all dilutions. To compare the reproducibility between 
assays (across the various range and readout units such as time, colony counts, cycle 
threshold, etc.) the mean coefficient of variance for BCG dilutions was calculated for 
each assay. 
4.3.5 Determination of assay costs 
The cost of each technique was assessed by taking into account consumables used. 
Quotes were requested from local suppliers for both major equipment as well as 
specific consumables required for each individual experiment. Costing was 
calculated in South African Rand (ZAR) and converted to United States dollars (USO). 
Personnel costs, general laboratory consumables and bio-safety equipment, were 











costing. The capital cost of major laboratory equipment (incubator, beta-counter, 
automated MGIT system etc.) was calculated for comparative purposes but not 
included in the basic cost per experiment. 
A hypothetical single experiment, containing 2 conditions (control and intervention) 
performed in triplicate, was used to standardise cost between assays. Where 
appropriate, 'pooling of wells' was allowed to reduce costs e.g. a single Xpert 
MTBjRIF cartridge for each condition (total of 2) as opposed to a single cartridge for 
each replicate (total of 6). Details of the costing sheet and costs for each assay are 
contained in Table 4-2. 
4.3.6 Labour intensiveness jcomplexity 
The complexity and labour intensiveness of each experiment was assessed on a 
qualitative scale. Factors included were: number of technical steps, degree of 
automation and use of specialized reagents such as radioactive isotopes or 
luminescence substrates, which require specialised handling. 
4.4 Results for the performance of each assay including costs 
A comparative overview of all the mycobacterial load assays is summarised in Table 
4-1 with the breakdown of the cost of each assay contained in Table 4-2. The 











Table 4-1 Performance characteristics of assays used to determine mycobacterial burden 
Turn-around Detection threshold 
Reproducibility 
Cost per Labour intensiveness/ 
Assay 
time (CFU) 
Dynamic range * (Coefficient of 
experiment" complexity 
Variance)+ 
Culture on 7HI0 solid 
Days to weeks 
1 CFU Wide provided appropriate Fair Low Labour intensive, learning 
media dilutions are made. (22%) ,., ZAR 49/ USD 7 curve for counting colonies -
Liquid culture using Excellent at range used from 1 Good Low/medium 
Automated system once 
MGIT 960 system 
Days to weeks 1-10 CFU 
to 1x 10
6 
CFU (2%) ,.,ZAR 84/ USD 12 
bottles inoculated - requires 
BACTEC 960 MGIT system 
Poor below 1x 10' CFU able to 
Poor Low/medium 
Requires radioactive isotope 
Tritiated Uracil assay 24 hours 1000 CFU detect dilution of up to 1x 10
6
handling skills and regulatory 
CFU 
(38%) ,.,ZAR 98/ USD 14 
approval 
Luminescence assay Poor below 1x103 CFU- but 
Extensive optimization 
using reporter < 2hours 100 CFU able to detect dilutions of up 
Fair Low required for each strain and 
construct to 1x 106 CFU 
(19%) ,.,ZAR 70/ USD 10 batch - requires organism 
with construct 
Limited skills required prior to 
PCR using Xpert 
2 hours 100 CFU 
Good at ranges between Good High automated processing -
MTB/RIF 1x102 and lx 106 CFU (3%) ,.,ZAR 252/ USD 36 requires Gene Xpert machine 
and supplies 
*AII experiments apart from CFU, require a standard curve to allow for actual CFU calculation from assay readout 
# Cost was calculated for the specific consumables for a hypothetical experiment containing 2 conditions performed in triplicate. For MGIT and PCR triplicate wells were pooled 
into a single bottle/cartridge to reduce costs. Costing does not include major equipment: Gene Xpert IV machine ,.,ZAR 126000/USD 18000, Scintillation counter ,.,ZAR 595000/USD 
85000, Luminometer ,.,ZAR 59500/USD 8500, BACTEC 960 MGIT machine ,.,ZAR 49000/USD 70000 












4.4.1 Costing for all assays 
The detailed costing for each assay is contained in Table 4-2. The assay with the 
lowest associated costs was CFU by solid media: ZAR 50.31 / USD 7.19. The most 
expensive assay was the automated gene Xpert MTB/RIF PCR at ZAR 255.70/ USD 
36.53. Although the uracil incorporation and automated liquid culture assays were 
less expensive than the Xpert MTB/RIF, the capital cost of the equipment was 
approximately 5 times higher. Further details of the comparative costing are 











Table 4-2 Costing overview of mycobacterial load quantification assays 
Experiment Equipment Basic cost/volume Unit cost 
No. per Cost per Total cost 
experiment experiment ZAR/USD 
PCR using Xpert Gene Xpert IV 
MTB/RIF machine R127 500,00 
XPERT MTB/Rif R2SS,70 / 
Cartridge R126,00 R126,00 2 R2S2,00 $36,53 
Micro centrifuge tubes R400/1000 ROAD 3 R1,20 
Pipette tips R24S/1000 RO,2S 10 R2,SO 
Tritiated Uracil 
assay Beta counter RS24 000 R99,89/ 
Harvester R100000 $14,27 
[3Hl- Uracil R2692/ml R2,70 6 III R16,20 
Opaque 96 well plate R8S8/S0 R17,00 1 R17,00 
Fibre filter paper RSOOO/100sheets RSO,OO 1 RSO,OO 
Pipette tips R24S/1000 RO,2S 36 R9,00 
lSml conical tubes R86S/S00 R1,73 3 RS,19 
RPM I R124/S00ml RO,2S 10ml R2,SO 
Scintillation fluid R3110/S I RO,62 6ml R3,72 
Scintillation tubes 3623/2500 R1AS 6ml R8,70 
Culture on 7H10 
solid media Incubator R63000 RSO,31 / 
Autoclave R22000 $7,19 
Microscope R10000 
7h10 Agar R493/S00g RO,99 1,18 g R1,18 
OADC RS36/200ml R2,68 7ml R18,76 
Micro centrifuge tubes R400/1000 ROAD 16 R6AO 
Lysate (saponin) R742/100g RO,Ol 6mg RO,06 
Autoclave tape R211 for 20m roll R11,00 0,01 m RO,ll 
Pipette tips R24S/1000 RO,2S 66 R16,SO 




construct Luminometer R63000 R71,07/ 
Opaque 96 well plates RS700/100 RS7,00 1 RS7,00 $10.15 
Pipette tips R24S/1000 RO,2S 20 RS,OO 
Lysate (saponin) R742/100g RO,Ol 6mg RO,06 
Decanal R344/2S0ml R1,37 O,Sml RO,69 
70% Ethanol R120/L 70% R1,20 O,Sml RO,60 
Sterile water R83/1 RO,80 1ml RO,80 
15m I conical tubes R86S/S00 R1,73 4 R6,92 
Liquid culture 
using MGIT 960 BACTEC 960 MGIT 
system machine R490000 R81,06/ 
MGIT bottles R2S96/100 R2S,96 2 RS1,92 $11,58 
Culture supplement R837/100 tests R8,37 2 R16,74 
Micro centrifuge tubes R400/1000 ROAD 16 R6AO 
Pipette tips R24S/1000 RO,2S 24 R6,00 
Conditions in triplicate = 6 wells pooled for analysis either 6 or 2 tests 











4.4.2 Solid media culture 
Although technically simple to perform, plating for CFU is time consuming and 
pipetting skills as well as visual counting of colonies affect accuracy and 
reproducibility. Counting of CFUs and determination of mycobacterial load was 
possible approximately 10 - 14 days after plating. (Figure 4-1) Determination ofthe 
CFU count was limited by the visual ability to accurately count organisms and thus 
only dilutions of 1, 1x101 and 1x102 CFU were used for plating on 7H10 agar. The 
coefficient of variance across the three dilutions ranges was 22%. The assay is 
relatively cheap to perform at approximately ZAR 50.31/ USD $7.19 and requires 
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Figure 4-1 Mycobacterial load determination using solid media (Middlebrook 7H10) 
Stock dilutions are presented on the x-axis for BCG (a) and H37RV (b) with the calculated CFU on the y-axis 











4.4.3 Automated liquid culture 
The turn around time for the BACTEC-MGIT-960 system was defined as time to 
positivity (TTP) ranged from 117 hours (- 5 days) to 467 hours (- 19 days) for BCG 
and 123 hours (- 5 days) to 528 hours (-22 days) for H37RV (dilution range lxl06 to 
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Figure 4-2 Automated liquid culture (using BACTEC MGIT 960) time to positivity 
Time to positivity was calculated as the automated time from culture initiation to bacterial detection (on 
the y-axis) for serial dilutions of BeG (a) and H37RV (b) on the x-axis 
The lower limit of detection was less than 10 CFU (1 CFU detected in 3/3 BCG bottles 
and 2/3 H37RV bottles). Reproducibility of the BACTEC-MGIT-960 system was 
excellent as most replicates become positive within a few hours of each other at all . 
dilutions (coefficient of variance = 2%). The range of detection was from 1 to lxl06 
CFU. BACTEC-MGIT-960 was able to detect differences in mycobacterial load as small 











major cost for the experiment was the culture bottles, and estimated experimental 
costs were ZAR 81.56/ USD 11.08. The BACTEC MGIT machine costs approximately 
ZAR 490 000/ USD 70 000 (developing country pricing). 
4.4.4 Luminescence assay 
The lower limit of detection was lx 102 CFU as no discrimination was possible below 
100 organisms. Discrimination between mycobacterial loads was possible at ranges 
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Figure 4-3 Luminescence assay (using luminescent reporter construct) relative light 
units 
Relative light units measure for each serial dilution are represented on the y-axis with serial dilutions of BeG 
(a) and H37RV (b) on the x-axis 
Reproducibility was comparable to CFU with a coefficient of variance of 19%. 
Mycobacterial load determination was potentially available within minutes of RLU 











assay was approximately ZAR 71.07 / USD 10.15 but requires a luminometer ( .... ZAR 
63 000/ USD 8,500), to be permanently situated in the bio safety laboratory. 
4.4.5 Uracil incorporation 
Uracil incorporation assays were complex and time consuming to perform although 
the time to acquiring a result was approximately 24 hours. Specific training and 
equipment was required to use radioisotopes as well as provision for isotope storage 
and waste disposal. The effective lower limit of detection was 1000 CFU as the 
tritiated uracil assay could detect, but not discriminate between loads at ranges 
below lx 103 CFU. However, it was effective at lxl03 to lxl0s CFU. (Figure 4-4) The 
cost per experiment was approximately ZAR 99.89/ USD 14.27 but requires a 
harvester and scintillation counter ( .... ZAR 524 000/ USD 85,000). 
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Figure 4-4 Uracil incorporation assay counts per minutes (CPM) 











4.4.6 peR using the Xpert MTB/RIF system 
The automated real time MTB/RIF cartridge in the Gene Xpert IV system was user 
friendly with minimal technical steps required prior to inserting the cartridge into 
the machine. Xpert MTB/RIF results were available within 2 hours of the experiment 
using the Gene Xpert IV machine with 4 bays (only 4 samples could be run at once). 
BCG reproducibility was excellent (coefficient of variance 3%) and the automated 
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Figure 4-5 Automated PCR (using Xpert MTB/RIF) changes in cycle threshold (CT) 
Cycle threshold (CT) is depicted on the y-axis with serial dilutions of BCG(a) and H37RV(b) on the x-axis. For 
BCG, CT values were significantly different between serial dilutions (following correcting for multiple 
comparisons) except where indicated. For H37Rv, significant differences between CT values were only 
present for 2 log changes in CFU when correcting for multiple comparison (*) CT values of zero indicate 











At the lowest dilution of 1 CFU, only 2 out of 3 cartridges were positive. The H37RV 
had greater variability in cycle threshold (CT) values as compared to BCG (coefficient 
of variance 6%) and did not detect less than 100 CFU. For the BCG experiments mean 
CT values were statistically significant across all ranges thus providing excellent 
discriminative ability. Although the mean CT values across the range of loads tested 
were statistically different for the H37RV experiments (1 way ANOVA p <0.001), when 
correcting for multiple comparison (Tukey), statistical significance was only present 
at a 2 log change in CFU i.e. 1x104 vs. 1x106• 
For the costing analysis the 3 replicates were pooled so that only 2 cartridges were 
used. The Xpert MTB/RIF PCR was the most expensive costing a total ofZAR 255.70/ 
USD 36.53 per experiment. The cost of the Gene Xpert IV machine and software is 
approximately ZAR 127 500/ USD 18,000 (2011 pricing). 
4.5 Discussion 
Accurate determination of mycobacterial burden is an essential requirement in basic 
and translational research and for effective implementation of TB control 
programmes. Although determination of mycobacterial burden by CFU is considered 
the gold standard, newer techniques offer a variety of advantages but also limitations. 
These have been examined in the series of experiments described here. 
The key findings of these studies are that (i) Xpert MTB/RIF is a rapid and accurate 
measure of mycobacterial load above a threshold of 100 organisms/sample; (ii) TTP 
using MGIT 960, whilst also an accurate measure of burden with better discriminative 
ability and a detection threshold down to 1 CFU, has a substantially longer turn-
around-time, and (iii) bioluminescence and uracil incorporation assays are limited by 
lack of discrimination below 1000 organisms. 
Thus, no single assay has 'ideal' performance characteristics and the selection of an 
assay will be determined by the intended use or requirement of the experiment. 











obtaining rapid results, desired reproducibility and financial and laboratory 
resources available. In resource-limited settings CFU using solid media is likely to 
remain the method of choice as it remains the cheapest alternative. 
The Xpert MTBjRIF assay may in theory overcome several drawbacks of real time 
PCR. DNA from degraded organisms is removed in a pre-PCR wash step with only 
intact organisms retained in the cartridge mesh for the PCR step.140 This allows for 
quantification of organism load with cycle threshold198 not possible with traditional 
PCR. The data presented here supports this notion as Xpert-related results correlated 
with those obtained from solid culture CFU counts. However, Xpert MTBjRIF assay 
detects intact organisms and cannot distinguish viable from non-viable organisms 
and thus suffers from similar drawbacks to conventional NAATs and smear 
microscopy. Whilst CT correlated with mycobacterial burden as has been shown in 
other studies,198 to what extent it will correlate with risk of infection in contacts of 
index cases remains to be determined. It is possible that Xpert MTBjRIF CT might 
correlate poorly with infectiousness, as discrimination between viable and non-viable 
organisms is likely to be poor. Given its rapid turn-around-time and detection of 
smear negative patients, clinical studies will be required to evaluate the utility of 
Xpert for monitoring treatment response, disease prognosis and for evaluating risk of 
disease transmission. 
Rapid turn-around-time is an attractive advantage of the Xpert assay particularly in 
drug development-related EBA studies providing 'real time' serial quantification of 
bacterial burden. By contrast liquid culture results although accurate, may take up to 
6 weeks. The clinical value of rapid turn around will need to be weighed up against 
the greater cost::::: ZAR1750jUSD250 (ZAR126jUSD18 per cartridge) compared to 
ZAR686jUSD98 (ZAR49jUSD7 per MGIT bottle) per subject over a 14 day EBA 
study]. Consequently, in basic science laboratory study settings the rapid turn 
around of results is highly attractive but comes at a significantly higher cost 
compared to solid culture. Another key drawback in this setting is the detection 
threshold of 100 organisms, which may be inadequate for experimental models 











Liquid culture using the automated BACTEC 960 MGIT system is an attractive 
technology for both clinical and laboratory studies. Already incorporated into EBA 
studies134, 135 time to positivity serves as a surrogate for bacterialload.135, 141, 142 Its 
user-friendly format, automation, high discriminative ability and low detection 
threshold (less than 10 organisms) makes it well suited for laboratory studies. The 
key disadvantages compared to Xpert MTBjRIF and solid culture, are slow turn 
around time (days to weeks) and cost respectively.143 
Bioluminescence and uracil incorporation assays both provide rapid turn around 
time and have been widely used in laboratory studies.25, 136, 137 They have limited 
application to clinical and public health studies given the requirement for specific 
M.tb-reporter construct cultures and the high risk of bacterial contamination 
respectively. In addition both methods have limited discriminative ability below 
1000 organismsj sample. Uracil incorporation methods offer little advantage over 
bioluminescence yet require significant additional infrastructure to accommodate the 
storage and disposal of radioactive waste. Establishing this technique in a new 
laboratory is unlikely to be cost effective especially in resource-poor settings. As with 
all the other "indirect" techniques of quantitative load determination, a standard 
curve is required for calculation of CFUs. 
The studies described here have several limitations. Firstly, they were performed in a 
research rather than a service laboratory. Secondly, assays were performed with 
only a single strain of virulent mycobacteria, and were prepared in a standard 
medium. The findings might therefore not apply to other clinical mycobacterial 
strains and samples in which contaminating biological materials might dilute or 
inhibit mycobacteria. The former will apply most to the findings of the MGIT 
method. Thirdly, in costing each method we assumed that the time spent by a 
technologist would be the same for each method. Nevertheless, economy of scale will 
apply in high throughput laboratories. However in this setting, the savings in labour 
costs (time spent plating and counting CFU on solid media) may be offset by the cost 











In summary, no single mycobacterial quantitative technique has ideal performance 
characteristics. Thus, the choice of assay will largely depend on the research context, 
study question, and the relative tradeoffs such as cost versus turn around time. 
Automated systems like MGIT are sensitive and discriminatory but have a long turn 
around time. Xpert MTBjRIF is a good quantitative tool with rapid turn-around-time, 
but its detection threshold was not as good as automated liquid culture. Although 
solid culture is the most labour-intensive, it remains the cheapest option for a highly 











5 Mycobacteria-induced monocyte-derived macrophage 
responses to nicotine and cigarette smoke extract 
5.1 Introduction 
The immune response to mycobacterial infection is a complex interaction between 
innate and adaptive immune responses.199 The immune response is initiated after 
ingestion of aerosolised M.th organisms by alveolar macrophages.148, 151 In active 
disease there is an exuberant local pulmonary immune response characterized by 
inflammation in which recently recruited immature macrophages play a central 
role.2oo This reaction is strongly enhanced by M.th antigen-specific Thl responses201, 
202 with large amounts of locally secreted IFN-y. M.th-induced immune evasion 
mechanisms203 with production of suppressive cytokines and effector molecules204, 
205 may counteract protective immune responses and abrogate bactericidal immune 
mechanisms.206 
The important role of IFN-y and TNF-a has been demonstrated by susceptibility to 
active TB in patients receiving therapeutic TNF-alpha blockade207, 208 and with 
hereditary IFN-y and IL-12 receptor abnormalities.209, 210 TNF-a is likely to play an 
important role in killing intracellular M.th through reactive nitrogen intermediates 
and IFN-y is important in granuloma formation.211 TNF-a is furthermore important 
in the control of latent TB infection since the anti-TNF antibody Infliximab 
(Remicade®) increases the risk of activating latent TB.207 
Although the effects of tobacco smoke on the immune system in general have been 
well described,12, 14 there are little data on the impact on mycobacteria-specific 
immune responses and the mechanisms involved.12, 113, 114 Cigarette smoke turns off 
production of TNF-a by macrophages in the lungs212, 213 and alveolar macrophages 
from smokers have reduced phagocytic ability.214 Cigarette smoke prevents 
pathogen-specific expansion and activation of CD4 T cells124 and reduces IFN-y-
producing adenoid-specific CD4 and CD8 T cell numbers.119 Nicotine enhances the 
replication of intracellular organisms such as Legionella and can down regulate TNF-











apoptosis,64 an important component of mycobacterial controP17, 118 which promotes 
the killing of virulent mycobacteria.215 
Although there is epidemiological evidence of a harmful smoking-TB association, 
several factors including; poverty, alcohol and socio-economic status are confounders 
and the lack of convincing mechanistic proof has led to uncertainty about the 
importance of Cigarette smoke as opposed to other social or environmental factors in 
this apparent association. Proof of association will assist advocacy for smoking 
cessation programmes and elevate their status as part of global TB control efforts, 
and inform policy on appropriate smoking cessation strategies. These considerations 
provided the basis for the experiments described in this thesis to examine the effects 
of cigarette smoke constituents on host defence against mycobacterial infection. The 
focus on their effects on important defence mechanisms against mycobacteria in 
human monocyte-derived macrophages in Chapter 5 and in vitro infected 
bronchoalveolar lavage harvested alveolar macrophages in Chapter 6. 
5.1.1 Hypothesis 
Constituents of tobacco smoke (nicotine vs. whole CSE) attenuate protective 
mycobactericidal host immune responses (effector cytokines and bacterial staSis). 
5.1.2 Specific aims 
1. To determine whether tobacco smoke constituents modulate mycobacterial 
ingestion by macrophages. 
2. To determine whether cytokine production in response to mycobacterial 
infection, is impaired by exposure to cigarette smoke extract and nicotine in 
particular. 
3. To determine if nicotine impairs cytokine production, and if this is mediated 
via the nicotinic a-7 receptor. 
4. To determine whether tobacco smoke-exposed human monocyte-derived 












5.2 Overview of methods 
5.2.1 Preparation of monocyte-derived macropbages 
Monocyte-derived macro phages (MDM) were prepared from whole blood obtained 
from healthy HIV negative volunteers. As detailed in Chapter 2 peripheral blood 
mononuclear cells were prepared by density centrifugation and plated in flat bottom 
tissue culture plates. Following a 6-day culture, non-adherent cells were washed off 
and fresh media added prior to infection or exposure. THP-1 cells were prepared as 
described in Chapter 2. 
5.2.2 Preparation of cigarette smoke and nicotine extract 
Fresh cigarette smoke extract was prepared for each experiment using the 
standardised protocol described in Chapter 2. CSE was prepared from Marlboro 
Red® cigarettes and used at a final concentration of 10%. Nicotine was diluted in PBS 
to achieve a final concentration of 1f!g/ml that was employed for all nicotine 
experiments. CSE was added to the cells immediately prior to BCG infection. 
5.2.3 Infection ofmacropbages 
Macrophages were infected with BCG at a multiplicity of infection (MOl) of 2:1. 
Aliquots of frozen stock w re thawed immediately prior to infection. Following 18-
hour exposure, non-ingested bacteria were washed off prior to further experimental 
steps. A 4-hour infection period was used for certain preliminary experiments. 
Infection of macrophages by green fluorescent protein (gfp) labelled BCG was 
confirmed by light and fluorescent microscopy following washing of the cells to 
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exposll ,·c. hJrvest.ed cells were incub~led with CfJ1 4 Jll~gnet i c ])yn" be~d s 
(Invitrogen) to sepJrate the C014 pos itive (elis (CDH+ fraction) from non-COl 4 











solution prior to adding 25"",1 of magnetic beads to the cell suspensions. Cells were 
then incubated on a rotator/mixer at 4°C with the magnetic beads. CD14-bead-bound 
cells were adhered using magnetic attraction and the remaining cells aspirated and 
stored as the "non-CD14 fraction". CD14-bead-bound cells were washed a further 3 
times to remove possible non-bound cells. Aliquots of cells to be used for PCR 
analysis were spun down and preserved in RL T buffer and stored at -80°C. 
To assess the purity of the extraction method, an aliquot of cells was retained prior to 
RLT preservation for flow cytometric analysis. Cells were stained with CD33 (APC) to 
identify macro phages as the CD14 receptor was bound to the magnetic beads. CD3 
(PE), CD4 (PerCP) were used to indentify any contaminating lymphocytes. Following 
surface staining, cells were resuspended in 4% paraformaldehyde (PFA) prior to 
acquisition using the BD LSRII (BD Biosciences) flow cytometer and analysed using 
the BD FACSDiva ™ software V6.1.3. 
5.2.4.2 Determining IFN-y production by qRT-PCR 
PCR was performed with assistance from the Centre for Proteomics and Genomics 
and the Institute of Infectious Diseases and Molecular Medicine, University of Cape 
Town. 
IFN-y mRNA production was determined using two-step RT-qPCR. RNA was isolated 
from harvested CD14+ cells using the RNeasy® Mini Plus kit (Qiagen) according to the 
manufacturer's instructions and all precautions for handling and storage of RNA were 
considered. The purified RNA was quantitatively and qualitatively assessed using 
Agilent 2100 Bioanalyzer with the RNA 6000 Pico Labchip kit (Agilent Technologies, 
Palo Alto, CA, USA). The amount of total RNA extracted ranged from 30 - 300ng and 
RIN values obtained were> 7.0. Reverse transcription reactions were performed 
using the Sensiscript® Reverse Transcriptase (Qiagen) kit according to the 
manufacturer's instructions. 
All PCR reactions were run on the Rotor-Gene 6000 (Qiagen). The PCR reactions 











manufacturer's instructions. IFN-y mRNA values were normalized using a previously 
validated reference gene, HUPO.195 Primer sequences for IFN-y and HuPO were used 
from a previously published studyl96 and primers were added at a concentration of 
800nM. cDNA copy numbers were quantified by absolute quantification. Standard 
curves were generated using serially dilutions of linearised plasmids containing the 
appropriate gene targets. All reactions were run in duplicate. The PCR cycling 
conditions were: initial step of 95°C for 10 min, followed by 40 cycles of 90°C for 10 s 
and 60°C for 30 s, in a 12.5-IlL reaction volume). Reaction efficiencies were within 
acceptable limits and R2 values were >0.99. IFN-y copy numbers were expressed per 
106 copies of HuPO. 
5.2.5 Determination of monocyte-derived macrophage stasis/killing of 
ingested mycobacteria 
Macrophages were infected as described in 5.2.3. 18 hours following infection non-
ingested organisms were removed by washing adherent cells three times with warm 
RPMI. Fresh culture medium supplemented with 10% FBS was added to all 
experimental wells. CSE was added to triplicate wells post infection to a final 
concentration of 10%. No further CSE was added on subsequent days. 
At each time point (days 1, 2, 3, 5) visual inspection of control and CSE exposed wells 
was performed to identify excess cell loss in either condition. At day five, triplicate 
wells of CSE exposed and unexposed infected macro phages were harvested with cold 
PBS and the number of viable cells in both conditions was determined using trypan 
blue exclusion dye. Additional adherent cells prepared on glass chamber slides and 
exposed to the same conditions, were stained with 7 AAD for fluorescent microscopy. 
On days 1, 2, 3 and 5 post infection, supernatants were removed and adherent cells 
lysed with 0.3% saponin (Sigma Aldrich) to release intracellular organisms for 
plating for CFU. Following lysis of the macrophages, serial dilutions were made and 
plated on 7H10 Middlebrook solid media agar to establish the colony count of BCG. 
organisms at each time point. (Described in chapter 4) Three dilutions for each 
condition were plated in 6 replicates. CFU counting was performed using an inverted 












5.3.1 Th ... effect of cigarette smoke extr;lct on macrophage survival 
Adherent THP-l cells and monocyte·derived mJcrophJges wel'e prepJred JS 
described previously. :.1~crophilges were expo~ed to fresh ly prepared cigarette 
smoke extract ill increasing conccntl'dtions for 21- hours Jnd then harvested \Jsing 
rold PBS with 20mM EDTA 
5.3.1.1 THP-l cells 
Vi~bility of harvested ildhercnt THP-1 cells as assessed using trYP'lrl bluc exdusion 
dye, showed d rnedn (SllJ viJbility of 9('.('%(.~.OJ in unexpo~ed "fliP-! cells, 
91.6%(2.3J in 10% CSE expose(j il nd 8'1.33%(7.6) in 25% (SE exposed THP-l cells 
respectively; p=0.71 (ANOVAJ. (Figure 5-2) 
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Figure 5-2 Adherent THP-l cell viability after 24-hour eXp05Ure to increasing 
concentrations of cigarette smoke extract 
5.3.1.2 Monocyte·derived mauophages 
Vi~bility of monocyte-derived macrophages ~ssessed at 24 hours showcd a ~imil~r 
pattern to THP-l cells: no sign ificant difference in cell viability beh."een unexposed 
dnd 10% CSE exposed: H('5%(5.3J dmI75.7% (5.6J respertively (p=O.I.~) h mdl-ked 
reduction in cell vidbil ity at concentr~tions of 20% and greJter WdS noted: 20% CSE 
exposure 54.8%(0.3); 50% (SE exposure: (,2.5%(1.(,); dnd 90% CSE expos ure: 
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Figur@ 5-3 Adherent monocyl~-dNived m<l(toph<lge viability after 24-hour e~posurl! to 
incre,,~i ng concentr"tion~ of cigarette smokl! l!xtract 
The experiment \~'<lS repe~ted to JSSC SS the effect oj increasing crlncen(nliun$ of CSE 
on ce ll detachment. Alter 24 hours the vIab ility uf bUlh $pllnt~nco1l51y detMhed cell s 
(in the cul ture supernatant] ,md h~rvested (adherent) cel ls we)"e cr>mpared. The 
del,uhed fractio n (6%) ,111(j viJbility (100%) rlf det~ch C{J mdcrlJphages was 
equ l"Jlel lt in unexposcu nl~crorh;Jgc, tom pared ({) 10% CSE exposed Ill:JCTop hJp,es. 
At 20% Jnd 50% expusure, ,[ slgmficJlltly hIgher number of macrophages had 
detJched during the 24 hou rs of eXpOSltre ,Ilthuugh 83% Jnd 79% remJined viab le 
respect ively_ When expused to 90% eSE, [ln ly 15% [If t he original numher 01 pI J(l.'d 
{ells were recovered in the supernatant with 29% refllJining vidble_ The low {ell 
reCCtVelY at 90% CSE exposu re is likely dlle tox icity with resultdnt cell lysis, (Figure 
S-4] 
• c.", ,_ ... 
z:iO v ..... c." 
Figure 5-4 The effect of cigarette smoke on macrophage det;J(hment and viability 
E. ch b., repre,enh the perce n t"~ e of cell , re cove red i ~ the ,upernat,"t , fte r 24 hour., The vellow sh oded 
Ir. ction ond nll mber Ind'Glte, the proport ion of the re(oYffed cells that were viab le, t he red 1r.,tion lh e 











5.3.2 The effect of tobacco smoke extract on mycobacterial uptake by 
monocyte-del"ived macruphages 
Myrub<lcterial uptake was assessed using gfp-Iabc lled BCG org<lnisms and cont1rmed 
hy tluorescent microscnpy. Prepared marrophages were infected at In MOl of 2: 1 in 
tr iplie'le wel ls. M<lcrophages were either co·expowU to lOoil) CSf dur ing infection or 
unexposed. Following in fec tio n. nnn-adherent cd ls wel·e ,·emoved and adherent cells 
\wrp hJrvpstcd using cold PBS an(1 20mM EDTII. Cells were WJsh("d in I'ACs buffer 
p '·ior to acquisition on the FACSCJl ibur (Bf). IHl lJ ios("iences). Immediately before 
acquiring the cells on t il(" flow cytomete r HJ~d of 711AD was auded to Jssess the 
viability of the cells. 
MJcroph<lge vj<lbi lity was not affected by lKG infection a l\<· r 18 hou ,·s or hy ro-
('xposure to either exposure to nicot ine nr cig~rett~ smoke. lifte r 18 hours, 
uninfected unexposeu macro phages h"d d mean (SD) viah ili ty of (d.3%(S.S) JS 
determi npU by 7 AAI) stdining. Viability was llnchanged hy expnsure to 10% c ' g~ 'Ttte 
smoke: 67.7% (1.0~) or l ~,g/ml nicotine (,1 ,I%(3 ,8J: p=0.59. ]'ollowing the III hour 
RCG intixtinn , viab ility W<I~ 67.:3%(5.8) which was not significantly u ifh>r("nt f,-om the 
(Jninfected macrnphages [exposed or unexposed) no r thf inr~cted/l0% cigdrette 
exposed macroph~ges: (,rl.!%(2.7J nr inr~cted/lf,g/ml nicotine exposeu 
macrophages: 60.,)%(,).7), p= 0.63. (Fi gure S-SJ 
"' .. '" ' ' .. , 
,1Jccc-'-'-~-L-1-.--J--'-.-'-~ __ -1-'-cc-'- .~~~ 
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Figure 5-5 Viability of monocyte-derived macrophages after 18 hour BeG infection 
tea ch b" repr~scnt' the ,TIe,n vi,bility (7I1I1D nep,ot;"e) of MDM, un ~xpo ",d or ~xpo,d to \ 1)')\ cig arette 










Mycobacterial uptake was assessed ~t 4 ~nd IB hours. VJri~bility in uptJke w~s seen 
ben.vcen individuJ ls ~t both tinH's poi n t~. (Fig\Jrc 5-6A. Figure S-7A) At1 hours, the 
perccnt«p,e of macrophages that were [JU;-gfp positive in the unexposed w.<I1 ~ 
compared to the cigarette smoke extr~(t expos.<d wel ls W~~: rne~[l (51)) ~ . 5%(2 . 6) 




10% .mo'. v,"~L 
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Figure 5-6 BeG- gfp uptake bV monocyte-derived macrophages after 4 houls 
LJplok . i, d. picted tor md",dua l ,uole" < (p ...-tm mO'{i In trip licate ! IAi , od .,umm' led re, ul(s of a ll ",bj eGt, 
(R I wi l h c ' ro,u re I reO b,,, i ,.; th ,od wilhoul l OX cir,arH le , me k •• ,Ir "01 (wh ,t~/;h"d.d I 
1!uweve r, at 18 hours very little difference in mean (SD) rnycob~neriJI \Jptake wJ S 
seen: 23.2%(7.9) in unexp(J~ed control welb com pared to 20.12%(7.0) in cigarette 














Figure 5-7 BCG-gfp uptake by monocyte-derived macrophages after 18 hour~ 
U pt"k~ j , d ' pict_d for i ~d i vidu' l , ubj eU, perfor med ie, tnp li c"t~ (Ai .r.d summated resullS 01 , II , ubJecl> 
iB) with expo,u r. (re d b",) with on d wlth"ut 11)% ci ~",ette smo.e e<tr det (wh llej,h, ded I 
When s uhjects were stra tified by LTRl status (LIlll negative: TST and IGRA neg~tive 
vs. LTB I pos it ive: T ST ur rCRA positive) , sign ificJntly higher RCC·gfp uptake was 
noted in LTR! positive sub jects 28.1%(7.6) comp~r~ (j to LTIJI negative 18.3%(4.84); 
p=O.OOl. Uptake was not Jffcctcd by (igar~tte smuke co-exposure Jnd did not ri iffer 
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Figure 5-8 Monocyte-derIved macrophage§ BCG-gfp uptakl! stratified by presumed LTBI 
status 
Uplake i, depicled for 10% (iE"ene smoke e,po>ed fred b",) ,nd "ne'posed (do".r b,rs) "nd str.tlfie d by 
lot cnt TB infe ctIOn >l;ltu" Inc 4 fur I I ~I pO> llive ,nd 3 I()( LTBI neg' t ive) 
5.3.3 Cytokine production lollowing mycobacterial infection 
Given ~ ltenu~ li on of secretion of all the cytokines studied, to exclude a possible effect 
of cigdrelte smoke extract on the reagents used in the commercial ELISA, lFN-y 
st~nd~rds provided in the lIu dntiFEIl.O N ~TB Glllt!- In-Tube El.lSII Kil were mJd c up in 
j}()lh RPM! ;mt! RPM! containing 10% CS E. Using three sep~ra t e standClrds, llO 
d ifferl'llce in liet<'fl<'d IFN-';, was ,.i<'mollslrilted in the sWndJrds made up in 10% 
eSE/RPM I c(lmp"n'd to RPM! alnne. lFigure 5·9) 
","" ,~"" "" "", 
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Figure 5-9 The effect of 10% CSE on IFN-y concentrations dl!tected by the commerci31 
QFT-GIT ELISA kit 
E;lCh "or repre><n l, th e me ol n (SEMI (on(entrolt iOl1 of IFN·Y '" determ ined by ti)(' H ISA kit u,ing the t hr", 










5.3.3 .1Interrcron gamma (lFN ·y) 
lFN·"( I'ruduc li un by munucy te-u~riv~ u mdcrol'hages was nwaS\lred at both 4 and Hl 
hours pos t infe("tion. ,\t fuu r hOllf,. the mean (SO) lFN-y pruuucliun wa, minimdl dt 
0.05(0.01) llJ / lll! a nu not a[f~ cted by co-~xposu re to 11l 'J-h CSE 004[OHl) llJ/ml 
(p =O.41j At 13 hour'. IFN ·y production by uo·stim ul ated manuphages dS well dS 
macru phage, ~ x ~oseu to IO 'K eSE, rem~ i ned negligib le: (l.()6[O.(l3) llJ/m l "nd 
1I .1I 6(1l.(l3 j llJ/ ml re,pectively [p=1.0]. Following BeG in fectiun, a significJn l rise in 
meJ n [SD] lFN·"( was d~lecic d O.LS (O.IS) IV/m!. How~ ver, lll acroph~g~' co·e~po'ed 
wit h 10')1, CSE dllring infection, demon,trJted ,ignificanlly Ie", IFN-"( pruductiun: 
mean (SO) 0.10(0.04) [[J/m!; p=O.OO1. (Figure S-lO] The pro duct ion of IF"-'I ~nd the 
effect of to b,cco smoke ext ract wa, not sign ificant ly difterent when ,trMified by L TEl 
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Figure 5·10 Interferon gamma production at 18 hours by monocyte derived 
macrophage, with and without exposure to cigarette smoke extract 
5.3.3.1.1 Confirming the production of IFN-y by monocyte·d erived mal' r()plmge~ 
ll11m~n ~nd muri ne macro phage, have been shown to produce lFN-"(, .l llhuugh T cell, 
predumi ndnlly s l"lr~le it in r~, ~unse 10 in fectiol1 ."'· '''. '" Therefo re to collfirm that 
t he macro phage, in t his )"lD)"1 model were producing IFN-"(, hlflher experirnen", were 
cuIlducle u. Thr~e audili olldl sub ject; were recruited ~ n d following the same 
ex ~ ~ri ment, l method , " previous ly de,cribed. hJrvested ce ll s were prepJred for 










c~n, were st~i ll e'" wit h surfo,e lIl~rkers nu. CD4. CD33. CDI 4 and for Intracellular 
lr N-y. The cells were ident ifi ed hy a general gdte fr"I11.1 rl"t -I'l()t dericting !c,rw.l rd 
' nd , irl ~ ,caltel' rha l ·~rtel'ist"-'. The g~ling str;llegy is dep icted be low: IJ rie ny. Cll3 .. 
cells were g~ted to identify T· ly m~h"cyte s and NK T-cells dnd th is gate was excluded 
fmm further "'~Iy-'i-'_ Cells nCi:~(ivc tor the myeloid mark~r O:n:l were also 
slaillillg w ilh ant i CD1 4, ~ U'S n'wplor found on macrophogl·S. (i'"ig llre 5-1 1) 
Usin~ Illi , gating 'tr~legy .1-0% ot th~ cell s were CD3:" po, it ivc and 70% ()j ClB3 .. 
wlls were CD I 4 posi tive . jn the nUhCU14+ I)Opllblion. 60% were l' o"l"-e for IFN-
I ' (l:igure 5-11) In the excluded rDhve ~ o ~ul ation (uot shownJ O.L% Wl'n' IFN-j' 
Figure 5-11 Flow cytometry gating ,trategv for the definition of cell types producing 
IFN~f in response to BeG infection 
Macrophages have TFN-r r eceptors ,nd conw guently posith'e intracellular stain ing 
does not prove prodll~ti on of IFN ·" hy the macrophages bllt may represell l 
internaliz.'tion of h,-"md IFN-y. Tn determ ine the s()urce ()f II'N-,' product ion, further 
ex periments were condllcted in order to isolate the C[J14 positive ce ll ' and t() 
determine the prod uction of I FN -'I in these cells using I'CR 
CD14 positive cells were isolatl,d as descr ihed in S.L.4.1. To confirm the purity of lhe 
CD14 positive fra<:tion prio r to PCR. dual staining of anti CD3-jCD33+ w,~ ~ h()\vn to 
he greater than Yo/Yo (duplicate exper imentsJ in the CUl4 fraction . (Table 5· 1J /I 
s mall perc entage ()f rD~~. cells r emai ned in the non-rD 14 fraction. which was 111 
kee ping with the prev ious expeliment' demon~trating the prewnce oj CDB pos itive 










Table 5-1 Purity of C014 magnetic bead extracted cell fraction in unexposed and BCG 
infected condit ions 
-
%en 3 ->'c ,)" e n 33 h'C e n 3 e n 13' pu c; l), 
en 14 1,,,,,,, ;0" 99.~ '\6 99.4 '" 99.2 % 
Une.po,.d n 'll> -" -NOI- CO j·1 f,.aLo n 67"'(. 1. 5'k . 'F', 
-
CVHf"ctiuu .- 99,6% 99,6'Y. "--' n~r. · in tootod 
\ U" Cll' ·' I, .' 'C': ;,,, , SS y .. , ".S'X, GS.1 ,y, 
5.3.3. 1.2 peR for IFN-y mRNA 
peR for IFN-':' WJS Ded urmed on the C])1 4 4ve ce ll fract ion "" J e~CI"i hed ~ bpve, 
Mini mJ I IFN-'l mRJ\ A copies, mCdn (S!)], were preSCl1 tl1 ' t llc control (1! l1 cxJlosr rl and 
lUllnfe;.; tp.d ) mJCl"o)!io Jges: 91,5 (106,8] mRN A Cuplt'b per 10'" WPJ ~S of ll ul'O 
Foliowmg !:lCG tIl fectwn, IFN··:' mRNII expr~~s Lon mO'cJsed Siglll flC.!IItly tP.l me;;)] 
(Sfll1n 1(,(1(, .97) copies per I no t opics o f Huf'O ; p= O. ll O:l , In BCG infrcted ~ l1 d CSF. 
~xDu~t' d mJtroph"ge~ the lev~1 of IF N·y express ion, me~n(S flJ, WJ, numerirdlly 
Ipwt'r: 32 0 ( ~ 90J but Jid no t 1"<' ,1ch sla lis ti cJ l si l:l1 ifi cJ l1 cC (p=l1 06) These dMa, 
althoLlgh ('ln ly frum twu iudivlduals, demonstratc t h~ production p[ IFN ·'! mRNA by 
lhe CD14 pus iti y ~ cells shown in the prior experi ments tp he IFN-': posi li ve by 
inlr;;ce llul ~ r ~tai n in g. The trend towards a reduced lFN-y by co-eXpOSl!re to cigal'ette 
smoke supports the ELISA fi ndings. 
, , , , 
"",,",eL, 
Figure 5-12 Interferon gamma (IFN·y) mRNA transc ript ion following BCG infection in 
C0 14 positille cells 
tFN-y mRNA w"' l r. n>criLe " Irom CD14 , eit, (m acrophages) purified by magnet ic bead , eparot icn, 
f o t lo win ~ co nve rs io n of RNA to ,ONA, r~. t tim~ PCR w;" performe d " nd q" , ntlt"t"e "moun t , o f trN y 












5.:1.:1.2 Tumour "ecrn.,is fa c t()r alpha (TNF·CI] 
T,,'i'-<t l,roduction was mc· . surc·d at 111 hours post infection wi th Bet;. A, seen with 
[[lalTOI,hagl'" me,Ul (SD] O.73(UI] I'g/ml and 1.7(5.3]l'g/ml r~ sp" t tively (1' =0.3]. 
Fo llowing inh'fliQ n. TNF·u proriLlctio" incr~",~ rl significa nlly 10 " me,," (SD) uf 
137.5( I 11.7J pg/ml. Tl\F-a product io n WdS sil:n iliunt ly red un ·d wit h l·(H"Xpo., ure 
tu 10% eSE: 2 Ud( 45.'17J pg/ml (p<U,oOl). [Figure S- 1:1] TIle" prOd\lction of TN F·" 
and th e eJtect ot tOI~lCCO smoke ex trMl w," nul "gnitkantly di fferell l whell ,( r"li fwd 
hy Un! status (rla ta containerl ill Jppendix A]. 
!!CG .,~, .... j 
Figu re 5-13 TN F-u production bV monocyte·derived macrophage' 
,;,h b;, ' " p' e>ent > e,tn. , lIne'PQ",d '" C5I' ox",,>ed MDM pmdu_,,", of T Nf ." in " i ,feded mnd lio n, 
ilott) Of tnl .w''\1 '" If· '"'''' WG ; nr~ , li on l,i8" ' 1 
:'.3.J.2.1 Th ~ ('ff~cl of okoli oe (liS. whole CS E) on TNF alph a productioll 
It ha.' bee n suggrsled th~1 nicotinr, ,1S <kpicted in Fig"r~ 5· 14. acting thro ugh 
"k"llrl ~ <llph<l 7 recq' \ol". CUllum "ffT"'j' -,, production. A, TN !'-,! is i" vol v~tI (he 
rnain\enanc~ of t he i.1tpn( stdte with in rndCfoph"ges, re.Ktiv"t ion n",y Ol'l\lr. ' ?'; To 
~x pl orp th is hypothesi" Jurthe r experiments were COnd\lcted \lsu1g t he commernally 
available u7-rece l' \or h lot:ker, u -bungaro \uxin (Sigmd Al tlrit:hJ. MaGophage , we re 
pre·inC\lhJlerl wi th C\-bungarotoxin-FITC (1.5~!g/mj) tur 15 minutes p rio r \0 the 











Figure 5-14 Hypothet ical effect of nicotine act ing t hrough the a-7 receptor promoti ng 
M.tb infecti on 
r~ ," e reo -,>J ,,, <'(I r,,"n D •• i., ... , I witt, p""ni"i"o , M.lt> !,'e' up int" " ph,g'''''''' " in ,,",,", II., 
"",groon" , y,tt",, ;, . n" -0 0"'0 0/ TNF-(j , ao Iotont "ato ~ ",, ;nto ; ,cd Jnt;1 t ho oqu; l;b-;um ;, ";"",0001 
Th k ,,0 be oJe neJ"" '''' ;''o cf TNf-u by 11"'(1'< th"'-,p e ,, ' k TN f_a bb( , ,,,, c< to """,o_reg," .,;"o cf 
TNf_u by O''''' lin . bind i~ t" til. u 7 " ,bun it or tt., n'-'ol ln " ,e. tylcho" ' e "'("I't(.-" , ~, 
Thc l ~vc l ()f TNI'-rt produced by m3crDp il al{es in fected w;th ReG and l'o-exp()scd to 
nicoline, all ho ugh numeril'dlly IOIH'r, d id 1Io t r~ach stalistk a l signifildn le: mean (SU] 
TNI'-rt In unex p()wd 1111 ,fi ( l!l fi.l ) pgjml compared t() nimt;ne CO-€xpos~d 
78,7(51.48) Pl{j IIlI (p~O , O Il ). Addition () f th~ 1Ii l'oti1lc rt- 7 r~cl'pto r bl ()cker fo r the 111-
il au r infect ion Ili'ri ad di d not r€store TNF -u production , (FiglJre 5 -1 ~l BeCJ11Se of th e 
negal ive rl'sull s us ing th ~ <t7 -wlcp to r blocker nO fllrth~r experiments wew 
conducted w it h (,-bu ngarotox in 
........ ,,, ,',,,, .. 
~ ,,"'. ~ ~,,,," .... " _.. .,"-. "'-~""" ., " ",' , ~' ..... '0'''''''' .'. "" ....,.... 
Figu re 5- 15 The effect of nicotine on TNF-a production by monocyte-derived 
macrophages 
loch I", '.p ro,e,t tho ","o"Jet;G n of TNr~, by rnon Gcyto-"o.-;vod ~ .. "ooh,go, o,tho , u,",xoo>Cd 0' 
",,,,,«'d to 1m; C>f 0' 1,'Wm l oicot; no_ nCG ;nfw"d m"",ph.~e< (18ho Jr< i ,,,er" "'"" '''" du ';n~ 










;'.3 . .1.3 lnterleukin 10 (H.-IO) 
,->J 001 
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figure 5-16 The effect of 10"; CSE on monocyte-derived macrophage I L·1O production 
r" .. , ,w ' '' pre,"nI S >'i l .... ,.' "n" I""><'O ,,,, CS E " pu, eo MllM proo",liu" uf Il -1O i,' IH"" rf'Cl . d wnOili,.,", 
':'ottl o r fo llo"' i"" .. 0 18·~oo, BeG inloction r ri ~htl. 
5, :L3.3.1 The effect of nicotine alone On I L· 1 0 prorluction 
A red uction in IL-I O production hd' been dernon,trdt d Ln non-TH 1110tleb follow Lllg 
expowre to nicotine.' '' To t~5t the eff~ct of nicotine in <l myco h<lCte ri,'1 mod~l , th ~ 
H('G infeclio n experJ Ill enls were repedled wi I II lhe dddil H'" of n ,Wli ne dione, (b'igu re 
5-1 7J Following 18 hour, of HCG expo,ure, the flIe,Lll (S[)J productioll of lL-I 0 by 
lJlonocyt~ · d eriv e d IJl dcropha~~ s w<t.' 40.1(60.3J wJml. When mf~lt io n occurred 
with co-expo,un' to eith,'r CSIi Or nicoti n~ . l'xpo,ed lIIac rophdg~, protlucl'd 
,ignificdllt ly Ie" lL-10 with d lJledn (SD] product ion of 6,9(12) p~/lJll (p=O,02J dml 
11 3( 16,4 J p~! mil p=O.O 3) r~.'p~ctively. The effect of n ;cotine wo.' les5 prono ull ced 










Figure 5-17 The effe(t of nicotine alone on monocyt~-deriv~d mauophage IL·lO 
production 
E.,h b. r repre,~n l th e Woo ll( liu n u1 IL 10 by monoC\'t~ dNrvcd m."Qr l"g~' either ,,,' e'po,ed or 
c'lX',ed to 10% (SIC or 1"r./n>1 n'",otin e , Uni nfecltd ,"""oph.et r~'pon,;~' "'~ on th~ left w it h BeG 
re'p un> 6 f ullowmg IntKtion dep<[ted o n tile ri ohl 
5.3 .4 The effect of to hac co smoke exposure over 5 days on liCC stasis/killing 
by monocyte-derived macrophages. 
Following overnight infection with BeG. MDMs were w~shec.l to remove non-ingested 
mycobJcteriJ ~nd fresh mec.li~ ~ dd ec.l w ith or withuut lO% eSE. :-.1acrophages were 
lysed un d~ys 0,1, 2, 3 and 5 tu release tbe il1tracellulJr organisms, which were plJted 
fo r CPUs. 
To compJre mJcrophJge viJbility Jt d~y S post BCG infectiun between C5E and non· 
CSE expm;ed experiments, ~c.ldition ~ 1 experiments were prepared on glass chJmber 
slides ~ nc.l culture plates. lIarvested cells were stained with trypJn blue exci usirm dye 
and no difference in cell viJhility WJS nnted behveen exposed ~nd \Jnexpused 
mJcrophJges. lI c.l berent m~crnph~ges were w~sbed with PUS and then stained with 
7AAD v i ~bil ity dye in situ to avoid any tramnJ to ce lls JssnciJted with bJrvesl ing, Nn 
difference in (e ll numbers WJS seen between CSE exposed and unexposed 










Figure 5-18 M onocyte deri ved macrophage viabilit y aft cr 5 day BeG in fection 
~dh • • ent ,,"ono ,,1< '"," 'Yed m c-op" f,", ,t"red ..... lth 7AAD v 00 Ilty dyo i rodi folIQ"'in~ 5 dJy, ,n/oetloo 
with ncr, ~I r I;;,,' , n 11.,,) 'e" enl I,,)h '; n; fl •• UI'I''' ' j __ o p, n.', d"~,,,\ "foc\,," out one,po,.d 
cucroph","' " " th e Ir)we'r 1'.110 p" ,er, , ; ~" >'I ' p ".,,, ,,, "' P "\>~ ~"' rl ",· 11 , "'- "rl ;',o l" d w;" 'd, '«)W\, 
" nd yi, 010 coli, with in,[,l co ll" :',, Ref; with , roo" mow< in rI'o Ii,ht clicro \,op , I II' ~"-,, ""t p;lr,I'1I <\C, ' hI' 
'. ft " ~ flU0 ,"" . nt "' ''0''npy p, ne " 00 ,"0 -i &ht 
Thl' CI :U t rends for both eSE-exposed ,md ull ex posed n1" cropbages ar p depicted in 
Figure .'i -19 DdY ZPrO CFlJ COUlltS, totlowing infect ion witho ll ! CSE expo,u)'e. wer'e 
conSidered to be equJ l: meJIl (SD] L4xlO
' 
( ~ , 7xl O J ] eru. "'rom dJy I to day 3 t he 
CSE exposed wells had LllM~ i n ally lll~hl'r e Fll COUI,ts " lt hou~h no t s tdt ist<c"lly 
significant. Un d,ly 5, CH I counts in t he CSE ex posed macro r hdge wpUs WPrP 
Slgni ficd ntty higher comp",,~ ~ to thp non- CSE exposed mJ(]'ophJges: me,' ]) [Sll ) Cl"'U 
COUll t o f 5.6x lO ' (7,Sx l 0 ' ] (FU "S, 4,lxIO ' (4 .6xl03] CFU r espect ively; p_O,OO fJ, No 
si~ n i f i c~ n t differences ill 1:1'11 counts ove r the ~ - ddy ppriod ,,'e re discP rlublp whpn 
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Figure 5-19 Serial BeG colony counts OVer 5 days in monocyte-derived macrophage. 
Mooocyto dOfi.od mcrop hoile, in focteo with BCG wo ," , opt in Gu ltero for \ d,y , ,Ile r th e ",,,, iIi,, ,, o! 10l'; 
CIE to (U ltlirO ", oil , on doy ' ",0 (po,1 in!", li onl. 1 h. >olio blu~ lin~ rep," ,\~"IS u".'p"<ed 'n , ,,oph. ~e, >n c 
'he \tippled re d I; "e [Sf e'p"<ed m"roplu §e" £" h d' 1 rep"'''' '''' th" timo point po" inf""ti on tl", 
nHc roph' i e, woro Iy,,·c one or.o"i,,,, ~d col" at ed by colony coonh on soli d moe;, . 
5.4 Discussion 
III this mon,,~yt~·deriVl'd macwrha~e model of rny~oba~tel'i<ll (BCG] infection ~nd 
,cute ciga retre smoke exposu re ((SEI, I h,ve shown that Vidhil ity "f m'>l:wphages is 
tlot "fterted by 10% CSE exposure. Production of key cytokille, in th~ immurw 
response to TB inf~ctio , namely TNF-u, [FN-y and 11.-10, however, , r e s igtlific,ntl y 
r educed by 5moke expo5ure. Furthermore, prnductioll of 11.-10 , nd TNF -(t dre dl", 
reduc~d hy ~"powre to niwtirw alone (TNF-H H"t reaching s\<l ti stic,, [ s ignitlc<lnce· l 
Nicotine r eceptor blocbde did tlor r estore TNr-(l prnduct ion. Desp ite th ~ 
ohservation that "" effect of c i ~drette sn1(}k~s extrdct on the lLpt"k~ of org<ln i sm ~ 
owr 18 hour, WJ, ob,erverl , over a S-day period, macrorha~e, expo,ed to CSIi h,,,l 
sign,ficantl y higher intracelllLlJr bJcillJry iOJd5. 
III th is aClLte l i~aretle sfH"kc ~x t rac t ~"posure mode!. although s fH<l1l di ffe rences in 










differences were evident at 18 hours. Significant inter-subject variation in uptake 
was seen between individuals, which probably reflects both biological differences in 
macrophage phagocytic function, and experimental variability in actual MOL When 
stratifying by L TBI status those with L TBI had a higher uptake of BCG although the 
effect of cigarette smoke remained constant. 
The effect of tobacco smoke on macrophage phagocytic function has been examined 
using several models. In chronic cigarette exposure models in humans and mice 
using a variety of infecting organisms, phagocytosis of several bacteria and fungal 
species has been shown to be reduced by chronic cigarette smoke exposure 
("smokers" vs. "non smokers")' These include bacteria such as Listeria,99 
Haemophilus,100, 101 Staphylococcus93, 102 and Streptococci103 in addition to fungi such 
as CryptococcuS104 and Candida.10s A reduction in phagocytic index has also been 
demonstrated in acute cigarette smoke/extract «24 hour) exposure models.102, 103, 
105,106 Interestingly, Berenson demonstrated reduced phagocytosis of Haemophilus in 
alveolar but not blood-derived macrophages from smokers suggesting functional 
differences between cells of the small lineage from different sites.100 
There are limited data for mycobacterial uptake. In a myelomonocytic cell line (THP-
1) model, Shang and colleagues infected differentiated THP-1 cells with H37Rv during 
co - exposure to cigarette smoke extract or nicotine. The number of ingested 
mycobacteria was only measured at 1 hour post infection at which time no difference 
in uptake was noted.116 There are no published data on the effect of cigarette smoke 
exposure on monocyte-derived phagocytic function for mycobacterium (M.tb or BCG). 
(The effect of cigarette smoke exposure on alveolar macrophages will be discussed in 
chapter 6.) 
Production of IFN-y and TNF-a and IL-10 was consistently reduced by co-exposure to 
tobacco smoke. A possible effect of the cigarette smoke extract on the ELISA 
reagents was excluded and no difference in cell viability in exposed and unexposed 
macrophages was shown to account for the reduced cytokine production. These data 











following mycobacterial infection and co-exposure to tobacco smoke or nicotine 
using human cells. 
The reduction in cytokine production shown in this study is consistent with several 
published non-TB models. Ouyang demonstrated reduced TNF-a, IL-~, and IFN-y in a 
human peripheral blood mononuclear cell (PBMC) model stimulated with PHA 
following CSE exposure. Wewers and Hagiwara, in a bronchoalveolar lavage cell 
model, showed reduction in TNF-a (following LPS stimulation) and IFN-y (following 
PMA stimulation) respectively.94,111 
The effect of cigarette smoke and nicotine on IL-10 production has not been 
consistent across non-TB-related experimental models with some demonstrating a 
reduction in IL-10 production112 but not others.1°B The reduced IL-10 production by 
MDM exposure to either nicotine or cigarette smoke is in keeping with the 
Madretsma study, in which in a model of healthy non-smokers exposed to nicotine 
patches, IL-10 production by PBMCs was reduced.112 In contrast, Matsunaga and 
colleagues, using a murine alveolar macrophage cell line infected with Leg ion ella, 
showed a reduction in IL-6, IL-12, and TNF-alpha, but not IL-10 when infected 
macrophages were exposed to nicotine. lOB 
Although a consistent effect of nicotine in reducing cytokine production was shown 
for IL-10, there was significant variability in TNF-a production with a non-significant 
reduction in TNF-a production. Blocking of the a7-receptor additionally did not 
show any reversal of the effect of nicotine. The hypothesis suggested by Davies et al. 
that the reduction in TNF-a production is potentially a nicotine effect, remains 
convincing although the current experiments neither support· nor refute this 
hypothesis. A trend towards a reduction in TNF-a production was seen, but this did 
not reach statistical significance (p=O.08). Furthermore a restoration of TNF-a 
production should occur if the mechanism is purely mediated through the a7-
receptor and the a-bungarotoxin receptor blockade over the 18-hour infection period 
was effective. Alternatively, the effect of nicotine on TNF-a production may be 











induced TNF-a production is TLR dependent,218 The expression of TLR2 on alveolar 
macro phages is reduced in patients with COPD219 and furthermore, there is evidence 
from non-tuberculous models that macrophages from smokers have impaired 
signalling through TLR2j4.220 Tobacco smoke potentially impairs three major 
pathways resulting in impaired cytokine production (NFKB, PI3K and MAPK), which 
could further facilitate escape of M.tb from the protective immune response.221, 222 
It appears from these results that both pro inflammatory and anti-inflammatory 
cytokines responses are impaired by cigarette exposure. Stampfli and Andersen 
suggested that the effects of tobacco smoke may not merely suppress cytokine 
function but may skew the 'inflammatory mediator profile' and the nature of the 
skewing may be being a determinant of the disease.14, 107 Macrophages do not act in 
isolation but are involved in complex interactions with several other immune cells 
such as T-cells, NK-cells, and neutrophils. Contamination by T-cells may account for 
some of the minor differences seen when correcting for L TBI status, as macrophages 
do not have immunological memory. 
Although regulatory T cells (T -reg) have not been implicated in control of 
macrophage function, they appear to play a pivotal role in preventing 
immunopathology and limiting collateral damage to the host caused by exuberant 
immune responses to the pathogen. Yet, T-regs significantly inhibit protective Thl 
responses especially with respect to IFN-y production.191, 223 T -regs are increased in 
active TB.190, 191, 224 Additionally, there is evidence that regulatory T cell number may 
be affected by smoking in conditions like COPD.225, 226 It remains unclear what effect 
smoke exposure may have on T -reg function in the context of TB or on the induction 
of alternatively activated macrophages. 
Failure to inhibit intracellular mycobacterial replication is a key factor in disease 
progression and is related to both the virulence of the infecting organisms and to 
bacterialload.118,227 TNF-a is important for granuloma formation and impaired TNF~ . 
a production may result in progression of primary disease. In the 5-day infection 











higher in macro phages exposed to tobacco smoke. This suggests that cigarette smoke 
impairs pathways involved in the containment of intracellular infection. Possible 
mechanisms are impairment of phagosome-lysosome fusion, or modulation of TLR 
responses. 
There are no published studies examining intracellular BCG growth in monocyte-
derived macro phages exposed to cigarette smoke extract in humans. In the 
experiments over 5 days, excess cell death in the CSE exposed macrophages might 
release organisms resulting in a higher MOL No difference in cell numbers or 
viability was detected between exposed and unexposed macro phages after the 5-day 
culture. Thus excess cell death is an unlikely explanation. This model is limited as the 
timing of macrophage exposure to smoke and M.tb in the human lung is highly 
variable - these experiments thus need to be expanded on in alveolar macrophages 
from smokers and non-smokers. 
In a mouse model where mice were exposed to cigarette smoke for 14 weeks prior to 
aerosolised infection, smoke exposed mice had significantly higher bacterial burden 
in the lungs and spleen 30 days after infection.116 Shang and colleagues suggested 
that in this mouse model, the higher CFU counts were the result of a smoke induced 
impairment of both innate and adaptive responses resulting in a greater number of 
foci of inflammatory cells but reduced influx of CD4 and CDB effector and memory T 
cells. 
In summary and to my knowledge, I have demonstrated for the first time a direct 
deleterious effect of cigarette smoke extract on cytokine production in response to 
mycobacterial infection using a human in vitro model. This study has also shown that 
cigarette smoke extract exposure facilitates intracellular mycobacterial (BCG) growth 
in macro phages. The signalling pathways affected by CSE exposure are yet to be 
defined, as are the intracellular mechanisms by which intracellular mycobacterial 











6 The effect of tobacco smoke constituents on 
mycobacteria-induced alveolar macrophage responses 
6.1 Introduction 
The lung is the primary route of entry for mo~t lases of t\lberl\l l %i~. Inhaled 
infeCliuus drop let nudei if m't tr:Jpped by the upper ai rway cilia and airway mucus. 
m~y se tlie in the luwer respiral(Jry l roln. II lvc"lolr Illolcropholgcs in [(J [Kerl with 
dendritic cdls1ol. m Jnd ncu trophilsn" constitute the primary defence Jgainst Til: 
phagocytosing the organisms.us I:;, If organisms are no t clearcd, Jctive disease 
develups. ch~r~clerised by ex uberclnt inllarnmcltiun involvi ng recenUy recnJ ited 
immature mJcrophJges '"" and M.th antigen-specific ThI r esponse~,"l. '"' with large 
amounts of locally secreted IF~~;,. These protcctive immune respon~es may be 
counter~cted by M./h- indIJced im mun e eVcls ion ''') involving the prod uction 01 
suppressive cytuki ne~ and effector muleC\de~. '"'· ""."~' The~ e inleraclion~ clre 
summarized in Figure 6-1, reproduced from a recent article hy SchwJnder and 
Dheda.l'YJ 
.. - . 
" --,:' 
• 
Figure 6-1 The spectrum and immunopathogenesis of M. tubercuJo5i~ infection 
Mywb"Ct",i. " . 'ln h,l . d into th e lu nS . Iv. o li Ill.nd m.y b. cl •• red (21 by , t . n li, ;n?, Inn"," Or .d.pli.e 
immu n. mech.ni,"" (w hic h m.y delerm in e Ih. , .," 11' 01 the TST and IGRtI a>,"y'. In th e rem.inder (31 
in!",li on m.y proS " " to lISI(4). or lo , et iv. 18 «5%1 (51, 50m. in div'K1u ol, may , eyert lo n.goliv •• her a 
t ron,; . nl p!' riod of po" I'", ity (6) Tho>e .ft.r cl . iI,",,'?, Ih . " infect ion (2) may b. r.-infec led m.y ole., Ih.ir 
in!"'t,"n (2 1 proS"" 10 lTSI (4) or .eti •• di'.iI'. (5), d'pend in?, On lhe pre.'i fln p. Imm unily. Fi?,ur •• nd 
"'s . nd reprod uc.d Wit h p!'rmi" io n, -'" 
TNF·a, in conj lmction w ith IFN-',', plays an important role, not only in killing 











formation. Therapeutic TNF-alpha blockade208, 229 and hereditary IFN-y and IL-12 
receptor abnormalities are associated with susceptibility to TB.209, 210 TNF-a drives 
polymorph apoptosis and inhibits clearance of apoptotic cells230 controlling 
mycobacterial growth by promoting the killing of virulent mycobacteria.!17, 118 
Tobacco smoke is thought to increase macrophage apoptosis,231 although not all 
studies support this view.119·123 
As discussed in Chapter 5 there is little mechanistic data on the effect of tobacco 
smoke on TB-specific immune responses. In a mouse model examining the role of 
tobacco smoke in mycobacterial infections, Shang and colleagues confirmed a greater 
number of organisms in both the lungs and splenic tissue 14 to 30 days in mice 
exposed for 14 weeks to both a aerosol of M.tuherculosis Erdman and tobacco smoke, 
than those exposed to the organisms alone.116 Furthermore they showed that in 
alveolar macro phages from 2 healthy non-smokers (human) infected with M.th over a 
4 day period, higher M.th CFU were recovered from 10% CSE exposed macro phages 
compared to unexposed macrophages.!16 The effects of nicotine and cigarette smoke 
on cell viability, acute cytokine production and apoptosis were not studied. Since 
mouse models of mycobacterial infections do not adequately represent human 
disease, evidence from studies using human cells and pathology are required.199 The 
experiments described below were designed to examine the short-term effects of 
cigarette smoke and nicotine on the responses of human alveolar macrophages 
infected in vitro with non-pathogenic mycobacteria. 
6.1.1 Hypothesis and specific aims 
Constituents of tobacco smoke may attenuate protective alveolar macrophage 
effector cytokine responses to mycobacteria. 
6.1.2 Specific aims 
1. To determine whether cigarette smoke constituents modulate mycobacterial 
uptake by alveolar macro phages. 
2. To determine whether mycobacteria-infected human alveolar macrophages 












3. To determine if effector cytokine production by mycobacteria-infected 
alveolar macrophages is impaired by short-term in vitro cigarette smoke 
extract exposure. 
4. To determine if impairment of alveolar macrophage TNF-a production is 
mediated through the nicotinic a-7 receptor pathway. 
6.2 Overview of methods 
6.2.1 Preparation of alveolar macrophages 
Alveolar macrophages were obtained via bronchoalveolar lavage from healthy HIV 
negative, non-smoking controls, as described in Chapter 2. Briefly, harvested alveolar 
macro phages were allowed to adhere to flat bottom tissue culture plates for three 
hours in complete culture medium (10% AB serum in RPM! supplemented with 
100U/ml Penicillin and 0.1 %FunginTM). The cells were then washed to clear the 
culture of non-adherent cells prior to infection with mycobacteria or exposure to 
tobacco smoke. 
6.2.2 Preparation of cigarette smoke and nicotine extract 
Fresh cigarette smoke extract (CSE) was prepared for each experiment using the 
standardised protocol described n Chapter 2. CSE was prepared from Marlboro 
Red® cigarettes and used at a final concentration of 10%. Nicotine was diluted in PBS 
to achieve a final concentration of 1 Ilg/ml, which was used for all nicotine exposure 
experiments. 
6.2.3 Infection of macro phages 
Macrophages were infected with BCG at an MOl of 2.5:1 as described in Chapter 2. 
Aliquots of frozen stock where thawed prior to infection. Following an 18-hour 
exposure, non-ingested bacteria were washed off prior to further experimental steps. 
6.2.4 Macrophage viability and extent ofapoptosis 
Flow cytometric analysis was performed to determine macrophage viability (necrotic 











exposure to cigarette smoke extract and nicotine. Adherent macro phages were 
dislodged from the culture plate with cold PBS containing 20% EDT A (Sigma-
Aldrich). Macrophages were washed with FACS buffer and Annexin-binding buffer 
(10 mM Hepes, 0.14 M NaCl; 2.5 mM CaCh; pH 7.4) (eBiosciences). Annexin-V APC 
(eBiosciences) was added to the cell pellet and incubated for 15 min in the dark at 
room temperature. After a final wash and immediately preceding cell acquisition, 10 
III of 7 AAD (eBiosciences) was added to the cells to enumerate cell death. 
Macrophages were acquired using the FACSCalibur (BD biosciences) flow cytometer 
and analysed using Cell Quest and Flow Jo software v9.2. With the application of three 
different fluorochromes, the uptake of the bacteria (BCG-gfp) as well as the apoptotic 
(Annexin V) and necrotic indices (7 AAD) of the cells could be assessed. 
6.2.5 Cytokine production 
Cytokine production was measured in the culture supernatants after 18-hour 
infection with or without CSE or nicotine exposure as described in Chapter 2. 10% 
CSE or 1 "",g/ml nicotine were used for exposure experiments. To examine the 
potential role of the nicotinic a7-receptor in TNF-a responses to infection and 
nicotine exposure, alpha bungarotoxin was used as described in Chapter 5. 
6.3 Results 
6.3.1 The effect of cigarette smoke extract and nicotine on BCG uptake by 
alveolar macrophages 
BCG-gfp uptake was assessed at 18 hours following infection and exposure to either 
cigarette smoke extract or nicotine alone. Infection of macro phages by gfp labelled 











Figure 6·2 Alveolar macrophages contJining ingested green fluorc s<cnt protein Igfp) 
I~bclled BeG orgJnisms 
T' . g' « " '''CM'' o. p'd BCG-gfp wi",n m.:loroph'g.' , ,',e tl"" rod ,rrow" 'in.,l. non-molo 7AAD po,i'"o 
rrkovol",,~e io Ih. t..-o P''' ''!>: t, ,, 1m po,.1 ,how" I,ght micro>co "'c View of non-,eh .,,,,, .01",1 .. 
m.crol;,,~el con l, ining fl oo ' e,(iog b<k orgdni,m> 1 he , 3' I p"e l cemumt,"I", I, e ""'" .,,,,oph<oge, 
hy 11",,'o«onoo micr""'lpy, ag,i" oeClO".\Ir"I"'~ II c-rescenl orgM,"- ,n\, hu l .110 ,lome non_<I""'ili ' 
macrop"~o ,uto_ll"" ' o,,omo 
The mcan (SLll rcrcentd ~e af .,lvl'alar rnacrorh.,~e, (unexpa,ed ta wlOke or 
n icoti nej positive for gli) labe ll ed neG WJS: 3 5_8°Ir, (2 0_3J and was not different to that 
in ciga rett e smoke dnd nieotlJle ex!-'osed alvcolar macrorha~es 37,0%(19,7J dnd 
:l2, (j 'X,(1fl.5) re'pectively: p =(U8 (Figu r e 6-3) No diffe rellc€ ill uptJk€ W.'S w€n 
wll€n st rau fying by L THI status (1\ p!-'endix C] , Thus cigarctte smokc anti nicotine tlitl 
no\ dfkc t the lIr take of BeG into alveo ldr rn.,erophage, in vitro. 
Figure 5-3 Uptak€ 01 BeG organi~m5 by alveolar macrophages 
M,crophdge' ""ere "th...- LK ,e'poleci 0' e'I""ec 10 loh'cc0 >er ok" 0' nICol,, " du"i,,!: Ihe lS-huu, I""iud ur 
mycoi .. "o, i,1 inloctioo . from lett '0 'ight 'ti e th 'ee ikors 'eprel on t u nexp owd """ro""~o" 1m.; "g" ptte 
,moko o'po,oe , nd lu~/ml n;ooti"o o,>,moo rt'kK'Op"~""_ IJp"'o """ mo,_, u,oo hy llow cy'""",'ry 
6.3.2 The €tfect of tohacco smoke extract. Ilicotin€ and R(G-gfp uptake on 
alveolar macrophage death 
In ltnexroscd dnd un infectcd alve,olar 1Il.,eroph.,~e,. viah ility VII." )(l'€ater t h.,n 70%; 











Lminfectprl .1lveol~r m~croph~gps exposerl to ei ther de~rette smoke e~t r'lrt or 
ILLco! ilLl" 28.0%[17, IJ and 2').0%[1 5,OJ 7!IJ\[) I"-" lllvl' lell> re, pl' ~\ively [p-O,14J, 
AlthoLJeh nLltlL e rk~lly lower, t he vi<"\b ility of ' \L ~c rop l1'lges WJS not sienitlc,llltly 
dffeu,'tl hy BU; infl'e\lon dlonL' or whl'n w-CXpOSLl "~ to ngdn'ttl' smoke extract or 
nicotinp ocwrr l'd durine infection: Vi,lhility of BCI. infected/unexposed , lwolar 
m"<Toph~ges WC<S neMly 80% ' mean (S])J 7 A,A]) posit ive cell s 20.8%('l1J This w~s 
compaLlhll' to t he BCG inf<·cted /smoke expo_,cd mdlrnpha!;e>: 11:l. 1% (5,I J and BCG 





Figure 6·4 Viability of alveo lar macrophages fo llowing BeG inf ection 
lllveo l" ,,,wop lkOg. ,"~", I;'y "'"' <:le I. ",,;·,." l>\' IM D ;I " ;'I;"~ ro l..,,,, ;,..: 18 1'00' " feGl;or or" "'PO;" e 
10 e ;lh ", lob«,o <rT'" ,e e . I,oc' "r ";ruline Perc, "',,!; e ce ll d", Ii> d"PI'·I," 01' II" yo,,;' rep"' ,,, ,!; Ihe 
DC[( UTI,,!:e ,";r , ,,~ f'v,iL~'e w; 1 to 7MD 
Kl'pre_,cntdtivl' do! pin!, of Illacrophage> viab ility '\dining with 7J\'\U for BeG 
inflTted/ un<'X I,o',etl , lvcoIar m~(ro~ha!;L" dnd BeG infel'll'd 10% cL!;dreHl' smoke ur 
1 Ilg/mi nicotine exposed ~ I vl'olar m,lnophaRes ~ rp shown in Figurl' 6-S , Vi,h ili ty 
[7A,A]) neg~t ive J of HCG-gfp po, iUve mdlropllage, \','d' ~pproxJtn,,\dy ~ t % f,H· 
expo;L'tl and unL'xl"-'sed dlveolar n",uophdgl's, NC1 \her l i!;arelte _"noke flur niwtilll' 










Figure 6-5 Flow cytometry dot-plots of alveolar m;)crophage~ BCG-gfp upt~ke and 
vi~bility 
The reprt,~n t "t'" " fl ow cytom "try dot -plo" depict BCG-Bfp UPT"'" On th t , -" ,; s J od 1 MD v1oIlW,ty , t ,m ln p, 
on th e Y-d';S P~n . 1 A: BU; gfp infection without £,po,u r£. P~n"1 B; Inf<'<Mn with ( 0 " pa,ur e to 10""; CSt 
P"nel C: In l tlt'an with co e<po,u re to 1 "!jm I "'(ottne. T h. bottom fl r,ht qWd'dnt of . 11 p",, " I, repre'£I1\s 
,live an d BC(; -~tp infected m,crop h"ce, 
6 .3.3 Alveolar macrophage apoptosis following BeG infection and exposure to 
cigarette smoke extract or nicotine. 
As cell death was not Jrrected hy elhcr (igJrette smoke extract ICSE) or nicotine. the 
etlect on JPopl.Osis WJS investigJted. Apoptosis was determ ined by Ilow cytometry 
positive Annexin-V I eillOsciences) stJining using ~ FACSCJlibur (BD bioscwnces) How 
cytometer FACS cJ libur after hJrvesting of thc Jdhnent cells post infection. There 
WJS no di fference in macrophJgc JPoptosis (Annexin V positive cells) hetween 
uninfected co ntrol, and CSF: or n icotine exposed alveolar mJcrophJgc$: me~n%(SD) 
control 7.2%(1.2). CSE exposed 8.0%(S.(,j and nicotine exposed 8.9%(6.2J; p=0.4. 
(Figure 6-6) Following inkction the exlent of Jpoptosis in infected mJcrophJges WJS 
no different from \Jll infecte ti mJcrophJges. J\lthough J similJr pJtlel-n of slight 
inu-c~ses in apoptosis in CSE and nicotine cxposed mJcroph~ges WJS seen following 
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Figure 6·6 Apopto,j, of alveolar macrophage, fol lowing BeG infection 
Apapto,', "''' det Nminod ',y ."",iti,." .\nno,i r.-V '''i''lng. ,,,,I- 'Of"'"'" I"" rep,...,.,n" "l "'iX"LJrc 
co ,ditioo. Tho I. ft te.-" ~or, x··,~ un;,toctd ,no tr.o r ; ~ht th roo hi", GCG intoctod m,croph'~o" 
re'P.ctl "".,. 
Repr ese ntative flow cy,()melry dor plo ts depict ing flC(; -gfp uplake and Annex in-V 
staining in unexposed Jnd CSE or nicotine exposed " lveolJ!' lll<lCl'opilages wi lh om! 
witho ut IlGC infection a re showll in l' ig UL-e 6-7. Nvither necrosis nor programmed 
cel l deat h of al ,'eoi"r m<lcroph<lges ap pe <lred to be J lIected by expOS\Jre to r 'g<lrell e 
sllwh ~xlr"cl Or nicoti ne ;n th is model. 
,,. ----------
• Ie<' • ________ ~,.'"' , 
,,~---
Figure 6-7 Flow cytometry dot -plots of a l veol~r m3[roph~ge, with Annexin-V 5taining 
n. G p. 'l .l , " "pi, t r.p' "," nl,I". Ilu w c'/lo""' I"I dot-p lob fro ," 0'. eq,.ri",,, nl wllh 5CG-gfp Jpl,,'" 0' 
tr.O <-0,1, " d Anno,ln_" " a ining 00 11'.0 y_a,i,_ Tho :op 'hoe p",o l, ><0 ReG "", "Ied"o (.a"o lllo,,, P. "" I 
A: Uni , fo" t< d/u,oxpmed ( 011,,; P. nol B. Un"toctoo/lo<!i ' ; .",0110 c,mo'e o,I"".t o,.""sNl; P. n.1 C: 
U"n f"c l "d/l~Lg/',,1 ,'(o lin " ", po><d ~h " low", "~ CO" P' ,.1, aro GCG infwed (Q ,dil·0",_ P.~f 0: BCG-~fp 
int N.tod/LJne'pa<.Co; P. ne l ,_ ~c:G-gtp inl "O"d/l<fr ('ig, r' lI " <mo •• ",I'cc l " ' iX'''o; p.nel f. BCG-g lp 
;n f"c l ",I/l ~ Lg/',,1 n ~ ol' n " "xpo,od_ ~~.o upper r i ~hH"d QU,d ' ,"1 of ""~ p.., ,.1 r.pr."" nt , oolh inf. " t<d 











6.3.4 Cytokine prmluction fonowing mycob~cterial infection 
6.3.4.1 Interfe ron gamma (IFN·y) 
The ba,al (un-,ti mula ted] production. mean (SD] of IFN'"I after IS-hours waS 
O.OS(O.OOlj lli /m l. CigHr~tt~ .mok~ expo.ur~ did not "I t er IFN-y proJuction me3n 
[SD): 0.05(0.02) IU/ml (1' =0. 43). In cont ra, t. post BCG infection [18 hours). ",mall 
but sign ific"nr incre<1se in IrN-y occurr~d wit il a me"n [SD) prod uction of lFN-y by 
CSt: unexpo,e J alveolar macrophage of 0.0'01(0.03) IU/ml (IFO.OJ). Another 
, ignii1c<lnt find i n~ wa. of" ,m,l]] but ,t"ti,tically 'i~nificant reduction in II:N-,' 
productioll hy alveolar m"nopioage, exposed to 10% CS E during infection: 
0,07(0 ,01) Ill/ m I U)mp3 r~J to unexpo,~J m3uoph3ges O,OY (0,03) jlJ / ml, ( p ~ O , 04~ ). 
[F igll re (;-8) 
., I ... ,.., 
",,,,,",, ","""'", 
Figure 6-g Interferon gamma production by alveolar macrophages 
ItN-:,' production i, reporto" in IU!ml on th. Y-"i " Th.lc!t two b", repre, ,,,,t Jninlt"Cted corKMk'1' lit 
hour unlnlect"'; "ltJr.) ,,0 the two 'i~ht b,,, It ' our ~(G inle,"on with or ", ;rilo"t 10:; d~"e"" ,Oloke 
"'po,"," 
6.3.4.2 Tumour necrosis (actor alpha (TN~'-(X) 
The bJs,,1 [un-stimulated] pt'oduction of TNF-" by a lveolar macrophJges waS high: 
me"n [SD) g 2'1. I[ ~ 7'1 Jl) pg/m li n un~xpo,ed macropi1 "g~' cOIn p3red to 720, S(42.'i.fi j 
pglml antI S~ 0, 1 (3'l'j.l;) pglml in ,moke ex posed antI nicoli ne-e.'posed m"croph" ges 
respectively (p=O,3], (Figure 6-Y) Fo llowing Ill -hour infect ion . the product ion of 
TNF-u. w", si~n ific "ntly lower than that from bas"l condition" flO; in f~cted 
mJcro~h"ge, 42~.4 [1 36.7) ~g/m l vs. uninfeCled m"U'o~hage, n'l. 1(37'l.8) pgjml 
(p<O.OO l'). No etfect of ~ i ti1er lig" r ~tt~ .moke extract o r nicot ine w", Jemon,trable 










on TN F -(1 prorlllction when 8CG-in!ec rerl Jnrl \ln € xpnserl tl)~cro]lh<lgPS ,11 LO Ur, 7.2] 
pelm ! ~nd ·)fl(U (c.ll C.] pelm! '1S_ 1 2'H('B6_7] rc/m l re_'pefli \!e ll' wen' compared 
[p=O,2) . [Figure 6-')) 
To rler,>rmine whether n"'otine a lone mJl' impJir (yrnkin ~ production thrnneh the 
nkoline u.7 -J'el€l'to r, the nkoline ,,7-re<;ep tor blocker U·bullgMotoxin Wd' ddded to 
cultures prior to nicotine c:.posure. This dld not s ignLJl<-antly dltcr TNF-", production 
i~ eIthe r cig" rl'tte snwhe exposed 1 11-0[157,2) pg/ml to 1132[1-73,8) pg/ml "nr 
nicotine e"posed mMrol'h"g~s 4H1U1S I I,S) r gJml to 477,2(S:1S.6) pg/ml; (I' - O,i 1), 
(FigLlre 6-<)) 
Figure 6-9 TN F-alpha production by a Iveo lar macrophage~ 
~.pl"' l e expemT'enl, of ''Yeul" "M(Coph,~el '''' depICted b'l . ",h b" wllh ,h., lefl to ree b,,, uninfec,ed 
h.,,1 ennditi,, ", uno'po.lod 0' C'P""'" tn 10'''; CSf 'o lug/ml n~_n'i"c. The _I rigllt_':"od I,.." 'c p.-o<Cl1t 
infect'" (ol1["io" with or wito e'pmu ' . to (i~',"tto ,moke e,' ''ct !l1icOl".;n th e pre,.". or ab,eme 
of a n~_otin" ,'",op,o,' blodo' ,,_o,ng''-oro. ',,_ 
6.3.4.3 In t e rleukin 10 ( 11 .·1 0) 
As for TN l' -r1, P roducti on of 11. -11l by un-stimu bted ., lveoiar m.,crop hage" W.1S high: 
meall [SD) 19.3{' [ll.{, 7) p~/mL There WdS no sig~ifildnt ~hdnge in IL-IO prO!luctio~ 
in uninfeded macrophdges when exposed to cigarette smoke ~xtract or nicotine 
IS.S[H.6] pg/ml ., nd l Y_1112,2] pg/ml respect ively ip=(12) (Figure 6-11l] 11.-10 
production hy ~I\!eolar macrophages after 1(1 hours [Jet. infection was numerically 
lower wmpat'etlto u~i~ felled mdU'ophdge, 7.4(li,8) pg/ml vs. 1~.3li[ I 1.7J pg/ml 
(p ~ Il . 06) . No effect of co-exposure of BeG infected macrophages to either cigarette' 











p~/ml vs. :;. I(7 .0J pgfml ~nd 7 .1(7.0] pg/llli in U1K'Xpos~d. (igaL-dte sIlKJke exlL-,,,,t 
<lnd ni ('oti [le-expos~d c lI ll' lI res respec i ,v~ l y [p=O.31. A NOV A I. [Figu rp 6- 1 OJ 
! 
"'~" .. ~,., .-. .. ,,", . " .,~, "" .  ~ . 
Figure 6-10 Il-l() production by alveolar macrophage, 
R.p " ..t. well, or, 'eO . ' n""01-'""8"' or. depic'od hj o,,;h h" wi, h '-lO 1011 , he"" i),l r< uri,/ce'od b", 
condi'"" , noxpo",d or o'l'O",d '0 10% (S~ to 1LL~!",J nkotin ._ -h . ci~ht-~d od t hr.e bm r.p re,.r! 
i ,(<'Ct.d co ,do""" with or wit" «po , c·. to ci~ "eH . srnok. e ,\r. d (Or n'-;Olin •. 
6,4 Discussion 
This ~lveol~)' m<lcroph~ge BeG infeCtion model WRS wt up to npand on the 
monocyt~-derived malrophage (MDMJ IlCG-infection/ex])O,me mode l reportFd in 
[ha pteL- .'i to determinc the effc(t of c i ~dr('\te sllloke and n ilot iIK' Olt cells from !h~ 
l'0tenlbl _sil F of infection, the hlt1g Short-term FXpOS\l re ['W hours] to c i ~srette 
sIllo ke extr,,,,l [,CSEj or nicolilte dPpear~d ltot to an~l\ on <l lveolJI' )t1~croph<lge 
viahility or phsgocytosis of TlU; organisms. In ~ddition, no c'ons isten! dIce( of these 
eXpOS\lreS or in fection wilh BCG on "pop1'O_sis fOll ld he d e mon-'tr~tFd. Cytokine 
prodLoctiOlt in th~se e"p~ri rrl<Onts w~_s dift1C\lIl to inlerprel dlle to the hi gh h",,] 
producliolt of T,'-,JF -u "ltd IL-l0 wi!lun the firs! 24 houI's of brollcho~lwol<lr bVJ ge_ 
The reduction in IFN-,;-, seen with [SE expos u re, although sm~lI, cOJTesponds with that 
seen ill the MUM IlIodel. 
A hy finding in these experiments waS that alwoldI' m''''l'OphJge ph<lgocy to sis of 
TlCG was not ~ffected hy short-term exposure to e ithe r c igarette smoke extract OL-











To date, there are no reports documenting the use of cigarette smoke extract in BCG-
infected alveolar macrophages. However, Ando et al. reported no difference in the 
phagocytosis of BCG by alveolar macrophages from individuals who smoked 
compared to those from non-smokers.232 In view of these findings, it is possible that 
the increased epidemiological risk for TB infection and disease associated with 
smoking is not due to impaired alveolar macrophage phagocytosis, but to other 
mechanisms. In contrast to these findings for BCG, in non-TB models of short term in 
vitro alveolar macrophage exposure to cigarette smoke extract, a reduced phagocytic 
index for Staphylococci102 and Streptococci103 was observed. Smoking is a recognised 
risk factor for several forms of pneumonia. For pneumococcal pneumonia an odds 
ratio of 4.1 (95%CI: 2.4-7.3) and a population attributable fraction of 51% for active 
smokers has been reported.233 
Cigarette smoke and nicotine exposure did not alter apoptosis in this model, nor 
could an effect of BCG infection on alveolar macrophage apoptosis be shown. This 
may reflect an inadequate length or intensity (dose) of exposure, or might have been 
confounded by the high degree of biological variability seen in the experiments. In all 
experimental conditions, the number of cells positive for Annexin-V staining was less 
than 15% at 18 hours, necrotic cells (7AAD positive) were however more common: 
~30%. This could have been a consequence of technical issues such as disruption 
caused by harvesting of the adherent cells for flow cytometry. In-situ staining of 
adherent cells would be required to further investigate this question. 
Previous studies of the effect of cigarette smoke on apoptosis in non-TB models have 
also yielded inconsistent results. Tomita et al. showed reduced apoptosis in alveolar 
macrophages from smokers119 but several other authors have demonstrated 
increased apoptosis,121-123 Others have suggested that attenuated strains of 
mycobacteria induce apoptosis while virulent strains have the opposite effect and 
suppress apoptosis. 118, 234, 235 In addition the burden of infection may influence the 
mechanism of cells death. High organism numbers per cell may trigger necrosis 
rather than apoptosis.227, 236, 237 Intracellular growth of virulent organisms is 
facilitated by suppression of apoptosis prior to necrotic cell death when a 











Apoptosis has been shown to be important to intracellular control of mycobacterium 
117, 118 and is in part mediated via TNF-a with suppressed pro-apoptotic gene 
expression following virulent Mtb infection.234 Resident alveolar macrophages in the 
lungs of smokers may thus have reduced TNF-a-induced apoptosis via two 
independent mechanisms viz. M.tb induced repression of pro-apoptotic gene 
expression and cigarette smoke- induced reduction in TNF-a production. 
The basaljspontaneous production ofTNF-a and IL-10 by alveolar macrophages was 
higher than expected. Hyper-stimulation may explain the cytokine reduction post 
infection. Significant effects of tobacco smoke, as seen with the monocyte derived 
macro phages, could only be confirmed for IFN-y following BCG infection and cigarette 
smoke exposure. Moderate basal production (>400 pg/ml per 106 macrophages) of 
TNF-a has been shown in some studies of healthy volunteers238-240 and is high 
(>2000pg/ml) in patients with interstitial fibrosis, sarcoid and rheumatoid 
arthritis.241-244 All subjects recruited for lavage in this study were close contacts of 
TB index cases although otherwise healthy without symptoms. The high TNF-a and 
IL-10 production may reflect the high burden of exposure to both mycobacteria and 
pollutants in Cape Town or possibly activation of macro phages acutely following 
lavage. To my knowledge there are no other reports from high burden countries 
examining basal macrophage cytokine production in healthy controls. 
Cells from healthy volunteers compared to smokers were used as acute in vitro 
macrophage exposure models from healthy uninfected non-smokers offer several 
advantages over macro phages from chronic smokers. Acute effects and responses 
can be studied over a wide exposure gradient. The effect of individual smoke 
components such as nicotine, acrolein, tetrahydrocannabiol (marijuana) in addition 
to exposure to either the particulate or soluble components, can also be evaluated.102, 
110, 245-248 Furthermore, smoke from tobacco, marijuana, crack cocaine etc. can be 
studied. In short-term exposure models however, the magnitude of the effect on a 
particular response has to be balanced with the toxicity of the extract to the cells as 
demonstrated in Chapter 2. Using alveolar macro phages from smokers represents 
more chronic exposure - as in most mouse models examining the effects of smoking. 
Smoker's macrophages are different structurally and often contain significant 











persist for several years following smoking cessation and result in excess auto 
fluorescence by flow cytometry, making the interpretation of results very difficult.250-
253 In addition it is recognized that in COPD patients a persistent COB infiltrate is 
present even after the individual has stopped smoking suggesting an altered 
regulator phenotype that may affect cellular responses.254 
The experimental design, as proof of concept, utilised alveolar macrophages from 
healthy non-smokers with in vitro BCG infection and short-term cigarette smoke 
extract exposure. To confirm and advance these data, further experiments would be 
required using virulent M.th strains and macrophages from both smokers and non-
smokers with and without in vitro CSE exposure. Flow cytometric analysis may 
however prove more difficult given the complexities of auto-fluorescence. 
Inactivation of virulent M.th strains (usually with paraformaldehyde) prior flow 
cytometry will necessitate alternative techniques to identify cell death and apoptosis. 
The optimal concentration of CSE that should be used in in-vitro models that reflects 
physiological concentration in smokers remains controversial. Su and colleagues 
likened the concentration of cigarette smoke used (10%), to a "physiological" level of 
smoking greater than one pack per day. They equated a 2.5% - 10% cigarette smoke 
extract (using 1 cigarette per 10 ml media) to smoking "slightly less than 0.5 packs 
per day, to slightly more than 2 packs per day".248 The majority of cigarette smoke 
extract models employ a 10% solution for exposure. 115.248.255.256 Acute exposure 
models however do not mimic the true air/liquid interface within the alveoli nor the 
chronic but intermittent nature of smoking. 
In summary, the findings of the alveolar macrophage experiments have expanded on 
some aspects of the monocyte derived macrophage work, suggesting that acute 
exposure to cigarette smoke extract or nicotine at low concentrations does not impair 
phagocytosis of mycobacteria (BCG) in cells from the site of disease. Apoptosis was 
not significantly altered by BCG infection or cigarette smoke extract or nicotine 
exposure in this model. The cytokine responses are not easily interpretable due to 
the high baseline cytokine production, which may be a reflection of the recruits 
having been exposed to pollutants, mycobacteria or mechanical stimuli. Further 











7 Future directions 
The data presented in this dissertation and the work recently published by Shang and 
colleagues116 are preliminary steps in identifying the biological and molecular 
pathways responsible for the association between smoking and tuberculosis. 
However, many questions remain unanswered, some relating to the work presented 
and others of a more general nature. 
Firstly, in respect of the experiments reported here, it is important to establish 
whether the effects of cigarette smoke extract on macrophage function are influenced 
by the virulence of the organism. This can be addressed by repeating the 
experiments on cytokine production, apoptosis and mycobacterial stasis using 
different strains of virulent M.th instead of BCG. Secondly, alternative protocols for 
harvesting and preparing alveolar macro phages are needed to explore the reason for 
the high background levels of cytokine production; whether this reflects basal 
function in vivo or is a consequence of the method of lavaging the lung or the 
processing the cells. The latter is unlikely, as the methods used have been widely 
used in other studies. A more general question is the need to identify the intracellular 
signalling pathways responsible for the cellular and cytokine effects demonstrated. 
Evidence from non-tuberculous models of infection, suggest that macro phages from 
smokers have impaired signalling through TLR2j4.22o Engaging the TLRs initiates a 
complex cascade of intracellular and intercellular signals that facilitate protection 
against pathogens. Potentially, tobacco smoke may impair three major cytokine 
production pathways, those involving NFKB, PI3K and MAPK. This may enable M.th 
organisms to avoid protective immune responses.257, 258 This issue needs to be 
studied in a human TB model. 
M. leprae, a pathogen that evades host immunity, has been shown to down-regulate 
the induction of some pro-inflammatory (IL-6) cytokines and induce high levels of 
inhibitory cytokines and chemokines (IL-1Ra, MCP-l).259 These effects are mediated 
through activation of PI3K. Phosphorylation of PI3K mediates the activation of the 
downstream target Akt and in turn the phosphorylation of the glycogen synthase 











Zhang et a1.260 that may account for the reduced production of selected cytokines by 
BCG-infected macrophages. Thus examining the role of the PI3K pathway in the 
modulation of the profile of pro- and anti-inflammatory cytokines and chemokines in 
M.th and BCG-infected macro phages by tobacco smoke, may yield important results. 
MAPK activation leads to a wide range of cellular responses including cytokine 
production, inflammation and apoptosis. Tobacco smoke may inhibit or delay the 
activation of the MAPK pathway, thus affecting the nature and the magnitude of the 
cytokine and chemokine response. Tobacco smoke may also interfere with the 
activation of this signalling pathway independently of or via the PI3K / Akt pathway. 
The role of the nicotine a-7 receptor in the inhibition of macrophage cytokine 
production and apoptosis remains unanswered. There are other nicotinic receptors 
such as the a2f34 receptor the target of the anti-smoking drugs varenicline and 
cytosine although these receptors and the a7 receptor are not present on cell lines 
nor mice. 261, 262 Closer examination of the pathways by using an inhibitor of the 
nicotine a-7 receptor to confirm its role in the PI3K dependent reduced cytokine 
production may offer clearer insights. Furthermore it is known that activation of 
PI3K/ Akt pathway can prevent apoptosis through inhibition of Capsase-9 
activation.263 To determine if the effect oftobacco smoke on Capsase-9 is through the 
nicotine a-7 receptor /PI3K/ Akt pathway, further alternative methods of receptor 
antagonism such as pre treatment of macrophages with the nicotine a-7 receptor 
antagonist (quinolizidine) may reveal changes in caspase-9 activation. Given the 
technical complexities of flow cytometry using alveolar macrophages, alternative 
strategies for the detection of apoptosis such as in-situ staining of adherent cells 
(prior to fluorescent microscopy with Annexin-V and propidium iodide) in addition to 











8 Conclusion and recommendations 
History appears to be repeating itself. This time however, it might have a sting in its 
tail. A century ago a tobacco smoking was widespread and tuberculosis (TB) was 
rampant in many parts of the world. In 1918 the "Mother of all pandemics",264 
Spanish flu killed nearly 50 million people worldwide.264. 265 An interaction between 
smoking, tuberculosis and the influenza virus was not, to my knowledge, suspected or 
reported, but, in the light of modern research might well have played a significant 
role. Interaction between organisms, host and the environment are now recognised 
as the rule in all infections, including those that reach epidemic proportions, and 
likely determine their impact. 
At the beginning of the 21st century, the globe is facing the convergence of several 
potentially devastating infections. Faced with declining markets in the North, the 
tobacco industry is moving south, where smoking is on the increase, especially in 
countries such as China and India. Tuberculosis remains uncontrolled in the 
developing world with increasing rates of multi-, extensively- and pan-drug resistant 
tuberculosis. HIV has added a new facet to respiratory disease with associated 
increased rates of TB and pneumonia. In addition we are facing the looming 
possibility of a highly virulent H5Nl "avian" influenza pandemic, with the novel strain 
of HINl "swine" flu recently added to the mix. 
This dissertation, explores one aspect of these colliding epidemics namely the 
interaction of tobacco smoking and immunity to tuberculosis. Before this could be 
addressed several questions and issues including the standardisation of methodology, 
accurately defining study subjects with respect to their TB infection/immune status, 
and identifying the most accurate method to determine mycobacterial load in the 
proposed studies, needed to be answered. 
In basic science studies clear delineation of the TB infection status (uninfected, versus 
latent infection, versus active tuberculous disease) is important as it may affect 
immune responses. Additionally it will aid in distinguishing between TB-driven 
immune responses due to immunological memory rather than the intervention being 











several guidelines as a replacement for the tuberculin skin test. However, as reported 
in this thesis, this decision is not without problems. The interpretation of results 
requires refinement because of within-subject variability. Based on my data, an 
uncertainty zone around the cut-point was defined and a threshold for defining true 
conversions and reversions of L TBI status has been suggested. It was also shown that 
an antecedent tuberculin skin test can affect subsequent IFN-y responses. To avoid 
this potential boosting of IFN -y responses, a three 3-day window has been proposed 
in which to perform a confirmatory IGRA. This fortuitously falls on the same day 
required for reading of the TST. The extent and importance of this variability and 
boosting of IGRAs by prior TST requires investigation in low burden settings. 
Furthermore, my work has demonstrated that guidelines developed for low burden 
settings might not be valid in high burden countries. 
Having unravelled how IGRA results could optimally be defined and interpreted, the 
next step was to determine the best way to quantify mycobacterial load in the 
proposed studies. Although several techniques exist to quantify mycobacterial load, 
none has ideal performance characteristics. With the growth and development of TB 
research, newer approaches to quantifying mycobacterial load have emerged. For 
example, newer technologies such as automated liquid culture have been adopted in 
drug development in early bactericidal activity studies.266 Novel technologies such as 
Xpert MTBjRIF remain untested. In this dissertation,S techniques were evaluated 
using a wide range of performance characteristics to determine the optimal 
techniques for use in laboratory-based studies. Liquid culture and Xpert MTBjRIF 
offered advantages of sensitivity and rapid turn around time respectively but had 
other limitations, particularly higher cost. Solid culture, despite its limitations, 
remains the cheapest option and is therefore likely to remain the best option in 
resource-limited settings. The final choice of assay however, will largely depend on 
the experimental design and research context with a trade-off of cost versus 
turnaround time. Although the data is of primary relevance to basic science 
researchers, it has applicability to clinical researchers in both well resourced and 
resource constrained environments. Furthermore it provides a structured 
comparison of technologies that will aid decision making in capacity development· 
situations where new research infrastructures are being developed and technologies 











The paucity of data examining the cellular effects oftobacco smoke on mycobacterial-
specific immunity is striking. In this dissertation a human in vitro model of 
mycobacterial infection and exposure to a standardised cigarette smoke extract, 
using both monocyte-derived and alveolar macro phages is presented. Infecting 
macro phages with BCG organisms with co-exposure to cigarette smoke extract, 
showed a clear effect of reducing cytokine production. No effect on mycobacterial 
uptake or cell viability was demonstrated to account for this phenomenon. 
Intracellular containment of BCG growth was furthermore impaired by cigarette 
smoke extract over a 5-day period. These data are intriguing given the lack of 
published data on human tissues and supports recent findings in mouse models. The 
preliminary evidence that nicotine alone may have similar effects supports the call to 
regulate nicotine-containing products267, 268 and raises a concern about prescribing 
nicotine replacement therapy in tobacco cessation programmes in high TB burden 
settings. Randomised controlled trials are currently exploring the benefit of smoking 
cessation in active TB patients. It will be interesting to speculate that nicotine 
replacement therapy might be to blame if no beneficial outcome is seen in the tobacco 
cessation group. Together these data go some way in providing a mechanistic 
explanation for the epidemiological association between smoking and tuberculosis. 
The alveolar macrophage experiments expanded on several aspects of the monocyte-
derived macrophage work. The lack of effect on mycobacterial uptake was confirmed 
for both cigarette smoke extract and nicotine. The cytokine responses were difficult 
to interpret because of the high background cytokine production. Further work is 
required to clarify the findings. Although no conclusive effect on apoptosis could be 
demonstrated, apoptosis and intracellular survival of mycobacteria will need to be 
evaluated using virulent mycobacteria. 
This dissertation has presented evidence to support the epidemiological association 
between smoking and TB. Much work remains to be done and the molecular 
pathways involved have not yet been defined. Given that epidemiological data 
remains confounded by socioeconomic factors, these data provide policy makers with 
scientific evidence to support and strengthen tobacco control measures. In South 











enormous burden on the health care service. The final number of people who will 
succumb to TB, HIV and CO PO will depend on the combined efforts of government, 
health agencies, non-governmental bodies and researchers. 
Karl Marx said: "History repeats itself - first as a tragedy, second as a farce". It 
remains to be seen whether over the past hundred years we have learned enough to 













Cytokine production hy L Till status 
l 
Figure A 0-1 Monocyte-derived macrophage IFN-y production 'tratified by , ubject LTBI 
,tatu, 
I I ~ I rO " ! IYe , uhj C'<:t , arc dcr icted In , ollrl (Dlours wi th LT ~1-neptIYe ; uhject, ,n ,horled hor; 
Th c mcon (,D) IIN_j pcOOUCMn followlnR Infechon by unc<posed comp ared to (S[ ",posed 
mur1<Jcyte-deri~"d m . Lroph.g~> w." 0.27 (0.21) ~g/m l ~,. 0.29 (0.14) ~g/m l I~=O. 73) 
,.., " 
I , 
Figure A-0-2 Monocvte-derived mJcrophJge TNF-a produr:tion st rJtiiied by subject LTBI 
,tatu, 
l '81 PDSltlVC ;ubject;",e dePicted in ;olid colours with I.T81-ncgatiyc ;ubject, in 'haded h"rs, 
The mean (SO ) TNF-H production followin~ infection by unexpos.ed co mpared to (SE expos.ed 












Figure A- 0-3 Monocyte.derived macrophage IL·1O production stratified by subject LTBI 
status 
lTBI-pas i tiv~ ,.u bJ"c t., arc depicted in sol><i co lou rs with lTB I-""1l"at ive , ubj ect' i ~ 'h"ded bar< 
The m e,, " (SO) Il-l0 proouction followi ng in f~ctiun by ur .. "po,~d cump",~d to CSE e'posed 

















! .. ".' 







. . . . .. ' ,. , .. 
0." 
Figure 6-0-1 Seria l 6eG colony counts over 5 d~ys in monocyte-derived m~crophage. 
Mont>cy te-de rive;J macrophi\f(e, infec ted with BCG w ere kept j" cul ture for 5 doy, oftcr t he 
od dlt ion of I I)'{ eS [ to cu ltur e well ; on doy , c m lpo,t in f""tlonl. Ih. solid l i n ~' repr ~," nt I dt~nt 
T8 infected subject; ond the >t ipp led I,,)c; lotcnt 1 B unlnfected su bjects . '1 h~ bill ' l i n~ ,"p r e ,~ nt ' 
LJ ne,pmed ma "'Oph d~e, and Ihe re d line CS E e<pmed macrophage, Each day repre'"nts the 
t ime p<J<nt po" 'n fcclion thot m;o:; rorhogn wer~ Iys~d ond or~""i sm I"" d [o lrul "t . <I by [olony 
coun\, 0" "' lid mc dia, ilt day zcro (p rc C'>f expo,u re) the coiony counts we rc , llsht ly h i gh ~r in 
th e LTBI po."llve !!IOLJP wmp.<led 10 t r", lTBI ne!!"t ive group a, ",en i" pre.iou, ",perimcnt in 
choptc r ~d but "'0 ; not st.lt ist" "lIy slEnifico nt, 1.~X10' (8.8,10' 1 CI U!ml YS. 1.;.10' 14.9,10') 


















",:e" , .. ,''', 
1~' GSf 0"",'", 
f1C" .... ',.' -...- .. ,,,,,", 
Figure C 0-1 Alveolar macrophage BCG uptake by L TBI status 
lTBI-pos itive subjects " re depicted in ,oIid colou" ("=41 \"';th lTBI-neg.ti,e subjects in sh"ded 
""" 1[1=31. Tile me"n ISDI HCG up l"ke fo , unNPo,"d "1""01", rn>e,ophage, w,," lTBI neg.ti"" 
39.B% (n.BI "nd I IHI po,illve :),8% (16.BI p - O,IB, No difference in \Jrt,k~ w," demon,t'atpd 












1. World Health Organisation. WHO Report on the Global Tobacco Epidemic, 
2008. The MPOWER package. Geneva: World Health Organisation; 2008. 
2. Slama K, Chiang CY, Enarson DA, Hassmiller K, Fanning A, Gupta P, et al. 
Tobacco and tuberculosis: a qualitative systematic review and meta-analysis. Int J 
Tuberc Lung Dis. 2007; 11(10): 1049-61. 
3. World Health Organisation. Global Tuberculosis Control. Geneva; 2010. 
4. Webb G8. The effect of the inhalation of cigarette smoke on the lungs. A 
clinical study. Am Rev Tuberc. 1918; march: 25-7. 
5. Lin HH, Ezzati M, Murray M. Tobacco Smoke, Indoor Air Pollution and 
Tuberculosis: A Systematic Review and Meta-Analysis. PLoSMed. 2007; 4(1): e20. 
6. Bates MN, Khalakdina A, Pai M, Chang L, Lessa F, Smith KR. Risk of tuberculosis 
from exposure to tobacco smoke: a systematic review and meta-analysis. 
ArchlnternMed. 2007; 167(4): 335-42. 
7. van Zyl Smit RN, Pai M, YewWW, Leung CC, Zumla A, Bateman ED, et al. Global 
lung health: the colliding epidemics of tuberculosis, tobacco smoking, HIV and COPD. 
Eur Respir J. 2010; 35(1): 27-33. 
8. Lonnroth K, Castro KG, Chakaya JM, Chauhan LS, Floyd K, Glaziou P, et al. 
Tuberculosis control and elimination 2010-50: cure, care, and social development. 
The Lancet. 2010; 375(9728): 1814-29. 
9. Holt PG. Immune and inflammatory function in cigarette smokers. Thorax. 
1987; 42(4): 241-9. 
10. Dye JA, Adler K8. Effects of cigarette smoke on epithelial cells of the 
respiratory tract. Thorax. 1994; 49(8): 825-34. 
11. Sopori M. Effects of cigarette smoke on the immune system. Nature reviews 
Immunology. 2002; 2(5): 372-7. 
12. Arcavi L, Benowitz NL. Cigarette smoking and infection. ArchlnternMed. 2004; 
164(20): 2206-16. 
13. Mehta H, Nazzal K, Sadikot RT. Cigarette smoking and innate immunity. 
Inflamm Res. 2008; 57(11): 497-503. 
14. Stampfli MR, Anderson GP. How cigarette smoke skews immune responses to 












15. Farhat M, Greenaway C, Pai M, Menzies D. False-positive tuberculin skin tests: 
what is the absolute effect of BCG and non-tuberculous mycobacteria? Int J Tuberc 
Lung Dis. 2006; 10(11): 1192-204. 
16. Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the 
diagnosis of latent tuberculosis infection: an update. Ann Intern Med. 2008; 149(3): 
177-84. 
17. Mazurek GH, Jereb J, Lobue P, Iademarco MF, Metchock B, Vernon A. 
Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium 
tuberculosis infection, United States. MMWR Recomm Rep. 2005; 54(RR-15): 49-55. 
18. Mazurek GH, Jereb J, Vernon A, LoBue P, Goldberg S, Castro K. Updated 
guidelines for using Interferon Gamma Release Assays to detect Mycobacterium 
tuberculosis infection - United States, 2010. MMWR Recommendations and reports: 
Morbidity and mortality weekly report Recommendations and reports / Centers for 
Disease Control. 2010; 59(RR-5): 1-25. 
19. Canadian tuberculosis committee. Updated recommendations on interferon 
gamma release assays for latent tuberculosis infection. An Advisory Committee 
Statement (ACS). Can Commun Dis Rep. 2008; 34(ACS-6): 1-13. 
20. National Institute for Health and Clinical Excellence. Tuberculosis: Clinical 
diagnosis and management of tuberculosis, and measures for its prevention and 
control. London: National Institute for Clincal Excellence; 2006 March 2006. 
21. Pai M, O'Brien R. Serial testing for tuberculosis: can we make sense of T cell 
assay conversions and reversions? PLoS Med. 2007; 4(6): e208. 
22. Pai M, Dheda K, Cunningham J, Scano F, O'Brien R. T-cell assays for the 
diagnosis of latent tuberculosis infection: moving the research agenda forward. 
Lancet Infect Dis. 2007; 7(6): 428-38. 
23. Skinner MA, Ramsay AJ, Buchan GS, Keen DL, Ranasinghe C, Slobbe L, et al. A 
DNA prime-live vaccine boost strategy in mice can augment IFN-y responses to 
mycobacterial antigens but does not increase the protective efficacy of two 
attenuated strains of Mycobacterium bovis against bovine tuberculosis. Immunology. 
2003; 108(4): 548-55. 
24. Fremond CM, Togbe De, Doz E, Rose S, Vasseur V, Maillet I, et al. IL-1 Receptor-
Mediated Signal Is an Essential Component of MyD88-Dependent Innate Response to 












25. Snewin VA, Gares M-P, Gaora PO, Hasan Z, Brown IN, Young DB. Assessment of 
Immunity to Mycobacterial Infection with Luciferase Reporter Constructs. Infect 
Immun. 1999; 67(9): 4586-93. 
26. Freeman S, Post FA, Bekker LG, Harbacheuski R, Steyn LM, Ryffel B, et al. 
Mycobacterium tuberculosis H37Ra and H37Rv differential growth and 
cytokine/chemokine induction in murine macrophages in vitro. Journal of interferon 
& cytokine research : the official journal of the International Society for Interferon 
and Cytokine Research. 2006; 26(1): 27-33. 
27. Mackay J EM. The Tobacco Atlas. 2nd ed. Hong Kong: World Health 
Organisation 2006. 
28. Diaz PT, King MA, Pacht ER, Wewers MD, Gadek JE, Nagaraja HN, et al. 
Increased susceptibility to pulmonary emphysema among HIV-seropositive smokers. 
AnnInternMed. 2000; 132(5): 369-72. 
29. Halsey NA, Coberly JS, Holt E, Coreil J, Kissinger P, Moulton LH, et al. Sexual 
behavior, smoking, and HIV-1 infection in Haitian Women. JAMA. 1992; 267(15): 
2062-6. 
30. Burns DN, Hillman D, Neaton JD, Sherer R, Mitchell T, Capps L, et al. Cigarette 
smoking, bacterial pneumonia, and other clinical outcomes in HIV-1 infection. Terry 
Beirn Community Programs for Clinical Research on AIDS. J Acquir Immune Defic 
Syndr Hum Retrovirol. 1996; 13(4): 374-83. 
31. Sitas F, Urban M, Bradshaw D, Kielkowski D, Bah S, Peto R. Tobacco 
attributable deaths in South Africa. TobControl. 2004; 13(4): 396-9. 
32. Peer N, Bradshaw D, Laubscher R, Steyn K. Trends in adult tobacco use from 
two South African Demographic and Health Surveys conducted in 1998 and 2003. S 
Afr Med J. 2009; 99(10): 744-9. 
33. World Health Organisation. Tobacco atlas online. 2010 [cited 2011 20 June 
2011]; Available from: http://www.tobaccoatlas.org 
34. Tobacco products control ammenment act No. 12 of 1999. South Africa: 
Department of Health; 1999. 
35. Tobacco Products Control Amendment Act, 2008. South Africa; 2008. 
36. Brunet L, Pai M, Davids V, Ling D, Paradis G, Lenders L, et al. High prevalence 












37. Pai M, Mohan A, Dheda K, Leung CC, Yew WW, Christopher DJ, et al. Lethal 
interaction: the colliding epidemics of tobacco and tuberculosis. Expert Rev Anti 
Infect Ther. 2007; 5(3): 385-91. 
38. Jha P, Jacob B, Gajalakshmi V, Gupta PC, Dhingra N, Kumar R, et al. A nationally 
representative case-control study of smoking and death in India. N Engl J Med. 2008; 
358(11): 1137-47. 
39. Gajalakshmi V, Peto R. Smoking, drinking and incident tuberculosis in rural 
India: population-based case-control study. International journal of epidemiology. 
2009; 38(4): 1018-25. 
40. Lin HH, Ezzati M, Chang HY, Murray M. Association between tobacco smoking 
and active tuberculosis in Taiwan: prospective cohort study. American journal of 
respiratory and critical care medicine. 2009; 180(5): 475-80. 
41. Wang J, Shen H. Review of cigarette smoking and tuberculosis in China: 
intervention is needed for smoking cessation among tuberculosis patients. BMC 
Public Health. 2009; 9: 292. 
42. d'Arc Lyra Batista J, de Fatima Pessoa Militao de Albuquerque M, de Alencar 
Ximenes RA, Rodrigues LC. Smoking increases the risk of relapse after successful 
tuberculosis treatment. International journal of epidemiology. 2008; 37(4): 841-51. 
43. Lin HH, Murray M, Cohen T, Colijn C, Ezzati M. Effects of smoking and solid-fuel 
use on COPD, lung cancer, and tuberculosis in China: a time-based, multiple risk 
factor, modelling study. Lancet. 2008; 372(9648): 1473-83. 
44. Lawn SD, Bekker LG, Middelkoop K, Myer L, Wood R. Impact of HIV infection 
on the epidemiology of tuberculosis in a peri-urban community in South Africa: the 
need for age-specific interventions. Clin Infect Dis. 2006; 42(7): 1040-7. 
45. World Health Organisation. Global tuberculosis control : surveillance, 
planning, financing WHO report 2009. Geneva: World Health Organisation; 2009. 
Report No.: WHO/HTM/TB/2009.411. 
46. Sonnenberg P, Glynn JR, Fielding K, Murray J, Godfrey-Faussett P, Shearer S. 
How soon after infection with HIV does the risk of tuberculosis start to increase? A 
retrospective cohort study in South African gold miners. The Journal of Infectious 
Diseases. 2005; 191(2): 150-8. 
47. Selwyn PA, Hartel D, Lewis VA, Schoenbaum EE, Vermund SH, Klein RS, et al. A 
prospective study of the risk of tuberculosis among intravenous drug users with 











48. Whalen C, Horsburgh CR, Hom D, Lahart C, Simberkoff M, Ellner J. Accelerated 
course of human immunodeficiency virus infection after tuberculosis. American 
journal of respiratory and critical care medicine. 1995; 151(1): 129-35. 
49. Dheda K, Lampe FC, Johnson MA, Lipman MC. Outcome of HIV-associated 
tuberculosis in the era of highly active antiretroviral therapy. J Infect Dis. 2004; 
190(9): 1670-6. 
50. Munsiff SS, Alpert PL, Gourevitch MN, Chang q, Klein RS. A prospective study 
of tuberculosis and HIV disease progression. Journal of acquired immune deficiency 
syndromes and human retrovirology : official publication of the International 
Retrovirology Association. 1998; 19(4): 361-6. 
51. Wood R, Middelkoop K, Myer L, Grant AD, Whitelaw A, Lawn SD, et al. 
Undiagnosed Tuberculosis in a Community with High HIV Prevalence: Implications 
for Tuberculosis Control. American Journal of Respiratory and Critical Care Medicine. 
2007; 175(1): 87-93. 
52. Dhasmana DJ, Dheda K, Ravn P, Wilkinson RJ, Meintjes G. Immune 
reconstitution inflammatory syndrome in HIV-infected patients receiving 
antiretroviral therapy: pathogenesis, clinical manifestations and management. Drugs. 
2008; 68(2): 191-208. 
53. Rabe KF, Hurd S, Anzueto A, Barnes pJ, Buist SA, Calverley P, et al. Global 
strategy for the diagnosis, management, and prevention of chronic obstructive 
pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007; 
176(6): 532-55. 
54. Burrows B, Knudson RJ, Cline MG, Lebowitz MD. Quantitative relationships 
between cigarette smoking and ventilatory function. Am Rev Respir Dis. 1977; 
115(2): 195-205. 
55. Buist AS, Vollmer WM, Sullivan SD, Weiss KB, Lee TA, Menezes AM, et al. The 
Burden of Obstructive Lung Disease Initiative (BOLD): rationale and design. COPD. 
2005; 2(2): 277-83. 
56. Grobbelaar JP, Bateman ED. Hut lung: a domestically acquired pneumoconiosis 
of mixed aetiology in rural women. Thorax. 1991; 46(5): 334-40. 
57. Weinmann S, Vollmer WM, Breen V, Heumann M, Hnizdo E, Villnave J, et al. 












58. Gothi D, Shah DV, Joshi JM. Clinical profile of diseases causing chronic airflow 
limitation in a tertiary care centre in India. J Assoc Physicians India. 2007; 55: 551-5. 
59. Anno H, Tomashefski JF. Studies on the impairment of respiratory function in 
pulmonary tuberculosis. Am Rev Tuberc. 1955; 71(3, Part 1): 333-48. 
60. Hallett WY, Martin q. The diffuse obstructive pulmonary syndrome in a 
tuberculosis sanatorium. I. Etiologic factors. AnnInternMed. 1961; 54: 1146-55. 
61. Martin q, Hallett WY. The diffuse obstructive pulmonary syndrome in a 
tuberculosis sanatorium. II. Incidence and symptoms. AnnInternMed. 1961; 54: 1156-
64. 
62. Birath G, Caro J, Malmberg R, Simonsson BG. Airways obstruction in 
pulmonary tuberculosis. ScandJ RespirDis. 1966; 47(1): 27-36. 
63. Willcox PA, Ferguson AD. Chronic obstructive airways disease following 
treated pulmonary tuberculosis. RespirMed. 1989; 83(3): 195-8. 
64. Dheda K, Booth H, Huggett JF, Johnson MA, Zumla A, Rook GA. Lung 
remodeling in pulmonary tuberculosis. J Infect Dis. 2005; 192(7): 1201-9. 
65. Plit ML, Anderson R, Van Rensburg CE, Page-Shipp L, Blott JA, Fresen JL, et al. 
Influence of antimicrobial chemotherapy on spirometric parameters and pro-
inflammatory indices in severe pulmonary tuberculosis. Eur Respir J. 1998; 12(2): 
351-6. 
66. Jung KH, Kim SJ, Shin C, Kim JH. The Considerable, Often Neglected, Impact of 
Pulmonary Tuberculosis on the Prevalence of COPD. Am J Respir Crit Care Med. 2008; 
178(4): 431. 
67. Kuhlman JE, Knowles MC, Fishman EK, Siegelman SS. Premature bullous 
pulmonary damage in AIDS: CT diagnosis. Radiology. 1989; 173(1): 23-6. 
68. Diaz PT, King ER, Wewers MD, Gadek JE, Neal D, Drake J, et al. HIV Infection 
Increases Susceptibility to Smoking-Induced Emphysema. Chest. 2000; 117(90051): 
285S. 
69. Crothers K, Butt AA, Gibert CL, Rodriguez-Barradas MC, Crystal'S, Justice AC, et 
al. Increased COPD Among HIV-Positive Compared to HIV-Negative Veterans. Chest. 
2006; 130(5): 1326-33. 
70. Petrache I, Diab K, Knox KS, Twigg HL, III, Stephens RS, Flores S, et al. HIV 
associated pulmonary emphysema: a review of the literature and inquiry into its 











71. Crothers K. Chronic obstructive pulmonary disease in patients who have HIV 
infection. Clin Chest Med. 2007; 28(3): 575-87, vi. 
72. U.S. Department of Health and Human Services. How Tobacco Smoke Causes 
Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease: A 
Report of the Surgeon General. atlanta: U.S. Department of Health and Human 
Services, Centers for Disease Control and Prevention, National Center for Chronic 
Disease Prevention and Health Promotion, Office on Smoking and Health,; 2010. 
73. van Zyl-Smit RN, Brunet L, Pai M, Yew WW. The convergence of the global 
smoking, COPD, tuberculosis, HIV, and respiratory infection epidemics. Infect Dis Clin 
North Am. 2010; 24(3): 693-703. 
74. Rogers DF, Turner NC, Marriott C, Jeffery PK. Cigarette smoke-induced 'chronic 
bronchitis': a study in situ of laryngo-tracheal hypersecretion in the rat. Clin Sci 
(Lond). 1987; 72(5): 629-37. 
75. Hummer B, Purnama I, Hahn HL. Stimulation of submucosal glands by nicotine 
applied locally to the airway mucosa. Klin Wochenschr. 1988; 66 Suppl11: 161-9. 
76. Hobson J, Wright J, Churg A. Histochemical evidence for generation of active 
oxygen species on the apical surface of cigarette-smoke-exposed tracheal explants. 
The American journal of pathology. 1991; 139(3): 573-80. 
77. Sisson JH, Tuma DJ, Rennard SI. Acetaldehyde-mediated cilia dysfunction in 
bovine bronchial epithelial cells. The American journal of physiology. 1991; 260(2 Pt 
1): L29-36. 
78. Elliott MK, Sisson JH, Wyatt T A. Effects of cigarette smoke and alcohol on 
ciliated tracheal epithelium and inflammatory cell recruitment. Am J Respir Cell Mol 
BioI. 2007; 36(4): 452-9. 
79. Agnew JE, Lopez-Vidriero MT, Pavia D, Clarke SW. Functional small airways 
defence in symptomless cigarette smokers. Thorax. 1986; 41(7): 524-30. 
80. Agnew JE, Pavia D, Clarke SW. Mucus clearance from peripheral and central 
airways of asymptomatic cigarette smokers. Bull Eur Physiopathbl Respir. 1986; 
22(3): 263-7. 
81. Amin K, Ekberg-Jansson A, Lofdahl CG, Venge P. Relationship between 
inflammatory cells and structural changes in the lungs of asymptomatic and never 
smokers: a biopsy study. Thorax. 2003; 58(2): 135-42. 
82. Di Stefano A, Caramori G, Ricciardolo FL, Capelli A, Adcock 1M, Donner CF. 











overview. Clinical and experimental allergy: journal of the British Society for Allergy 
and Clinical Immunology. 2004; 34(8): 1156-67. 
83. Todisco T, Dottorini M, Rossi F, Baldoncini A, Palumbo R. Normal reference 
values for regional pulmonary peripheral airspace epithelial permeability. Influence 
of pneumonectomy and the smoking habit. Respiration; international review of 
thoracic diseases. 1989; 55(2): 84-93. 
84. Corre F, Lellouch J, Schwartz D. Smoking and leucocyte-counts. Results of an 
epidemiological survey. Lancet. 1971; 2(7725): 632-4. 
85. Friedman GD, Siegelaub AB, Seltzer CC, Feldman R, Collen MF. Smoking habits 
and the leukocyte count. Arch Environ Health. 1973; 26(3): 137-43. 
86. van Eeden SF, Hogg Je. The response of human bone marrow to chronic 
cigarette smoking. The European respiratory journal: official journal of the European 
Society for Clinical Respiratory Physiology. 2000; 15(5): 915-21. 
87. Ginns LC, Goldenheim PD, Miller LG, Burton RC, Gillick L, Colvin RB, et al. T-
lymphocyte subsets in smoking and lung cancer: Analysis of monoclonal antibodies 
and flow cytometry. The American review of respiratory disease. 1982; 126(2): 265-
9. 
88. Ferson M, Edwards A, Lind A, Milton GW, Hersey P. Low natural killer-cell 
activity and immunoglobulin levels associated with smoking in human subjects. 
International journal of cancer Journal international du cancer. 1979; 23(5): 603-9. 
89. Gerrard JW, Heiner DC, Ko CG, Mink J, Meyers A, Dosman JA. Immunoglobulin 
levels in smokers and non-smokers. Ann Allergy. 1980; 44(5): 261-2. 
90. Gonzalez-Quintela A, Alende R, Gude F, Campos J, Rey J, Meijide LM, et al. 
Serum levels of immunoglobulins (IgG, IgA, IgM) in a general adult population and 
their relationship with alcohol consumption, smoking and common metabolic 
abnormalities. Clinical and Experimental Immunology. 2008; 151(1): 42-50. 
91. Hoekstra T, Geleijnse J, Schouten E, Kluft C. Smoking and CRP: results of the 
Arnhem Elderly Study. CRP. 2001; 1: 018. 
92. Bazzano LA, He J, Muntner P, Vupputuri S, Whelton PK. Relationship between 
Cigarette Smoking and Novel Risk Factors for Cardiovascular Disease in the United 
States. Annals of Internal Medicine. 2003; 138(11): 891-7. 
93. Harris JO, Swenson EW, Johnson JE, 3rd. Human alveolar macrophages: 
comparison of phagocytic ability, glucose utilization, and ultrastructure in smokers 











94. Wewers MD, Diaz PT, Wewers ME, Lowe MP, Nagaraja HN, Clanton TL. 
Cigarette smoking in HIV infection induces a suppressive inflammatory environment 
in the lung. Am J RespirCrit Care Med. 1998; 158(5 Pt 1): 1543-9. 
95. Sopori M. Effects of cigarette smoke on the immune system. Nat Rev Immunol. 
2002; 2(5): 372-7. 
96. Honda Y, Takahashi H, Kuroki Y, Akino T, Abe S. Decreased contents of 
surfactant proteins A and D in BAL fluids of healthy smokers. Chest. 1996; 109(4): 
1006-9. 
97. Onari K, Seyama A, Inamizu T, Kodomari N, Takaishi M, Yorioka N, et al. 
Immunological study on cigarette smokers. Part I. Serum protein pattern in smokers. 
Hiroshima J Med Sci. 1978; 27(2): 113-8. 
98. Gotoh T, Ueda S, Nakayama T, Takishita Y, Yasuoka S, Tsubura E. Protein 
components of bronchoalveolar lavage fluids from non-smokers and smokers. Eur J 
Respir Dis. 1983; 64(5): 369-77. 
99. King TE, Jr., Savici D, Campbell PA. Phagocytosis and killing of Listeria 
monocytogenes by alveolar macrophages: smokers versus nonsmokers. The Journal 
of Infectious Diseases. 1988; 158(6): 1309-16. 
100. Berenson CS, Garlipp MA, Grove LJ, Maloney J, Sethi S. Impaired phagocytosis 
of nontypeable Haemophilus influenzae by human alveolar macrophages in chronic 
obstructive pulmonary disease. The Journal of Infectious Diseases. 2006; 194(10): 
1375-84. 
101. Marti-Lliteras P, Regueiro V, Morey P, Hood DW, Saus C, Sauleda J, et al. 
N ontypeable Haemophilus influenzae clearance by alveolar macrophages is impaired 
by exposure to cigarette smoke. Infection and immunity. 2009; 77(10): 4232-42. 
102. Green GM. Mechanisms of tobacco smoke toxicity on pulmonary macrophage 
cells. Eur J Respir Dis Suppl. 1985; 139: 82-5. 
103. Phipps JC, Aronoff DM, Curtis JL, Goel D, O'Brien E, Mancuso P. Cigarette smoke 
exposure impairs pulmonary bacterial clearance and alveolar macrophage 
complement-mediated phagocytosis of Streptococcus pneumoniae. Infection and 
immunity. 2010; 78(3): 1214-20. 
104. Reardon CC, Kim SJ, Wagner RP, Koziel H, Kornfeld H. Phagocytosis and 
growth inhibition of Cryptococcus neoformans by human alveolar macrophages: 











105. Ortega E, Barriga C, Rodriguez AB. Decline in the phagocytic function of 
alveolar macrophages from mice exposed to cigarette smoke. Comp Immunol 
Microbiol Infect Dis. 1994; 17(1): 77-84. 
106. Ortega E, Hueso F, Collazos ME, Pedrera MI, Barriga C, Rodriguez AB. 
Phagocytosis of latex beads by alveolar macrophages from mice exposed to cigarette 
smoke. Comp Immunol Microbiol Infect Dis. 1992; 15(2): 137-42. 
107. Gaschler GJ, Skrtic M, Zavitz CC, Lindahl M, Onnervik PO, Murphy TF, et al. 
Bacteria challenge in smoke-exposed mice exacerbates inflammation and skews the 
inflammatory profile. American journal of respiratory and critical care medicine. 
2009; 179(8): 666-75. 
108. Matsunaga K, Klein TW, Friedman H, Yamamoto Y. Involvement of nicotinic 
acetylcholine receptors in suppression of antimicrobial activity and cytokine 
responses of alveolar macrophages to Legionella pneumophila infection by nicotine. J 
Immunol. 2001; 167(11): 6518-24. 
109. Ouyang Y, Virasch N, Hao P, Aubrey MT, Mukerjee N, Bierer BE, et al. 
Suppression of human IL-lbeta, IL-2, IFN-gamma, and TNF-alpha production by 
cigarette smoke extracts. J Allergy Clin Immunol. 2000; 106(2): 280-7. 
110. Lambert C, McCue J, Portas M, Ouyang Y, Li J, Rosano TG, et al. Acrolein in 
cigarette smoke inhibits T-cell responses. J Allergy Clin Immunol. 2005; 116(4): 916-
22. 
111. Hagiwara E, Takahashi KI, Okubo T, Ohno S, Veda A, Aoki A, et al. Cigarette 
smoking depletes cells spontaneously secreting Th(l) cytokines in the human airway. 
Cytokine. 2001; 14(2): 121-6. 
112. Madretsma S, Wolters LM, van Dijk JP, Tak CJ, Feyerabend C, Wilson JH, et al. 
In-vivo effect of nicotine on cytokine production by human non-adherent 
mononuclear cells. Eur J Gastroenterol Hepatol. 1996; 8(10): 1017-20. 
113. Dheda K, Johnson MA, Zumla A, Rook GA. Smoking is not beneficial for 
tuberculosis. Am J Respir Crit Care Med. 2004; 170(7): 821; author reply 
114. Rook GA, Dheda K, Zumla A. Immune responses to tuberculosis in developing 
countries: implications for new vaccines. Nat Rev Immunol. 2005; 5(8): 661-7. 
115. Chan ED, Henao-Tamayo M, Bai X, Oberley-Deegan R, Shanley C, Orme I, et al. 
Cigarette Smoke Increases Susceptibility To Tuberculosis: An In Vivo And In Vitro 











116. Shang S, Ordway D, Henao-Tamayo M, Bai X, Oberley-Deegan R, Shanley C, et 
al. Cigarette smoke increases susceptibility to tuberculosis--evidence from in vivo and 
in vitro models. The Journal ofInfectious Diseases. 2011; 203(9): 1240-8. 
117. Keane J, Balcewicz-Sablinska MK, Remold HG, Chupp GL, Meek BB, Fenton MJ, 
et al. Infection by Mycobacterium tuberculosis promotes human alveolar macrophage 
apoptosis. Infect Immun. 1997; 65(1): 298-304. 
118. Keane J, Remold HG, Kornfeld H. Virulent Mycobacterium tuberculosis strains 
evade apoptosis of infected alveolar macrophages. J Immunol. 2000; 164(4): 2016-
20. 
119. Tomita K, Caramori G, Lim S, Ito K, Hanazawa T, Oates T, et al. Increased 
p21(CIP1/WAF1) and B cell lymphoma leukemia-x(L) expression and reduced 
apoptosis in alveolar macrophages from smokers. Am J Respir Crit Care Med. 2002; 
166(5): 724-31. 
120. Richens TR, Linderman DJ, Horstmann SA, Lambert C, Xiao Y-Q, Keith RL, et al. 
Cigarette Smoke Impairs Clearance of Apoptotic Cells through Oxidant-dependent 
Activation of RhoA. Am J Respir Crit Care Med. 2009; 179(11): 1011-21. 
121. Aoshiba K, Tamaoki J, Nagai A. Acute cigarette smoke exposure induces 
apoptosis of alveolar macrophages. Am J Physiol Lung Cell Mol Physiol. 2001; 281(6): 
L1392-401. 
122. Vayssier M, Banzet N, FranVgois D, Bellmann K, Polla BS. Tobacco smoke 
induces both apoptosis and necrosis in mammalian cells: differential effects of HSP70. 
American Journal of Physiology - Lung Cellular and Molecular Physiology. 1998; 
275(4): L771-L9. 
123. D'Agostini F, Balansky RM, Izzotti A, Lubet RA, Kelloff GJ, De Flora S. 
Modulation of apoptosis by cigarette smoke and cancer chemopreventive agents in 
the respiratory tract of rats. Carcinogenesis. 2001; 22(3): 375-80. 
124. Avanzini MA, Ricci A, Scaramuzza C, Semino L, Pagella F, Castellazzi AM, et al. 
Deficiency of INFgamma producing cells in adenoids of children exposed to passive 
smoke. IntJ ImmunopatholPharmacol. 2006; 19(3): 609-16. 
125. Davies PD, YeWWW.GangulyD.DavidowAL.Reichman LB, Dheda K, et al. 
Smoking and tuberculosis: the epidemiological association and immunopathogenesis. 











126. van Zyl-Smit RN, Pai M, Peprah K, Meldau R, Kieck J, Juritz J, et al. Within-
subject Variability and Boosting of T Cell IFN-{gamma} Responses Following 
Tuberculin Skin Testing. Am J Respir Crit Care Med. 2009; 180: 49-58. 
127. Veerapathran A, Joshi R, Goswami K, Dogra S, Moodie EE, Reddy MV, et al. T-
cell assays for tuberculosis infection: deriving cut-offs for conversions using 
reproducibility data. PLoS ONE. 2008; 3(3): e1850. 
128. Menzies D. Interpretation of repeated tuberculin tests. Boosting, conversion, 
and reversion. Am J Respir Crit Care Med. 1999; 159(1): 15-21. 
129. Pai M, Kalantri S, Dheda K. New tools and emerging technologies for the 
diagnosis of tuberculosis: part I. Latent tuberculosis. Expert Rev Mol Diagn. 2006; 
6(3): 413-22. 
130. Menzies D, Pai M, Comstock G. Meta-analysis: new tests for the diagnosis of 
latent tuberculosis infection: areas of uncertainty and recommendations for research. 
Ann Intern Med. 2007; 146(5): 340-54. 
131. Dheda K, van Zyl-Smit R, Badri M, Pai M. T-cell interferon-gamma release 
assays for the rapid immunodiagnosis of tuberculosis: clinical utility in high-burden 
vs.low-burden settings. Curr Opin Pulm Med. 2009; 15(3): 188-200. 
132. Pai M, Kalantri S, Dheda K. New tools and emerging technologies for the 
diagnosis of tuberculosis: part II. Active tuberculosis and drug resistance. Expert Rev 
Mol Diagn. 2006; 6(3): 423-32. 
133. Urdea M, Penny LA, Olmsted SS, Giovanni MY, Kaspar P, Shepherd A, et al. 
Requirements for high impact diagnostics in the developing world. Nature. 2006; 444 
Supp)1: 73-9. 
134. Pheiffer C, Carroll NM, Beyers N, Donald P, Duncan K, Uys P, et al. Time to 
detection of Mycobacterium tuberculosis in BACTEC systems as a viable alternative to 
colony counting. The international journal of tuberculosis and lung disease : the 
official journal of the International Union against Tuberculosis and Lung Disease. 
2008; 12(7): 792-8. 
135. Diacon AH, Maritz JS, Venter A, van HeIden PD, Andries K, McNeeley DF, et al. 
Time to detection of the growth of Mycobacterium tuberculosis in MGIT 960 for 
determining the early bactericidal activity of antituberculosis agents. Eur J Clin 
Microbiol Infect Dis. 2010; 29(12): 1561-5. 
136. Zhang T, Li SY, Converse pJ, Almeida DV, Grosset JH, Nuermberger EL. Using 











Mycobacterium ulcerans infection. Antimicrob Agents Chemother. 2011; 55(1): 56-
61. 
137. Andrew PW, Roberts IS. Construction of a bioluminescent mycobacterium and 
its use for assay of antimycobacterial agents. J Clin Microbiol. 1993; 31(9): 2251-4. 
138. Greco S, Rulli M, Girardi E, Piersimoni C, Saltini C. Diagnostic accuracy of in-
house PCR for pulmonary tuberculosis in smear-positive patients: meta-analysis and 
metaregression. Journal of clinical microbiology. 2009; 47(3): 569-76. 
139. Blakemore R, Story E, Helb D, Kop J, Banada P, Owens MR, et al. Evaluation of 
the analytical performance of the Xpert MTBjRIF assay. Journal of clinical 
microbiology. 2010; 48(7): 2495-501. 
140. Helb D, Jones M, Story E, Boehme C, Wallace E, Ho K, et al. Rapid detection of 
Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-
patient technology. Journal of clinical microbiology. 2010; 48(1): 229-37. 
141. Ritchie SR, Harrison AC, Vaughan RH, Calder L, Morris AJ. New 
recommendations for duration of respiratory isolation based on time to detect 
Mycobacterium tuberculosis in liquid culture. European Respiratory Journal. 2007; 
30(3): 501-7. 
142. Hesseling AC, Walzl G, Enarson DA, Carroll NM, Duncan K, Lukey PT, et al. 
Baseline sputum time to detection predicts month two culture conversion and 
relapse in non-HIV-infected patients. The international journal of tuberculosis and 
lung disease: the official journal of the International Union against Tuberculosis and 
Lung Disease. 2010; 14(5): 560-70. 
143. O'Sullivan DM, Sander C, Shorten RJ, Gillespie SH, Hill AVS, McHugh TD, et al. 
Evaluation of liquid culture for quantitation of Mycobacterium tuberculosis in murine 
models. Vaccine. 2007; 25(49): 8203-5. 
144. Langmack EL, Martin RJ, Pak J, Kraft M. Serum lidocaine concentrations in 
asthmatics undergoing research bronchoscopy. Chest. 2000; 117(4): 1055-60. 
145. Milman N, Laub M, Munch EP, Angelo HR. Serum concentrations of lignocaine 
and its metabolite monoethylglycinexylidide during fibre-optic bronchoscopy in local 
anaesthesia. Respir Med. 1998; 92(1): 40-3. 
146. Calafat AM, Polzin GM, Saylor J, Richter P, Ashley DL, Watson CH. 
Determination of tar, nicotine, and carbon monoxide yields in the mainstream smoke 











147. Vassallo R, Tamada K, Lau JS, Kroening PR, Chen L. Cigarette Smoke Extract 
Suppresses Human Dendritic Cell Function Leading to Preferential Induction of Th-2 
Priming. J Immunol. 2005; 175(4): 2684-91. 
148. Schlesinger LS, Bellinger-Kawahara CG, Payne NR, Horwitz MA. Phagocytosis 
of Mycobacterium tuberculosis is mediated by human monocyte complement 
receptors and complement component C3. J Immunol. 1990; 144(7): 2771-80. 
149. Tailleux L, Pham-Thi N, Bergeron-Lafaurie A, Herrmann JL, Charles P, Schwartz 
0, et al. DC-SIGN induction in alveolar macrophages defines privileged target host 
cells for mycobacteria in patients with tuberculosis. PLoS Med. 2005; 2(12): e381. 
150. Kang PB, Azad AK, Torrelles JB, Kaufman TM, Beharka A, Tibesar E, et al. The 
human macrophage mannose receptor directs Mycobacterium tuberculosis 
lipoarabinomannan-mediated phagosome biogenesis. J Exp Med. 2005; 202(7): 987-
99. 
151. Hirsch CS, Ellner JJ, Russell DG, Rich EA. Complement receptor-mediated 
uptake and tumor necrosis factor-alpha-mediated growth inhibition of 
Mycobacterium tuberculosis by human alveolar macrophages. J Immunol. 1994; 
152(2): 743-53. 
152. Tailleux L, Schwartz 0, Herrmann JL, Pivert E, Jackson M, Amara A, et al. DC-
SIGN is the major Mycobacterium tuberculosis receptor on human dendritic cells. J 
Exp Med. 2003; 197(1): 121-7. 
153. Geijtenbeek TB, Van Vliet SJ, Koppel EA, Sanchez-Hernandez M, 
Vandenbroucke-Grauls CM, Appelmelk B, et al. Mycobacteria target DC-SIGN to 
suppress dendritic cell function. J Exp Med. 2003; 197(1): 7-17. 
154. Dheda K, Smit RZ, Badri M, Pai M. T-cell interferon-gamma release assays for 
the rapid immunodiagnosis of tuberculosis: clinical utility in high-burden vs. low-
burden settings. Curr Opin Pulm Med. 2009; 15(3): 188-200. 
155. Lynn Johnston B, Conly JM. Re-examining treatment of latent tuberculosis 
infection. Can J Infect Dis. 2001; 12(4): 211-4. 
156. Dheda K, Chang JS, Kim LU, Huggett JF, Johnson MA, Zumla A, et al. Interferon 
gamma assays for tuberculosis. Lancet Infect Dis. 2005; 5(6): 324-5; author reply 5-7. 
157. Pape JW, Jean SS, Ho JL, Hafner A, Johnson WD, Jr. Effect of isoniazid 
prophylaxis on incidence of active tuberculosis and progression of HIV infection. 











158. Walzl G, Ronacher K, Hanekom W, Scriba TJ, Zumla A. Immunological 
biomarkers of tuberculosis. Nat Rev Immunol. 2011; 11(5): 343-54. 
159. Cohn DL, O'Brien R. Targeted tuberculin testing and treatment of latent 
tuberculosis infection. This official statement of the American Thoracic Society was 
adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the 
American Thoracic Society (ATS) and the Centers for Disease Control and Prevention 
(CDC). This statement was endorsed by the Council of the Infectious Diseases Society 
of America. (IDSA), September 1999, and the sections of this statement. Am J Respir 
Crit Care Med. 2000; 161(4 Pt 2): S221-47. 
160. Cellestis. QuantiFERON-TB GOLD (In-Tube Method) package insert Doc 
No.05990301A. Cellestis; 2005. 
161. Oxford Immunotec. TSPOT.TB Package insert PI-TB8-IVD-UK-V3. Oxford 
Immunotec; 2006. 
162. Zanetti S, Bua A, Delogu G, Pusceddu C, Mura M, Saba F, et al. Patients with 
pulmonary tuberculosis develop a strong humoral response against methylated 
heparin-binding hemagglutinin. Clin Diagn Lab Immunol. 2005; 12(9): 1135-8. 
163. Sechi LA, Ahmed N, Felis GE, Dupre I, Cannas S, Fadda G, et al. Immunogenicity 
and cytoadherence of recombinant heparin binding haemagglutinin (HBHA) of 
Mycobacterium avium subsp. paratuberculosis: functional promiscuity or a role in 
virulence? Vaccine. 2006; 24(3): 236-43. 
164. Bland M. An introduction to Medical statistics. 2 ed: Oxford Medical 
publishers; 1994. p. 273-6. 
165. Perry S, Sanchez L, Yang S, Agarwal Z, Hurst P, Parsonnet J. Reproducibility of 
QuantiFERON-TB Gold In-Tube Assay. Clin Vaccine Immunol. 2008; 15(3): 425-32. 
166. van Zyl-Smit RN, Zwerling A, Dheda K, Pai M. Within-Subject Variability of 
Interferon-g Assay Results for Tuberculosis and Boosting Effect of Tuberculin Skin 
Testing: A Systematic Review. PLoS ONE. 2009; 4(12): e8517. 
167. Pai M, Joshi R, Dogra S, Zwerling AA, Gajalakshmi D, Goswami K, et al. T-cell 
assay conversions and reversions among household contacts of tuberculosis patients 
in rural India. Int J Tuberc Lung Dis. 2009; 13(1): 84-92. 
168. Detjen AK, Loebenberg L, Grewal HM, Stanley K, Gutschmidt A, Kruger C, et al. 
Short-term Reproducibility of a Commercial Interferon-gamma Release Assay. Clin 











169. Belknap R, Kelahar J, Wall K, Daley C, Schluger N, Reves R. Diagnosis of Latent 
Tuberculosis Infection in U.S. Health Care Workers: Reproducibility, Repeatability 
and 6 month Follow-up with Interferon gamma release assays (IGRAs). Am J Respir 
Crit Care Med. 2009; 179: A4101. 
170. Ringshausen FC, Nienhaus A, Schab Ion A, Schlosser S, Schultze-Werninghaus G, 
Rohde G. Predictors of persistently positive Mycobacterium-tuberculosis-specific 
interferon-gamma responses in the serial testing of health care workers. BMC 
infectious diseases. 2010; 10: 220. 
171. Baker CA, Thomas W, Stauffer WM, Peterson PK, Tsukayama DT. Serial testing 
of refugees for latent tuberculosis using the QuantiFERON-gold in-tube: effects of an 
antecedent tuberculin skin test. Am J Trop Med Hyg. 2009; 80(4): 628-33. 
172. Belknap R, Feske M, Choung G, Weinfirter P, Wall K, Graviss E. Diagnosis of 
Latent Tuberculosis Infection in Health Care Workers: Impact of recent Tuberculin 
Skin test on the Inteferon-gamma release assays (lGRAs). Am J Respir Crit Care Med. 
2009; 179: Al0l1. 
173. Vilaplana C, Ruiz-Manzano J, Gil 0, Cuchillo F, Montane E, Singh M, et al. The 
tuberculin skin test increases the responses measured by T cell interferon-gamma 
release assays. Scand J Immunol. 2008; 67(6): 610-7. 
174. Choi JC, Shin JW, Kim JY, Park IW, Choi BW, Lee MK. The effect of previous 
tuberculin skin test on the follow-up examination of whole-blood interferon-gamma 
assay in the screening for latenttuberculosis infection. Chest. 2008; 133(6): 1415-20. 
175. Richeldi L, Bergamini BM, Vaienti F. Prior tuberculin skin testing does not 
boost QuantiFERON-TB results in paediatric contacts. Eur Respir J. 2008; 32(2): 524-
5. 
176. Ley ten EMS, Prins C, Bossink AWJ, Thijsen S, Ottenhoff THM, van Dissel JT, et 
al. Effect of tuberculin skin testing on a Mycobacterium tuberculosis-specific 
interferon-{gamma} assay. European Respiratory Journal. 2007; 29(6): 1212-6. 
177. Igari H, Watanabe A, Sato T. Booster phenomenon of QuantiFERON-TB Gold 
after prior intradermal PPD injection. The International Journal of Tuberculosis and 
Lung Disease. 2007; 11: 788-91. 
178. Naseer A, Naqvi S, Kampmann B. Evidence for boosting Mycobacterium 
tuberculosis-specific IFN-{gamma} responses at 6 weeks following tuberculin skin 











179. Cellestis Inc. QuantiFERON-TB GOLD (In-Tube Method) package insert Doc 
No.US05990301C. Cellestis Inc (USA). Valencia; 2007. 
180. Richeldi L, Ewer K, Losi M, Roversi P, Fabbri LM, Lalvani A. Repeated 
tuberculin testing does not induce false positive ELISPOT results. Thorax. 2006; 
61(2): 180. 
181. Nguyen M, Perry S, Parsonnet J. QuantiFERON-TB predicts tuberculin skin test 
boosting in U.S. foreign-born. IntI Tuberc Lung Dis. 2005; 9(9): 985-91. 
182. Pai M, Ramsay A, O'Brien R. Evidence-based tuberculosis diagnosis. PLoS Med. 
2008; 5(7): e156. 
183. Pai M, Joshi R, Dogra S, Mendiratta DK, Narang P, Kalantri S, et al. Serial testing 
of health care workers for tuberculosis using interferon-gamma assay. Am J Respir 
Crit Care Med. 2006; 174(3): 349-55. 
184. Mazzoccoli G, Bianco G, Correra M, Carella AM, Balzanelli M, Giuliani A, et al. 
[Circadian variation of lymphocyte subsets in health subjects]. Recenti Prog Med. 
1998; 89(11): 569-72. 
185. Palm S, Postler E, Hinrichsen H, Maier H, Zabel P, Kirch W. Twenty-four-hour 
analysis of lymphocyte subpopulations and cytokines in healthy subjects. Chronobiol 
Int. 1996; 13(6): 423-34. 
186. Pym AS, Brodin P, Majlessi L, Brosch R, Demangel C, Williams A, et al. 
Recombinant BCG exporting ESAT-6 confers enhanced protection against 
tuberculosis. Nat Med. 2003; 9(5): 533-9. 
187. Haile Y, Bjune G, Wiker HG. Expression of the mceA, esat-6 and hspX genes in 
Mycobacterium tuberculosis and their responses to aerobic conditions and to 
restricted oxygen supply. Microbiology. 2002; 148(Pt 12): 3881-6. 
188. Locht C, Hougardy JM, Rouanet C, Place S, Mascart F. Heparin-binding 
hemagglutinin, from an extrapulmonary dissemination factor to a powerful 
diagnostic and protective antigen against tuberculosis. Tuberculosis(Edinb). 2006; 
86(3-4): 303-9. 
189. Hougardy JM, Schepers K, Place S, Drowart A, Lechevin V, Verscheure V, et al. 
Heparin-binding-hemagglutinin-induced IFN-gamma release as a diagnostic tool for 
latent tuberculosis. PLoS ONE. 2007; 2(10): e926. 
190. Guyot-Revol V, Innes JA, Hackforth S, Hinks T, Lalvani A. Regulatory T Cells Are 
Expanded in Blood and Disease Sites in Patients with Tuberculosis. Am J Respir Crit 











191. Hougardy JM, Place S, Hildebrand M, Drowart A, Debrie AS, Locht C, et al. 
Regulatory T Cells Depress Immune Responses to Protective Antigens in Active 
Tuberculosis. American Journal of Respiratory and Critical Care Medicine. 2007; 
176(4): 409-16. 
192. Dheda K, Shean K, Zumla A, Badri M, Streicher EM, Page-Shipp L, et al. Early 
treatment outcomes and HIV status of patients with extensively drug-resistant 
tuberculosis in South Africa: a retrospective cohort study. Lancet. 2010; 375(9728): 
1798-807. 
193. Dheda K, Warren RM, Zumla A, Grobusch MP. Extensively Drug-resistant 
Tuberculosis: Epidemiology and Management Challenges. Infectious disease clinics of 
North America. 2010; 24(3): 705-25. 
194. Akhtar M, Bretzel G, Boulahbel D, Dawson DA, Fattorini L, Feldman K, et al. 
Sputum Examination for Tuberculosis by Direct Microscopy in Low Income 
Countries; 2000. 
195. Dheda K, Huggett JF, Bustin SA, Johnson MA, Rook G, Zumla A. Validation of 
housekeeping genes for normalizing RNA expression in real-time PCR. Biotechniques. 
2004; 37(1): 112-4,6,8-9. 
196. Dheda K, Huggett JF, Chang JS, Kim LU, Bustin SA, Johnson MA, et al. The 
implications of using an inappropriate reference gene for real-time reverse 
transcription PCR data normalization. Anal Biochem. 2005; 344(1): 141-3. 
197. Kampmann B, Gaora PO, Snewin VA, Gares MP, Young DB, Levin M. Evaluation 
of human antimycobacterial immunity using recombinant reporter mycobacteria. The 
Journal of Infectious Diseases. 2000; 182(3): 895-901. 
198. Theron G, Peter I, van Zyl-Smit R, Mishra H, Streicher E, Murray S, et al. 
Evaluation of the Xpert(R) MTBjRIF Assay for the Diagnosis of Pulmonary 
Tuberculosis in a High HIV Prevalence Setting. American journal of respiratory and 
critical care medicine. 2011. 
199. Schwander S, Dheda K. Human Lung Immunity against Mycobacterium 
tuberculosis: Insights into Pathogenesis and Protection. Am J Respir Crit Care Med. 
2011; 183(6): 696-707. 
200. Schwander SK, Sada E, Torres M, Escobedo D, Sierra JG, Alt S, et al. T 
lymphocytic and immature macrophage alveolitis in active pulmonary tuberculosis. J 











201. Schwander SK, Torres M, Sada E, Carranza C, Ramos E, Tary-Lehmann M, et al. 
Enhanced responses to Mycobacterium tuberculosis antigens by human alveolar 
lymphocytes during active pulmonary tuberculosis. J Infect Dis. 1998; 178(5): 1434-
45. 
202. Taha RA, Kotsimbos TC, Song YL, Menzies D, Hamid Q. IFN-gamma and IL-12 
are increased in active compared with inactive tuberculosis. Am J Respir Crit Care 
Med. 1997; 155(3): 1135-9. 
203. Pieters J, Gatfield J. Hijacking the host: survival of pathogenic mycobacteria 
inside macrophages. Trends Microbiol. 2002; 10(3): 142-6. 
204. Hirsch CS, Toossi Z, Othieno C, Johnson JL, Schwander SK, Robertson S, et al. 
Depressed T-cell interferon-gamma responses in pulmonary tuberculosis: analysis of 
underlying mechanisms and modulation with therapy. J Infect Dis. 1999; 180(6): 
2069-73. 
205. Almeida AS, Lago PM, Boechat N, Huard RC, Lazzarini LC, Santos AR, et al. 
Tuberculosis is associated with a down-modulatory lung immune response that 
impairs Thl-type immunity. J Immunol. 2009; 183(1): 718-31. 
206. Kursar M, Koch M, Mittrucker HW, Nouailles G, Bonhagen K, Kamradt T, et al. 
Cutting Edge: Regulatory T cells prevent efficient clearance of Mycobacterium 
tuberculosis. J Immunol. 2007; 178(5): 2661-5. 
207. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, 
et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-
neutralizing agent. NEnglJ Med. 2001; 345(15): 1098-104. 
208. Wallis RS. Mycobacterial disease attributable to tumor necrosis factor-alpha 
blockers. Clin Infect Dis. 2008; 47(12): 1603-5; author reply 5-6. 
209. Altare F, Durandy A, Lammas D, Emile JF, Lamhamedi S, Le Deist F, et al. 
Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency. 
Science. 1998; 280(5368): 1432-5. 
210. Newport MJ, Huxley CM, Huston S, Hawrylowicz CM, Oostra BA, Williamson R, 
et al. A mutation in the interferon-gamma-receptor gene and susceptibility to 
mycobacterial infection. N Engl J Med. 1996; 335(26): 1941-9. 
211. Flynn J, Chan J. Tuberculosis: latency and reactivation. Infect Immun. 2001; 69: 
4195-201. 
212. Matsunaga K, Klein TW, Friedman H, Yamamoto Y. In vitro therapeutic effect of 











pneumophila infection of established MH-S alveolar macrophages. J InfectDis. 2002; 
185(2): 229-36. 
213. Robbins CS, Dawe DE, Goncharova SI, Pouladi MA, Drannik AG, Swirski FK, et 
al. Cigarette smoke decreases pulmonary dendritic cells and impacts antiviral 
immune responsiveness. Am J RespirCell Mol BioI. 2004; 30(2): 202-11. 
214. Fisher GL, McNeill KL, Finch GL, Wilson FD, Golde DW. Functional evaluation of 
lung macro phages from cigarette smokers and nonsmokers. J Reticuloendothel Soc. 
1982; 32(4): 311-21. 
215. Proulx LI, Pare G, Bissonnette EY. Alveolar macrophage cytotoxic activity is 
inhibited by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), a carcinogenic 
component of cigarette smoke. Cancer Immunollmmunother. 2007; 56(6): 831-8. 
216. Fenton M, Vermeulen M, Kim S, Burdick M, Strieter R, Kornfeld H. Induction of 
gamma interferon production in human alveolar macrophages by Mycobacterium 
tuberculosis. Infect Immun.1997; 65(12): 5149-56. 
217. Robinson BW, McLemore TL, Crystal RG. Gamma interferon is spontaneously 
released by alveolar macrophages and lung T lymphocytes in patients with 
pulmonary sarcoidosis. The Journal of clinical investigation. 1985; 75(5): 1488-95. 
218. Means TK, Jones BW, Schromm AB, Shurtleff BA, Smith JA, Keane J, et al. 
Differential Effects of a Toll-Like Receptor Antagonist on Mycobacterium 
tuberculosis-Induced Macrophage Responses. The Journal of Immunology. 2001; 
166(6): 4074-82. 
219. Droemann D, Goldmann T, Tiedje T, Zabel P, Dalhoff K, Schaaf B. Toll-like 
receptor 2 expression is decreased on alveolar macrophages in cigarette smokers and 
COPD patients. Respiratory research. 2005; 6: 68. 
220. Chen H, Cowan MJ, Hasday JD, Vogel SN, Medvedev AE. Tobacco Smoking 
Inhibits Expression of Proinflammatory Cytokines and Activation of IL-1R-Associated 
Kinase, p38, and NF-CEJB in Alveolar Macrophages Stimulated with TLR2 and TLR4 
Agonists. The Journal of Immunology. 2007; 179(9): 6097-106. 
221. Hope JC, Thorn ML, McCormick PA, Howard q. Interaction of antigen 
presenting cells with mycobacteria. Veterinary immunology and immunopathology. 
2004; 100(3-4): 187-95. 
222. Tobian AA, Potter NS, Ramachandra L, Pai RK, Convery M, Boom WH, et al. 
Alternate class I MHC antigen processing is inhibited by Toll-like receptor signaling 











lipoprotein, CpG DNA, and lipopolysaccharide. Journal of immunology. 2003; 171(3): 
1413-22. 
223. Li L, Wu CY. CD4( + )CD25( +) Treg cells inhibit human memory gamma delta T 
cells to produce IFN-gamma in response to M tuberculosis antigen ESAT-6. Blood. 
2008; 111(12): 5629-36. 
224. Qin XJ, Shi HZ, Liang QL, Huang LY, Yang HB. CD4+CD25+ regulatory T 
lymphocytes in tuberculous pleural effusion. Chin Med J (Engl). 2008; 121(7): 581-6. 
225. Barcelo B, Pons J, Ferrer JM, Sauleda J, Fuster A, Agusti AG. Phenotypic 
characterisation of T-Iymphocytes in COPD: abnormal CD4+CD25+ regulatory T-
lymphocyte response to tobacco smoking. The European respiratory journal: official 
journal of the European Society for Clinical Respiratory Physiology. 2008; 31(3): 555-
62. 
226. Plumb J, Smyth LJ, Adams HR, Vestbo J, Bentley A, Singh SD. Increased T-
regulatory cells within lymphocyte follicles in moderate COPD. The European 
respiratory journal : official journal of the European Society for Clinical Respiratory 
Physiology. 2009; 34(1): 89-94. 
227. Lee J, Hartman M, Kornfeld H. Macrophage Apoptosis in Tuberculosis. Yonsei 
Med J. 2009; 50(1): 1-11. 
228. Dheda K, Schwander SK, Zhu B, van Zyl-Smit RN, Zhang Y. The immunology of 
tuberculosis: from bench to bedside. Respirology. 2010; 15(3): 433-50. 
229. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, 
et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-
neutralizing agent. N Engl J Med. 2001; 345(15): 1098-104. 
230. Borges VM, Vandivier RW, McPhillips KA, Kench JA, Morimoto K, Groshong SD, 
et al. TNFalpha inhibits apoptotic cell clearance in the lung, exacerbating acute 
inflammation. American journal of physiology Lung cellular and molecular 
physiology. 2009; 297(4): L586-95. 
231. Dini L. Phagocytosis of dying cells: influence of smoking and static magnetic 
fields. Apoptosis. 2010; 15(9): 1147-64. 
232. Ando M, Sugimoto M, Nishi R, Suga M, Horio S, Kohrogi H, et al. Surface 
morphology and function of human pulmonary alveolar macrophages from smokers 











233. Nuorti JP, Butler JC, Farley MM, Harrison LH, McGeer A, Kolczak MS, et al. 
Cigarette smoking and invasive pneumococcal disease. Active Bacterial Core 
Surveillance Team. The New England journal of medicine. 2000; 342(10): 681-9. 
234. Spira A, Carroll JD, Liu G, Aziz Z, Shah V, Kornfeld H, et al. Apoptosis Genes in 
Human Alveolar Macrophages Infected with Virulent or Attenuated Mycobacterium 
tuberculosis: A Pivotal Role for Tumor Necrosis Factor. Am J Respir Cell Mol BioI. 
2003; 29(5): 545-51. 
235. Molloy A, Laochumroonvorapong P, Kaplan G. Apoptosis, but not necrosis, of 
infected monocytes is coupled with killing of intracellular bacillus Calmette-Guerin. 
The Journal of Experimental Medicine. 1994; 180(4): 1499-509. 
236. Lee J, Remold HG, Ieong MH, Kornfeld H. Macrophage apoptosis in response to 
high intracellular burden of Mycobacterium tuberculosis is mediated by a novel 
caspase-independentpathway. Journal of immunology. 2006; 176(7): 4267-74. 
237. Park JS, Tamayo MH, Gonzalez-Juarrero M, Orme 1M, Ordway DJ. Virulent 
clinical isolates of Mycobacterium tuberculosis grow rapidly and induce cellular 
necrosis but minimal apoptosis in murine macrophages. Journal of leukocyte biology. 
2006; 79(1): 80-6. 
238. Zheng L, Teschler H, Guzman J, Hubner K, Striz I, Costabel V. Alveolar 
macrophage TNF-alpha release and BAL cell phenotypes in sarcoidosis. American 
journal of respiratory and critical care medicine. 1995; 152(3): 1061-6. 
239. Gosset P, Wallaert B, Tonnel AB, Fourneau C. Thiol regulation of the 
production of TNF -alpha, IL-6 and IL-8 by human alveolar macrophages. The 
European respiratory journal : official journal of the European Society for Clinical 
Respiratory Physiology. 1999; 14(1): 98-105. 
240. EI Solh A, Porhomayon J, Szarpa K. Proinflammatory and phagocytic functions 
of alveolar macrophages in obesity. Obesity Research & Clinical Practice. 2009; 3(4): 
203-7. 
241. Ziegenhagen M, W , Benner V, K., Zissel G, Zabel P, Schlaak M, Muller-
Quernheim J. Sarcoidosis: TNF-alpha Release from Alveolar Macrophages and Serum 
Level of sIL-2R Are Prognostic Markers. Am J Respir Crit Care Med. 1997; 156(5): 
1586-92. 
242. Losa Garcia JE, Rodriguez FM, Martin de Cabo MR, Garcia Salgado MJ, Losada 
JP, Villaron LG, et al. Evaluation of inflammatory cytokine secretion by human 











243. Gosset P, Perez T, Lassalle P, Duquesnoy B, Farre JM, Tonnel AB, et al. 
Increased TNF-alpha secretion by alveolar macrophages from patients with 
rheumatoid arthritis. The American review of respiratory disease. 1991; 143(3): 593-
7. 
244. Omidvari K, Casey R, Nelson S, Olariu R, Shellito JE. Alveolar macrophage 
release of tumor necrosis factor-alpha in chronic alcoholics without liver disease. 
Alcohol Clin Exp Res. 1998; 22(3): 567-72. 
245. Roth MD, Whittaker K, Salehi K, Tashkin DP, Baldwin Gc. Mechanisms for 
impaired effector function in alveolar macrophages from marijuana and cocaine 
smokers. J NeuroimmunoI. 2004; 147(1-2): 82-6. 
246. Sarafian TA, Tashkin DP, Roth MD. Marijuana smoke and Delta(9)-
tetrahydrocannabinol promote necrotic cell death but inhibit Fas-mediated 
apoptosis. Toxicology and applied pharmacology. 2001; 174(3): 264-72. 
247. Sawyer K, Mundandhara S, Ghio AI. Madden MC. The Effects of Ambient 
Particulate Matter on Human Alveolar Macrophage Oxidative and Inflammatory 
Responses. Journal of Toxicology and Environmental Health, Part A: Current Issues. 
2010; 73(1): 41 - 57. 
248. Su Y, Han W, Giraldo C, De Li Y, Block ER. Effect of Cigarette Smoke Extract on 
Nitric Oxide Synthase in Pulmonary Artery Endothelial Cells. Am J Respir Cell Mol 
BioI. 1998; 19(5): 819-25. 
249. Brody AR, Craighead JE. Cytoplasmic inclusions in pulmonary macrophages of 
cigarette smokers. Lab Invest. 1975; 32(2): 125-32. 
250. Marques LJ, Teschler H, Guzman J, Costabel U. Smoker's lung transplanted to a 
nonsmoker. Long-term detection of smoker's macrophages. American journal of 
respiratory and critical care medicine. 1997; 156(5): 1700-2. 
251. Agius RM, Rutman A, Knight RK, Cole PJ. Human pulmonary alveolar 
macro phages with smokers' inclusions: their relation to the cessation of cigarette 
smoking. British journal of experimental pathology. 1986; 67(3): 407-13. 
252. Skold CM, Hed I. Eklund A. Smoking cessation rapidly reduces cell recovery in 
bronchoalveolar lavage fluid, while alveolar macrophage fluorescence remains high. 
Chest. 1992; 101(4): 989-95. 
253. Umino T, Skold CM, Pirruccello SJ, Spurzem JR, Rennard SI. Two-colour flow-











respiratory journal : official journal of the European Society for Clinical Respiratory 
Physiology. 1999; 13(4): 894-9. 
254. Hodge S, Hodge G, Ahern J, Jersmann H, Holmes M, Reynolds PN. Smoking 
alters alveolar macrophage recognition and phagocytic ability: implications in chronic 
obstructive pulmonary disease. Am J Respir Cell Mol BioI. 2007; 37(6): 748-55. 
255. Baglole q, Bushinsky SM, Garcia TM, Kode A, Rahman I, Sime pJ, et aI. 
Differential induction of apoptosis by cigarette smoke extract in primary human lung 
fibroblast strains: implications for emphysema. Am J Physiol Lung Cell Mol PhysioI. 
2006; 291(1): L19-29. 
256. Baqir M, Chen C-Z, Martin RJ, Thaikoottathil 1. Case SR, Minor MN, et aI. 
Cigarette smoke decreases MARCO expression in macrophages: Implication in 
Mycoplasma pneumoniae infection. Respiratory Medicine. 2008; 102(11): 1604-10. 
257. Hope IC, Thorn ML, McCormick PA, Howard q. Interaction of antigen 
presenting cells with mycobacteria. Vet Immunol ImmunopathoI. 2004; 100(3-4): 
187-95. 
258. Tobian AA, Potter NS, Ramachandra L, Pai RK, Convery M, Boom WH, et aI. 
Alternate class I MHC antigen processing is inhibited by Toll-like receptor signaling 
pathogen-associated molecular patterns: Mycobacterium tuberculosis 19-kDa 
lipoprotein, CpG DNA, and lipopolysaccharide. J ImmunoI. 2003; 171(3): 1413-22. 
259. Sinsimer D, Fallows D, Peixoto B, Krahenbuhl J, Kaplan G, Manca C. 
Mycobacterium leprae actively modulates the cytokine response in naive human 
monocytes. Infect Immun. 2010; 78(1): 293-300. 
260. Zhang Q, Adiseshaiah P, Kalvakolanu DV, Reddy SP. A Phosphatidylinositol 3-
Kinase-regulated Akt-Independent Signaling Promotes Cigarette Smoke-induced FRA-
1 Expression. Journal of Biological Chemistry. 2006; 281(15): 10174-81. 
261. Sato KZ, Fujii T, Watanabe Y, Yamada S, Ando T, Kazuko F, et al. Diversity of 
mRNA expression for muscarinic acetylcholine receptor subtypes and neuronal 
nicotinic acetylcholine receptor subunits in human mononuclear leukocytes and 
leukemic cell lines. Neuroscience letters. 1999; 266(1): 17-20. 
262. Mikulski Z, Hartmann P, Jositsch G, Zaslona Z, Lips KS, Pfeil U, et al. Nicotinic 
receptors on rat alveolar macrophages dampen ATP-induced increase in cytosolic 
calcium concentration. Respiratory Research. 2010; 11: 133. 
263. Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes 











264. Taubenberger JK, Morens DM. 1918 Influenza: the mother of all pandemics. 
Emerging infectious diseases. 2006; 12(1): 15-22. 
265. Morens DM, Fauci AS. The 1918 influenza pandemic: insights for the 21st 
century. The Journal of Infectious Diseases. 2007; 195(7): 1018-28. 
266. Diacon AH, Maritz JS, Venter A, van HeIden PD, Dawson R, Donald PR. Time to 
liquid culture positivity can substitute for colony counting on agar plates in early 
bactericidal activity studies of antituberculosis agents. Clinical Microbiology and 
Infection. 2011: no-no. 
267. Ember L. FDA authorized to regulate nicotine as a drug. Chemical & 
Engineering News. 1995; 73(34): 5-null. 
268. Gilmore AB, Britton J, Arnott D, Ashcroft R, Jarvis MJ. The place for harm 
reduction and product regulation in UK tobacco control policy. J Public Health (Oxf). 
2009; 31(1): 3-10. 
150 
